

AMENDMENT NO. \_\_\_\_\_ Calendar No. \_\_\_\_\_

Purpose: In the nature of a substitute.

**IN THE SENATE OF THE UNITED STATES—115th Cong., 2d Sess.**

**H. R. 6**

To provide for opioid use disorder prevention, recovery, and treatment, and for other purposes.

Referred to the Committee on \_\_\_\_\_ and ordered to be printed

Ordered to lie on the table and to be printed

AMENDMENT IN THE NATURE OF A SUBSTITUTE intended to be proposed by \_\_\_\_\_

Viz:

1 Strike all after the enacting clause and insert the following:  
2

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) **SHORT TITLE.**—This Act may be cited as the  
5 “Opioid Crisis Response Act of 2018”.

6 (b) **TABLE OF CONTENTS.**—The table of contents for  
7 this Act is as follows:

Sec. 1. Short title; table of contents.

**TITLE I—OPIOID CRISIS RESPONSE ACT**

Sec. 1001. Definitions.

**Subtitle A—Reauthorization of Cures Funding**

Sec. 1101. State response to the opioid abuse crisis.

**Subtitle B—Research and Innovation**

## 2

- Sec. 1201. Advancing cutting-edge research.
- Sec. 1202. Pain research.
- Sec. 1203. Report on synthetic drug use.

## Subtitle C—Medical Products and Controlled Substances Safety

- Sec. 1301. Clarifying FDA regulation of non-addictive pain products.
- Sec. 1302. Clarifying FDA packaging authorities.
- Sec. 1303. Strengthening FDA and CBP coordination and capacity.
- Sec. 1304. Clarifying FDA post-market authorities.
- Sec. 1305. Restricting entrance of illicit drugs.
- Sec. 1306. First responder training.
- Sec. 1307. Disposal of controlled substances of hospice patients.
- Sec. 1308. GAO study and report on hospice safe drug management.
- Sec. 1309. Delivery of a controlled substance by a pharmacy to be administered by injection or implantation.

## Subtitle D—Treatment and Recovery

- Sec. 1401. Comprehensive opioid recovery centers.
- Sec. 1402. Program to support coordination and continuation of care for drug overdose patients.
- Sec. 1403. Alternatives to opioids.
- Sec. 1404. Building communities of recovery.
- Sec. 1405. Peer support technical assistance center.
- Sec. 1406. Medication-assisted treatment for recovery from addiction.
- Sec. 1407. Grant program.
- Sec. 1408. Allowing for more flexibility with respect to medication-assisted treatment for opioid use disorders.
- Sec. 1409. National recovery housing best practices.
- Sec. 1410. Addressing economic and workforce impacts of the opioid crisis.
- Sec. 1411. Career Act.
- Sec. 1412. Pilot program to help individuals in recovery from a substance use disorder become stably housed.
- Sec. 1413. Youth prevention and recovery.
- Sec. 1414. Plans of safe care.
- Sec. 1415. Regulations relating to special registration for telemedicine.
- Sec. 1416. National Health Service Corps behavioral and mental health professionals providing obligated service in schools and other community-based settings.
- Sec. 1417. Loan repayment for substance use disorder treatment providers.
- Sec. 1418. Protecting moms and infants.
- Sec. 1419. Early interventions for pregnant women and infants.
- Sec. 1420. Report on investigations regarding parity in mental health and substance use disorder benefits.

## Subtitle E—Prevention

- Sec. 1501. Study on prescribing limits.
- Sec. 1502. Programs for health care workforce.
- Sec. 1503. Education and awareness campaigns.
- Sec. 1504. Enhanced controlled substance overdoses data collection, analysis, and dissemination.
- Sec. 1505. Preventing overdoses of controlled substances.
- Sec. 1506. CDC surveillance and data collection for child, youth, and adult trauma.

## 3

- Sec. 1507. Reauthorization of NASPER.
- Sec. 1508. Jessie's law.
- Sec. 1509. Development and dissemination of model training programs for substance use disorder patient records.
- Sec. 1510. Communication with families during emergencies.
- Sec. 1511. Prenatal and postnatal health.
- Sec. 1512. Surveillance and education regarding infections associated with illicit drug use and other risk factors.
- Sec. 1513. Task force to develop best practices for trauma-informed identification, referral, and support.
- Sec. 1514. Grants to improve trauma support services and mental health care for children and youth in educational settings.
- Sec. 1515. National Child Traumatic Stress Initiative.
- Sec. 1516. National milestones to measure success in curtailing the opioid crisis.

## TITLE II—FINANCE

- Sec. 2001. Short title.

## Subtitle A—Medicare

- Sec. 2101. Medicare opioid safety education.
- Sec. 2102. Expanding the use of telehealth services for the treatment of opioid use disorder and other substance use disorders.
- Sec. 2103. Comprehensive screenings for seniors.
- Sec. 2104. Every prescription conveyed securely.
- Sec. 2105. Standardizing electronic prior authorization for safe prescribing.
- Sec. 2106. Strengthening partnerships to prevent opioid abuse.
- Sec. 2107. Commit to opioid medical prescriber accountability and safety for seniors.
- Sec. 2108. Fighting the opioid epidemic with sunshine.
- Sec. 2109. Demonstration testing coverage of certain services furnished by opioid treatment programs.
- Sec. 2110. Encouraging appropriate prescribing under Medicare for victims of opioid overdose.
- Sec. 2111. Automatic escalation to external review under a Medicare part D drug management program for at-risk beneficiaries.
- Sec. 2112. Testing of incentive payments for behavioral health providers for adoption and use of certified electronic health record technology.
- Sec. 2113. Medicare Improvement Fund.

## Subtitle B—Medicaid

- Sec. 2201. Caring recovery for infants and babies.
- Sec. 2202. Peer support enhancement and evaluation review.
- Sec. 2203. Medicaid substance use disorder treatment via telehealth.
- Sec. 2204. Enhancing patient access to non-opioid treatment options.
- Sec. 2205. Assessing barriers to opioid use disorder treatment.
- Sec. 2206. Help for moms and babies.
- Sec. 2207. Securing flexibility to treat substance use disorders.
- Sec. 2208. MACPAC study and report on MAT utilization controls under State Medicaid programs.
- Sec. 2209. Opioid addiction treatment programs enhancement.
- Sec. 2210. Better data sharing to combat the opioid crisis.

## 4

- Sec. 2211. Mandatory reporting with respect to adult behavioral health measures.
- Sec. 2212. Report on innovative State initiatives and strategies to provide housing-related services and supports to individuals struggling with substance use disorders under Medicaid.
- Sec. 2213. Technical assistance and support for innovative State strategies to provide housing-related supports under Medicaid.

Subtitle C—Human Services

- Sec. 2301. Supporting family-focused residential treatment.
- Sec. 2302. Improving recovery and reunifying families.
- Sec. 2303. Building capacity for family-focused residential treatment.

Subtitle D—Synthetics Trafficking and Overdose Prevention

- Sec. 2401. Short title.
- Sec. 2402. Customs fees.
- Sec. 2403. Mandatory advance electronic information for postal shipments.
- Sec. 2404. International postal agreements.
- Sec. 2405. Cost recoupment.
- Sec. 2406. Development of technology to detect illicit narcotics.
- Sec. 2407. Civil penalties for postal shipments.
- Sec. 2408. Report on violations of arrival, reporting, entry, and clearance requirements and falsity or lack of manifest.
- Sec. 2409. Effective date; regulations.

TITLE III—JUDICIARY

Subtitle A—Access to Increased Drug Disposal

- Sec. 3101. Short title.
- Sec. 3102. Definitions.
- Sec. 3103. Authority to make grants.
- Sec. 3104. Application.
- Sec. 3105. Use of grant funds.
- Sec. 3106. Eligibility for grant.
- Sec. 3107. Duration of grants.
- Sec. 3108. Accountability and oversight.
- Sec. 3109. Duration of program.
- Sec. 3110. Authorization of appropriations.

Subtitle B—Using Data To Prevent Opioid Diversion

- Sec. 3201. Short title.
- Sec. 3202. Purpose.
- Sec. 3203. Amendments.
- Sec. 3204. Report.

Subtitle C—Substance Abuse Prevention

- Sec. 3301. Short title.
- Sec. 3302. Reauthorization of the Office of National Drug Control Policy.
- Sec. 3303. Reauthorization of the Drug-Free Communities Program.
- Sec. 3304. Reauthorization of the National Community Anti-Drug Coalition Institute.
- Sec. 3305. Reauthorization of the High-Intensity Drug Trafficking Area Program.

## 5

- Sec. 3306. Reauthorization of drug court program.
- Sec. 3307. Drug court training and technical assistance.
- Sec. 3308. Drug overdose response strategy.
- Sec. 3309. Protecting law enforcement officers from accidental exposure.
- Sec. 3310. COPS Anti-Meth Program.
- Sec. 3311. COPS anti-heroin task force program.
- Sec. 3312. Comprehensive Addiction and Recovery Act education and awareness.
- Sec. 3313. Protecting children with addicted parents.
- Sec. 3314. Reimbursement of substance use disorder treatment professionals.
- Sec. 3315. Sobriety Treatment and Recovery Teams (START).
- Sec. 3316. Provider education.
- Sec. 3317. Demand reduction.
- Sec. 3318. Anti-drug media campaign.
- Sec. 3319. Technical corrections to the office of national drug control policy reauthorization act of 1998.

#### Subtitle D—Synthetic Abuse and Labeling of Toxic Substances

- Sec. 3401. Short title.
- Sec. 3402. Controlled substance analogues.

#### Subtitle E—Opioid Quota Reform

- Sec. 3501. Short title.
- Sec. 3502. Strengthening considerations for DEA opioid quotas.

#### Subtitle F—Preventing Drug Diversion

- Sec. 3601. Short title.
- Sec. 3602. Improvements to prevent drug diversion.

#### Subtitle G—Sense of Congress

- Sec. 3701. Sense of Congress.

### TITLE IV—COMMERCE

#### Subtitle A—Fighting Opioid Abuse in Transportation

- Sec. 4101. Short title.
- Sec. 4102. Rail mechanical employee controlled substances and alcohol testing.
- Sec. 4103. Rail yardmaster controlled substances and alcohol testing.
- Sec. 4104. Department of Transportation public drug and alcohol testing database.
- Sec. 4105. GAO report on Department of Transportation's collection and use of drug and alcohol testing data.
- Sec. 4106. Transportation Workplace Drug and Alcohol Testing Program; addition of fentanyl.
- Sec. 4107. Status reports on hair testing guidelines.
- Sec. 4108. Mandatory Guidelines for Federal Workplace Drug Testing Programs Using Oral Fluid.
- Sec. 4109. Electronic recordkeeping.
- Sec. 4110. Status reports on Commercial Driver's License Drug and Alcohol Clearinghouse.

#### Subtitle B—Opioid Addiction Recovery Fraud Prevention

Sec. 4201. Short title.

Sec. 4202. Definitions.

Sec. 4203. False or misleading representations with respect to opioid treatment programs and products.

1                   **TITLE I—OPIOID CRISIS**  
2                                   **RESPONSE ACT**

3   **SEC. 1001. DEFINITIONS.**

4       In this title—

5                   (1) the terms “Indian Tribe” and “tribal orga-  
6                   nization” have the meanings given the terms “In-  
7                   dian tribe” and “tribal organization” in section 4 of  
8                   the Indian Self-Determination and Education Assist-  
9                   ance Act (25 U.S.C. 5304); and

10                  (2) the term “Secretary” means the Secretary  
11                  of Health and Human Services, unless otherwise  
12                  specified.

13                   **Subtitle A—Reauthorization of**  
14                                   **Cures Funding**

15   **SEC. 1101. STATE RESPONSE TO THE OPIOID ABUSE CRISIS.**

16       (a) IN GENERAL.—Section 1003 of the 21st Century  
17   Cures Act (Public Law 114–255) is amended—

18                  (1) in subsection (a)—

19                          (A) by striking “the authorization of ap-  
20                          propriations under subsection (b) to carry out  
21                          the grant program described in subsection (c)”  
22                          and inserting “subsection (h) to carry out the

1 grant program described in subsection (b)”;  
2 and

3 (B) by inserting “and Indian Tribes” after  
4 “States”;

5 (2) by striking subsection (b);

6 (3) by redesignating subsections (c) through (e)  
7 as subsections (b) through (d), respectively;

8 (4) by redesignating subsection (f) as sub-  
9 section (j);

10 (5) in subsection (b), as so redesignated—

11 (A) in paragraph (1)—

12 (i) in the paragraph heading, by in-  
13 sserting “AND INDIAN TRIBE” after  
14 “STATE”;

15 (ii) by striking “States for the pur-  
16 pose of addressing the opioid abuse crisis  
17 within such States” and inserting “States  
18 and Indian Tribes for the purpose of ad-  
19 dressing the opioid abuse crisis within such  
20 States and Indian Tribes”;

21 (iii) by inserting “or Indian Tribes”  
22 after “preference to States”; and

23 (iv) by inserting before the period of  
24 the second sentence “or other Indian  
25 Tribes, as applicable”;

- 1 (B) in paragraph (2)—
- 2 (i) in the matter preceding subpara-
- 3 graph (A), by striking “to a State”;
- 4 (ii) in subparagraph (A), by striking
- 5 “State”;
- 6 (iii) in subparagraph (C), by inserting
- 7 “preventing diversion of controlled sub-
- 8 stances,” after “treatment programs,”;
- 9 and
- 10 (iv) in subparagraph (E), by striking
- 11 “as the State determines appropriate, re-
- 12 lated to addressing the opioid abuse crisis
- 13 within the State” and inserting “as the
- 14 State or Indian Tribe determines appro-
- 15 priate, related to addressing the opioid
- 16 abuse crisis within the State, including di-
- 17 recting resources in accordance with local
- 18 needs related to substance use disorders”;
- 19 (6) in subsection (c), as so redesignated, by
- 20 striking “subsection (e)” and inserting “subsection
- 21 (b)”;
- 22 (7) in subsection (d), as so redesignated—
- 23 (A) in the matter preceding paragraph (1),
- 24 by striking “the authorization of appropriations



1 under subsection (b)” and inserting “subsection  
2 (h)”;

3 (B) in paragraph (1), by striking “sub-  
4 section (c)” and inserting “subsection (b)”;

5 (8) by inserting after subsection (d), as so re-  
6 designated, the following:

7 “(e) INDIAN TRIBES.—

8 “(1) DEFINITION.—For purposes of this sec-  
9 tion, the term ‘Indian Tribe’ has the meaning given  
10 the term ‘Indian tribe’ in section 4 of the Indian  
11 Self-Determination and Education Assistance Act  
12 (25 U.S.C. 5304).

13 “(2) APPROPRIATE MECHANISMS.—The Sec-  
14 retary, in consultation with Indian Tribes, shall  
15 identify and establish appropriate mechanisms for  
16 Tribes to demonstrate or report the information as  
17 required under subsections (b), (c), and (d).

18 “(f) REPORT TO CONGRESS.—Not later than 1 year  
19 after the date on which amounts are first awarded after  
20 the date of enactment of the Opioid Crisis Response Act  
21 of 2018, pursuant to subsection (b), and annually there-  
22 after, the Secretary shall submit to the Committee on  
23 Health, Education, Labor, and Pensions of the Senate and  
24 the Committee on Energy and Commerce of the House  
25 of Representatives a report summarizing the information

1 provided to the Secretary in reports made pursuant to  
2 subsection (c), including the purposes for which grant  
3 funds are awarded under this section and the activities  
4 of such grant recipients.

5 “(g) TECHNICAL ASSISTANCE.—The Secretary, in-  
6 cluding through the Tribal Training and Technical Assist-  
7 ance Center of the Substance Abuse and Mental Health  
8 Services Administration, shall provide State agencies and  
9 Indian Tribes, as applicable, with technical assistance con-  
10 cerning grant application and submission procedures  
11 under this section, award management activities, and en-  
12 hancing outreach and direct support to rural and under-  
13 served communities and providers in addressing the opioid  
14 crisis.

15 “(h) AUTHORIZATION OF APPROPRIATIONS.—For  
16 purposes of carrying out the grant program under sub-  
17 section (b), there is authorized to be appropriated  
18 \$500,000,000 for each of fiscal years 2019 through 2021,  
19 to remain available until expended.

20 “(i) SET ASIDE.—Of the amounts made available for  
21 each fiscal year to award grants under subsection (b) for  
22 a fiscal year, 5 percent of such amount for such fiscal year  
23 shall be made available to Indian Tribes, and up to 15  
24 percent of such amount for such fiscal year may be set  
25 aside for States with the highest age-adjusted rate of drug

1 overdose death based on the ordinal ranking of States ac-  
2 cording to the Director of the Centers for Disease Control  
3 and Prevention.”.

4 (b) CONFORMING AMENDMENT.—Section 1004(c) of  
5 the 21st Century Cures Act (Public Law 114–255) is  
6 amended by striking “, the FDA Innovation Account, or  
7 the Account For the State Response to the Opioid Abuse  
8 Crisis” and inserting “or the FDA Innovation Account”.

## 9 **Subtitle B—Research and** 10 **Innovation**

### 11 **SEC. 1201. ADVANCING CUTTING-EDGE RESEARCH.**

12 Section 402(n)(1) of the Public Health Service Act  
13 (42 U.S.C. 282(n)(1)) is amended—

14 (1) in subparagraph (A), by striking “or”;

15 (2) in subparagraph (B), by striking the period  
16 and inserting “; or”; and

17 (3) by adding at the end the following:

18 “(C) high impact cutting-edge research  
19 that fosters scientific creativity and increases  
20 fundamental biological understanding leading to  
21 the prevention, diagnosis, or treatment of dis-  
22 eases and disorders, or research urgently re-  
23 quired to respond to a public health threat.”.

1 **SEC. 1202. PAIN RESEARCH.**

2 Section 409J(b) of the Public Health Service Act (42  
3 U.S.C. 284q(b)) is amended—

4 (1) in paragraph (5)—

5 (A) in subparagraph (A), by striking “and  
6 treatment of pain and diseases and disorders  
7 associated with pain” and inserting “treatment,  
8 and management of pain and diseases and dis-  
9 orders associated with pain, including informa-  
10 tion on best practices for utilization of non-  
11 pharmacologic treatments, non-addictive med-  
12 ical products, and other drugs or devices ap-  
13 proved or cleared by the Food and Drug Ad-  
14 ministration”;

15 (B) in subparagraph (B), by striking “on  
16 the symptoms and causes of pain;” and insert-  
17 ing the following: “on—

18 “(i) the symptoms and causes of pain,  
19 including the identification of relevant bio-  
20 markers and screening models and the epi-  
21 demiology of acute and chronic pain;

22 “(ii) the diagnosis, prevention, treat-  
23 ment, and management of acute or chronic  
24 pain, including with respect to non-phar-  
25 macologic treatments, non-addictive med-  
26 ical products, and other drugs or devices

1 approved or cleared by the Food and Drug  
2 Administration; and

3 “(iii) risk factors for, and early warn-  
4 ing signs of, substance use disorders; and”;  
5 and

6 (C) by striking subparagraphs (C) through  
7 (E) and inserting the following:

8 “(C) make recommendations to the Direc-  
9 tor of NIH—

10 “(i) to ensure that the activities of the  
11 National Institutes of Health and other  
12 Federal agencies are free of unnecessary  
13 duplication of effort;

14 “(ii) on how best to disseminate infor-  
15 mation on pain care and epidemiological  
16 data related to acute and chronic pain; and

17 “(iii) on how to expand partnerships  
18 between public entities and private entities  
19 to expand collaborative, cross-cutting re-  
20 search.”;

21 (2) by redesignating paragraph (6) as para-  
22 graph (7); and

23 (3) by inserting after paragraph (5) the fol-  
24 lowing:

1           “(6) REPORT.—The Director of NIH shall en-  
2           sure that recommendations and actions taken by the  
3           Director with respect to the topics discussed at the  
4           meetings described in paragraph (4) are included in  
5           appropriate reports to Congress.”.

6   **SEC. 1203. REPORT ON SYNTHETIC DRUG USE.**

7           (a) IN GENERAL.—Not later than 3 years after the  
8           date of the enactment of this Act, the Secretary shall sub-  
9           mit to the Committee on Health, Education, Labor, and  
10          Pensions of the Senate and the Committee on Energy and  
11          Commerce of the House of Representatives a report on  
12          the health effects of new psychoactive substances, includ-  
13          ing synthetic drugs, by adolescents and young adults.

14          (b) NEW PSYCHOACTIVE SUBSTANCE DEFINED.—  
15          For purposes of subsection (a), the term “new  
16          psychoactive substance” means a controlled substance  
17          analogue (as defined in section 102(32) of the Controlled  
18          Substances Act (21 U.S.C. 802(32))).

19   **Subtitle C—Medical Products and**  
20   **Controlled Substances Safety**

21   **SEC. 1301. CLARIFYING FDA REGULATION OF NON-ADDICT-**  
22   **IVE PAIN PRODUCTS.**

23          (a) PUBLIC MEETINGS.—Not later than one year  
24          after the date of enactment of this Act, the Secretary, act-  
25          ing through the Commissioner of Food and Drugs, shall

1 hold not less than one public meeting to address the chal-  
2 lenges and barriers of developing non-addictive medical  
3 products intended to treat pain or addiction, which may  
4 include—

5           (1) the manner by which the Secretary may in-  
6           corporate the risks of misuse and abuse of a con-  
7           trolled substance (as defined in section 102 of the  
8           Controlled Substances Act (21 U.S.C. 802) into the  
9           risk benefit assessments under subsections (d) and  
10          (e) of section 505 of the Federal Food, Drug, and  
11          Cosmetic Act (21 U.S.C. 355), section 510(k) of  
12          such Act (21 U.S.C. 360(k)), or section 515(e) of  
13          such Act (21 U.S.C. 360e(e)), as applicable;

14          (2) the application of novel clinical trial designs  
15          (consistent with section 3021 of the 21st Century  
16          Cures Act (Public Law 114–255)), use of real world  
17          evidence (consistent with section 505F of the Fed-  
18          eral Food, Drug, and Cosmetic Act (21 U.S.C.  
19          355g)), and use of patient experience data (con-  
20          sistent with section 569C of the Federal Food,  
21          Drug, and Cosmetic Act (21 U.S.C. 360bbb–8c)) for  
22          the development of non-addictive medical products  
23          intended to treat pain or addiction;

1           (3) the evidentiary standards and the develop-  
2           ment of opioid sparing data for inclusion in the la-  
3           beling of medical products; and

4           (4) the application of eligibility criteria under  
5           sections 506 and 515B of the Federal Food, Drug,  
6           and Cosmetic Act (21 U.S.C. 356, 360e–3) for non-  
7           addictive medical products intended to treat pain or  
8           addiction.

9           (b) GUIDANCE.—Not less than one year after the  
10          public meetings are conducted under subsection (a) the  
11          Secretary shall issue one or more final guidance docu-  
12          ments, or update existing guidance documents, to help ad-  
13          dress challenges to developing non-addictive medical prod-  
14          ucts to treat pain or addiction. Such guidance documents  
15          shall include information regarding—

16                 (1) how the Food and Drug Administration  
17                 may apply sections 506 and 515B of the Federal  
18                 Food, Drug, and Cosmetic Act (21 U.S.C. 356,  
19                 360e–3) to non-addictive medical products intended  
20                 to treat pain or addiction, including the cir-  
21                 cumstances under which the Secretary—

22                         (A) may apply the eligibility criteria under  
23                         such sections 506 and 515B to non-addictive  
24                         medical products intended to treat pain or ad-  
25                         diction;



1 (B) considers the risk of addiction of con-  
2 trolled substances approved to treat pain when  
3 establishing unmet medical need; and

4 (C) considers pain, pain control, or pain  
5 management in assessing whether a disease or  
6 condition is a serious or life-threatening disease  
7 or condition;

8 (2) the methods by which sponsors may evalu-  
9 ate acute and chronic pain, endpoints for non-addict-  
10 ive medical products intended to treat pain, the  
11 manner in which endpoints and evaluations of effi-  
12 cacy will be applied across and within review divi-  
13 sions, taking into consideration the etiology of the  
14 underlying disease, and the manner in which spon-  
15 sors may use surrogate endpoints, intermediate  
16 endpoints, and real world evidence;

17 (3) the manner in which the Food and Drug  
18 Administration will assess evidence to support the  
19 inclusion of opioid sparing data in the labeling of  
20 non-addictive medical products intended to treat  
21 pain, including—

22 (A) data collection methodologies, includ-  
23 ing the use of novel clinical trial designs (con-  
24 sistent with section 3021 of the 21st Century  
25 Cures Act (Public Law 114–255)) and real

1 world evidence (consistent with section 505F of  
2 the Federal Food, Drug, and Cosmetic Act (21  
3 U.S.C. 355g)), as appropriate, to support prod-  
4 uct labeling;

5 (B) ethical considerations of exposing sub-  
6 jects to controlled substances in clinical trials to  
7 develop opioid sparing data and considerations  
8 on data collection methods that reduce harm,  
9 which may include the reduction of opioid use  
10 as a clinical benefit;

11 (C) endpoints, including primary, sec-  
12 ondary, and surrogate endpoints, to evaluate  
13 the reduction of opioid use;

14 (D) best practices for communication be-  
15 tween sponsors and the agency on the develop-  
16 ment of data collection methods, including the  
17 initiation of data collection; and

18 (E) the appropriate format in which to  
19 submit such data results to the Secretary; and

20 (4) the circumstances under which the Food  
21 and Drug Administration considers misuse and  
22 abuse of a controlled substance (as defined in sec-  
23 tion 102 of the Controlled Substances Act (21  
24 U.S.C. 802) in making the risk benefit assessment  
25 under paragraphs (2) and (4) of subsection (d) of

1 section 505 of the Federal Food, Drug, and Cos-  
2 metic Act (21 U.S.C. 355) and in finding that a  
3 drug is unsafe under paragraph (1) or (2) of sub-  
4 section (e) of such section.

5 (c) DEFINITIONS.—In this section—

6 (1) the term “medical product” means a drug  
7 (as defined in section 201(g)(1) of the Federal  
8 Food, Drug, and Cosmetic Act (21 U.S.C.  
9 321(g)(1))), biological product (as defined in section  
10 351(i) of the Public Health Service Act (42 U.S.C.  
11 262(i))), or device (as defined in section 201(h) of  
12 the Federal Food, Drug, and Cosmetic Act (21  
13 U.S.C. 321(h))); and

14 (2) the term “opioid sparing” means reducing,  
15 replacing, or avoiding the use of opioids or other  
16 controlled substances.

17 **SEC. 1302. CLARIFYING FDA PACKAGING AUTHORITIES.**

18 (a) ADDITIONAL POTENTIAL ELEMENTS OF STRAT-  
19 EGY.—Section 505–1(e) of the Federal Food, Drug, and  
20 Cosmetic Act (21 U.S.C. 355–1(e)) is amended by adding  
21 at the end the following:

22 “(4) PACKAGING AND DISPOSAL.—The Sec-  
23 retary may require a risk evaluation mitigation  
24 strategy for a drug for which there is a serious risk  
25 of an adverse drug experience described in subpara-

1 graph (B) or (C) of subsection (b)(1), taking into  
2 consideration the factors described in subparagraphs  
3 (C) and (D) of subsection (f)(2) and in consultation  
4 with other relevant Federal agencies with authorities  
5 over drug packaging, which may include requiring  
6 that—

7 “(A) the drug be made available for dis-  
8 pensing to certain patients in unit dose pack-  
9 aging, packaging that provides a set duration,  
10 or another packaging system that the Secretary  
11 determines may mitigate such serious risk; or

12 “(B) the drug be dispensed to certain pa-  
13 tients with a safe disposal packaging or safe  
14 disposal system for purposes of rendering drugs  
15 non-retrievable (as defined in section 1300.05  
16 of title 21, Code of Federal Regulations (or any  
17 successor regulation)) if the Secretary has de-  
18 termines that such safe disposal packaging or  
19 system may mitigate such serious risk and ex-  
20 ists in sufficient quantities.”.

21 (b) ASSURING ACCESS AND MINIMIZING BURDEN.—  
22 Section 505–1(f)(2)(C) of the Federal Food, Drug, and  
23 Cosmetic Act (21 U.S.C. 355–1(f)(2)(C)) is amended—

24 (1) in clause (i) by striking “and” at the end;  
25 and

1 (2) by adding at the end the following:

2 “(iii) patients with functional needs;  
3 and”.

4 (c) APPLICATION TO ABBREVIATED NEW DRUG AP-  
5 PPLICATIONS.—Section 505–1(i) of the Federal Food,  
6 Drug, and Cosmetic Act (21 U.S.C. 355–1(i)) is amend-  
7 ed—

8 (1) in paragraph (1)—

9 (A) by redesignating subparagraph (B) as  
10 subparagraph (C); and

11 (B) inserting after subparagraph (A) the  
12 following:

13 “(B) A packaging or disposal requirement,  
14 if required under subsection (e)(4) for the ap-  
15 plicable listed drug.”; and

16 (2) in paragraph (2)—

17 (A) in subparagraph (A), by striking  
18 “and” at the end;

19 (B) by redesignating subparagraph (B) as  
20 subparagraph (C); and

21 (C) by inserting after subparagraph (A)  
22 the following:

23 “(B) shall permit packaging systems and  
24 safe disposal packaging or safe disposal systems  
25 that are different from those required for the

1 applicable listed drug under subsection (e)(4);  
2 and”.

3 **SEC. 1303. STRENGTHENING FDA AND CBP COORDINATION**  
4 **AND CAPACITY.**

5 (a) IN GENERAL.—The Secretary, acting through the  
6 Commissioner of Food and Drugs, shall coordinate with  
7 the Secretary of Homeland Security to carry out activities  
8 related to customs and border protection and response to  
9 illegal controlled substances and drug imports, including  
10 at sites of import (such as international mail facilities).  
11 Such Secretaries may carry out such activities through a  
12 memorandum of understanding between the Food and  
13 Drug Administration and the U.S. Customs and Border  
14 Protection.

15 (b) FDA IMPORT FACILITIES AND INSPECTION CA-  
16 PACITY.—

17 (1) IN GENERAL.—In carrying out this section,  
18 the Secretary shall, in collaboration with the Sec-  
19 retary of Homeland Security and the Postmaster  
20 General of the United States Postal Service, provide  
21 that import facilities in which the Food and Drug  
22 Administration operates or carries out activities re-  
23 lated to drug imports within the international mail  
24 facilities include—

1 (A) facility upgrades and improved capac-  
2 ity in order to increase and improve inspection  
3 and detection capabilities, which may include,  
4 as the Secretary determines appropriate—

5 (i) improvements to facilities, such as  
6 upgrades or renovations, and support for  
7 the maintenance of existing import facili-  
8 ties and sites to improve coordination be-  
9 tween Federal agencies;

10 (ii) the construction of, or upgrades  
11 to, laboratory capacity for purposes of de-  
12 tection and testing of imported goods;

13 (iii) upgrades to the security of import  
14 facilities; and

15 (iv) innovative technology and equip-  
16 ment to facilitate improved and near-real-  
17 time information sharing between the Food  
18 and Drug Administration, the Department  
19 of Homeland Security, and the United  
20 States Postal Service; and

21 (B) innovative technology, including con-  
22 trolled substance detection and testing equip-  
23 ment and other applicable technology, in order  
24 to collaborate with the U.S. Customs and Bor-  
25 der Protection to share near-real-time informa-

1           tion, including information about test results,  
2           as appropriate.

3           (2) INNOVATIVE TECHNOLOGY.—Any tech-  
4           nology used in accordance with paragraph (1)(B)  
5           shall be interoperable with technology used by other  
6           relevant Federal agencies, including the U.S. Cus-  
7           toms and Border Protection, as the Secretary deter-  
8           mines appropriate.

9           (c) REPORT.—Not later than 6 months after the date  
10          of enactment of this Act, the Secretary, in consultation  
11          with the Secretary of Homeland Security and the Post-  
12          master General of the United States Postal Service, shall  
13          report to the relevant committees of Congress on the im-  
14          plementation of this section, including a summary of  
15          progress made towards near-real-time information sharing  
16          and the interoperability of such technologies.

17          (d) AUTHORIZATION OF APPROPRIATIONS.—Out of  
18          amounts otherwise available to the Secretary, the Sec-  
19          retary may allocate such sums as may be necessary for  
20          purposes of carrying out this section.

21          **SEC. 1304. CLARIFYING FDA POST-MARKET AUTHORITIES.**

22          Section 505–1(b)(1)(E) of the Federal Food, Drug,  
23          and Cosmetic Act (21 U.S.C. 355–1(b)(1)(E)) is amended  
24          by striking “of the drug” and inserting “of the drug,  
25          which may include reduced effectiveness under the condi-



1 tions of use prescribed in the labeling of such drug, but  
2 which may not include reduced effectiveness that is in ac-  
3 cordance with such labeling”.

4 **SEC. 1305. RESTRICTING ENTRANCE OF ILLICIT DRUGS.**

5 (a) IN GENERAL.—The Secretary, acting through the  
6 Commissioner of Food and Drugs, upon discovering or re-  
7 ceiving, in a package being offered for import, a controlled  
8 substance that is offered for import in violation of any  
9 requirement of the Controlled Substances Act (21 U.S.C.  
10 801 et seq.), the Controlled Substances Import and Ex-  
11 port Act (21 U.S.C. 951 et seq.), the Federal Food, Drug,  
12 and Cosmetic Act (21 U.S.C. 301 et seq.), or any other  
13 applicable law, shall transfer such package to the U.S.  
14 Customs and Border Protection. If the Secretary identifies  
15 additional packages that appear to be the same as such  
16 package containing a controlled substance, such additional  
17 packages may also be transferred to U.S. Customs and  
18 Border Protection. The U.S. Customs and Border Protec-  
19 tion shall receive such packages consistent with the re-  
20 quirements of the Controlled Substances Act (21 U.S.C.  
21 801 et seq.).

22 (b) DEBARMENT, TEMPORARY DENIAL OF AP-  
23 PROVAL, AND SUSPENSION.—

1           (1) IN GENERAL.—Section 306(b) of the Fed-  
2           eral Food, Drug, and Cosmetic Act (21 U.S.C.  
3           335a(b)) is amended—

4                   (A) in paragraph (1)—

5                           (i) in the matter preceding subpara-  
6                           graph (A), by inserting “or (3)” after  
7                           “paragraph (2)”;

8                           (ii) in subparagraph (A), by striking  
9                           the comma at the end and inserting a  
10                          semicolon;

11                          (iii) in subparagraph (B), by striking  
12                          “, or” and inserting a semicolon;

13                          (iv) in subparagraph (C), by striking  
14                          the period and inserting “; or”; and

15                          (v) by adding at the end the following:  
16                          “(D) a person from importing or offering  
17                          for import into the United States a drug.”; and

18                   (B) in paragraph (3)—

19                           (i) in the heading, by striking  
20                           “FOOD”;

21                           (ii) in subparagraph (A), by striking  
22                           “; or” and inserting a semicolon;

23                           (iii) in subparagraph (B), by striking  
24                           the period and inserting a semicolon; and

1 (iv) by adding at the end the fol-  
2 lowing:

3 “(C) the person has been convicted of a  
4 felony for conduct relating to the importation  
5 into the United States of any drug or controlled  
6 substance (as defined in section 102 of the Con-  
7 trolled Substances Act);

8 “(D) the person has engaged in a pattern  
9 of importing or offering for import—

10 “(i) controlled substances that are  
11 prohibited from importation under section  
12 401(m) of the Tariff Act of 1930 (19  
13 U.S.C. 1401(m)); or

14 “(ii) adulterated or misbranded drugs  
15 that are—

16 “(I) not designated in an author-  
17 ized electronic data interchange sys-  
18 tem as a product that is regulated by  
19 the Secretary; or

20 “(II) knowingly or intentionally  
21 falsely designated in an authorized  
22 electronic data interchange system as  
23 a product that is regulated by the  
24 Secretary.”.

1           (2) PROHIBITED ACT.—Section 301(cc) of the  
2       Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
3       331(cc)) is amended by inserting “or a drug” after  
4       “food”.

5           (c) IMPORTS AND EXPORTS.—Section 801(a) of the  
6       Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381(a))  
7       is amended—

8           (1) by striking the second sentence;

9           (2) by striking “If it appears” and inserting  
10       “Subject to subsection (b), if it appears”;

11          (3) by striking “regarding such article, then  
12       such article shall be refused” and inserting the fol-  
13       lowing: “regarding such article, or (5) such article is  
14       being imported or offered for import in violation of  
15       section 301(cc), then any such article described in  
16       any of clauses (1) through (5) may be refused ad-  
17       mission. If it appears from the examination of such  
18       samples or otherwise that the article is a counterfeit  
19       drug, such article shall be refused admission.”;

20          (4) by striking “this Act, then such article shall  
21       be refused admission” and inserting “this Act, then  
22       such article may be refused admission”; and

23          (5) by striking “Clause (2) of the third sen-  
24       tence” and all that follows through the period at the  
25       end and inserting the following: “Neither clause (2)

1 nor clause (5) of the second sentence of this sub-  
2 section shall be construed to prohibit the admission  
3 of narcotic drugs, the importation of which is per-  
4 mitted under the Controlled Substances Import and  
5 Export Act.”.

6 (d) CERTAIN ILLICIT ARTICLES.—Section 801 of the  
7 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381)  
8 is amended by adding at the end the following—

9 “(t) ILLICIT ARTICLES CONTAINING ACTIVE PHAR-  
10 MACEUTICAL INGREDIENTS.—

11 “(1) IN GENERAL.—For purposes of this sec-  
12 tion, an article that is being imported or offered for  
13 import into the United States may be treated by the  
14 Secretary as a drug if the article—

15 “(A) is not—

16 “(i) accompanied by an electronic im-  
17 port entry for such article submitted using  
18 an authorized electronic data interchange  
19 system; and

20 “(ii) designated in such a system as  
21 an article regulated by the Secretary  
22 (which may include regulation as a drug, a  
23 device, or a dietary supplement; and

24 “(B) is an ingredient that presents signifi-  
25 cant public health concern and is, or contains—

1 “(i) an active ingredient in a drug—  
2 “(I) that is approved under sec-  
3 tion 505 or licensed under section 351  
4 of the Public Health Service Act; or  
5 “(II) for which—  
6 “(aa) an investigational use  
7 exemption is in effect under sec-  
8 tion 505(i) of this Act or section  
9 351(a) of the Public Health Serv-  
10 ice Act; and  
11 “(bb) a substantial clinical  
12 investigation has been instituted,  
13 and such investigation has been  
14 made public; or  
15 “(ii) a substance that has a chemical  
16 structure that is substantially similar to  
17 the chemical structure of an active ingre-  
18 dient in a drug or biological product de-  
19 scribed in subclause (I) or (II) of clause  
20 (i).

21 “(2) EFFECT.—This subsection shall not be  
22 construed to bear upon any determination of wheth-  
23 er an article is a drug within the meaning of section  
24 201(g), other than for the purposes described in  
25 paragraph (1).”.

1 **SEC. 1306. FIRST RESPONDER TRAINING.**

2 Section 546 of the Public Health Service Act (42  
3 U.S.C. 290ee-1) is amended—

4 (1) in subsection (c)—

5 (A) in paragraph (2), by striking “and” at  
6 the end;

7 (B) in paragraph (3), by striking the pe-  
8 riod and inserting “; and”; and

9 (C) by adding at the end the following:

10 “(4) train and provide resources for first re-  
11 sponders and members of other key community sec-  
12 tors on safety around fentanyl, carfentanil, and  
13 other dangerous licit and illicit drugs to protect  
14 themselves from exposure to such drugs and respond  
15 appropriately when exposure occurs.”;

16 (2) in subsection (d), by striking “and mecha-  
17 nisms for referral to appropriate treatment for an  
18 entity receiving a grant under this section” and in-  
19 sserting “mechanisms for referral to appropriate  
20 treatment, and safety around fentanyl, carfentanil,  
21 and other dangerous licit and illicit drugs”;

22 (3) in subsection (f)—

23 (A) in paragraph (3), by striking “and” at  
24 the end;

25 (B) in paragraph (4), by striking the pe-  
26 riod and inserting “; and”; and

1 (C) by adding at the end the following:

2 “(5) the number of first responders and mem-  
3 bers of other key community sectors trained on safe-  
4 ty around fentanyl, carfentanil, and other dangerous  
5 licit and illicit drugs.”;

6 (4) by redesignating subsection (g) as sub-  
7 section (h);

8 (5) by inserting after subsection (f) the fol-  
9 lowing:

10 “(g) OTHER KEY COMMUNITY SECTORS.—In this  
11 section, the term ‘other key community sectors’ includes  
12 substance abuse treatment providers, emergency medical  
13 services agencies, agencies and organizations working with  
14 prison and jail populations and offender reentry programs,  
15 health care providers, harm reduction groups, pharmacies,  
16 community health centers, tribal health facilities, and  
17 mental health providers.”; and

18 (6) in subsection (h), as so redesignated, by  
19 striking “\$12,000,000 for each of fiscal years 2017  
20 through 2021” and inserting “\$36,000,000 for each  
21 of fiscal years 2019 through 2023”.



1 **SEC. 1307. DISPOSAL OF CONTROLLED SUBSTANCES OF**  
2 **HOSPICE PATIENTS.**

3 (a) IN GENERAL.—Section 302(g) of the Controlled  
4 Substances Act (21 U.S.C. 822(g)) is amended by adding  
5 at the end the following:

6 “(5)(A) An employee of a qualified hospice program  
7 acting within the scope of employment may handle, in the  
8 place of residence of a hospice patient, any controlled sub-  
9 stance that was lawfully dispensed to the hospice patient,  
10 for the purpose of assisting in the disposal of the con-  
11 trolled substance—

12 “(i) after the hospice patient’s death;

13 “(ii) if the controlled substance is expired; or

14 “(iii) if—

15 “(I) the employee is—

16 “(aa) the physician of the hospice pa-  
17 tient; and

18 “(bb) registered under section 303(f);

19 and

20 “(II) the hospice patient no longer requires  
21 the controlled substance because the plan of  
22 care of the hospice patient has been modified.

23 “(B) In this paragraph:

24 “(i) The term ‘employee of a qualified hospice  
25 program’ means a physician, physician assistant,  
26 registered nurse, or nurse practitioner who—

1           “(I) is employed by, or is acting pursuant  
2           to arrangements made with, a qualified hospice  
3           program; and

4           “(II) is licensed or certified to perform  
5           such employment, or such activities arranged by  
6           the qualified hospice program, in accordance  
7           with applicable State law.

8           “(ii) The terms ‘hospice care’ and ‘hospice pro-  
9           gram’ have the meanings given those terms in sec-  
10          tion 1861(dd) of the Social Security Act (42 U.S.C.  
11          1395x(dd)).

12          “(iii) The term ‘hospice patient’ means an indi-  
13          vidual receiving hospice care.

14          “(iv) The term ‘qualified hospice program’  
15          means a hospice program that—

16               “(I) has written policies and procedures for  
17               employees of the hospice program to use when  
18               assisting in the disposal of the controlled sub-  
19               stances of a hospice patient in a circumstance  
20               described in clause (i), (ii), or (iii) of subpara-  
21               graph (A);

22               “(II) at the time when the controlled sub-  
23               stances are first ordered—

24                       “(aa) provides a copy of the written  
25                       policies and procedures to the hospice pa-

1           tient or hospice patient representative and  
2           the family of the hospice patient;

3                   “(bb) discusses the policies and proce-  
4           dures with the hospice patient or hospice  
5           patient’s representative and the hospice  
6           patient’s family in a language and manner  
7           that such individuals understand to ensure  
8           that such individuals are informed regard-  
9           ing the safe disposal of controlled sub-  
10          stances; and

11                   “(cc) documents in the clinical record  
12          of the hospice patient that the written poli-  
13          cies and procedures were provided and dis-  
14          cussed with the hospice patient or hospice  
15          patient’s representative; and

16                   “(III) at the time when an employee of the  
17          hospice program assists in the disposal of con-  
18          trolled substances of a hospice patient, docu-  
19          ments in the clinical record of the hospice pa-  
20          tient a list of all controlled substances disposed  
21          of.

22           “(C) The Attorney General may, by regulation, in-  
23          clude additional types of licensed medical professionals in  
24          the definition of the term ‘employee of a qualified hospice  
25          program’ under subparagraph (B).”.

1 (b) NO REGISTRATION REQUIRED.—Section 302(c)  
2 of the Controlled Substances Act (21 U.S.C. 822(c)) is  
3 amended by adding at the end the following:

4 “(4) An employee of a qualified hospice pro-  
5 gram for the purpose of assisting in the disposal of  
6 a controlled substance in accordance with subsection  
7 (g)(5), except as provided in subparagraph (A)(iii)  
8 of that subsection.”.

9 (c) GUIDANCE.—The Attorney General may issue  
10 guidance to qualified hospice programs to assist the pro-  
11 grams in satisfying the requirements under paragraph (5)  
12 of section 302(g) of the Controlled Substances Act (21  
13 U.S.C. 822(g)), as added by subsection (a).

14 (d) STATE AND LOCAL AUTHORITY.—Nothing in this  
15 section or the amendments made by this section shall be  
16 construed to prevent a State or local government from im-  
17 posing additional controls or restrictions relating to the  
18 regulation of the disposal of controlled substances in hos-  
19 pice care or hospice programs.

20 **SEC. 1308. GAO STUDY AND REPORT ON HOSPICE SAFE**  
21 **DRUG MANAGEMENT.**

22 (a) STUDY.—

23 (1) IN GENERAL.—The Comptroller General of  
24 the United States (in this section referred to as the  
25 “Comptroller General”) shall conduct a study on the

1 requirements applicable to and challenges of hospice  
2 programs with regard to the management and dis-  
3 posal of controlled substances in the home of an in-  
4 dividual.

5 (2) CONTENTS.—In conducting the study under  
6 paragraph (1), the Comptroller General shall in-  
7 clude—

8 (A) an overview of challenges encountered  
9 by hospice programs regarding the disposal of  
10 controlled substances, such as opioids, in a  
11 home setting, including any key changes in poli-  
12 cies, procedures, or best practices for the dis-  
13 posal of controlled substances over time; and

14 (B) a description of Federal requirements,  
15 including requirements under the Medicare pro-  
16 gram, for hospice programs regarding the dis-  
17 posal of controlled substances in a home set-  
18 ting, and oversight of compliance with those re-  
19 quirements.

20 (b) REPORT.—Not later than 18 months after the  
21 date of enactment of this Act, the Comptroller General  
22 shall submit to Congress a report containing the results  
23 of the study conducted under subsection (a), together with  
24 recommendations, if any, for such legislation and adminis-

1 trative action as the Comptroller General determines ap-  
2 propriate.

3 **SEC. 1309. DELIVERY OF A CONTROLLED SUBSTANCE BY A**  
4 **PHARMACY TO BE ADMINISTERED BY INJEC-**  
5 **TION OR IMPLANTATION.**

6 (a) IN GENERAL.—The Controlled Substances Act is  
7 amended by inserting after section 309 (21 U.S.C. 829)  
8 the following:

9 “DELIVERY OF A CONTROLLED SUBSTANCE BY A  
10 PHARMACY TO AN ADMINISTERING PRACTITIONER

11 “SEC. 309A. (a) IN GENERAL.—Notwithstanding  
12 section 102(10), a pharmacy may deliver a controlled sub-  
13 stance to a practitioner in accordance with a prescription  
14 that meets the requirements of this title and the regula-  
15 tions issued by the Attorney General under this title, for  
16 the purpose of administering the controlled substance by  
17 the practitioner if—

18 “(1) the controlled substance is delivered by the  
19 pharmacy to the prescribing practitioner or the prac-  
20 titioner administering the controlled substance, as  
21 applicable, at the location listed on the practitioner’s  
22 certificate of registration issued under this title;

23 “(2) in the case of administering of the con-  
24 trolled substance for the purpose of maintenance or  
25 detoxification treatment under section 303(g)(2)—

1           “(A) the practitioner who issued the pre-  
2           scription is a qualifying practitioner authorized  
3           under, and acting within the scope of that sec-  
4           tion; and

5           “(B) the controlled substance is to be ad-  
6           ministered by injection or implantation;

7           “(3) the pharmacy and the practitioner are au-  
8           thorized to conduct the activities specified in this  
9           section under the law of the State in which such ac-  
10          tivities take place;

11          “(4) the prescription is not issued to supply any  
12          practitioner with a stock of controlled substances for  
13          the purpose of general dispensing to patients;

14          “(5) except as provided in subsection (b), the  
15          controlled substance is to be administered only to  
16          the patient named on the prescription not later than  
17          14 days after the date of receipt of the controlled  
18          substance by the practitioner; and

19          “(6) notwithstanding any exceptions under sec-  
20          tion 307, the prescribing practitioner, and the prac-  
21          titioner administering the controlled substance, as  
22          applicable, maintain complete and accurate records  
23          of all controlled substances delivered, received, ad-  
24          ministered, or otherwise disposed of under this sec-  
25          tion, including the persons to whom controlled sub-

1 stances were delivered and such other information as  
2 may be required by regulations of the Attorney Gen-  
3 eral.

4 “(b) MODIFICATION OF NUMBER OF DAYS BEFORE  
5 WHICH CONTROLLED SUBSTANCE SHALL BE ADMINIS-  
6 TERED.—

7 “(1) INITIAL 2-YEAR PERIOD.—During the 2-  
8 year period beginning on the date of enactment of  
9 this section, the Attorney General, in coordination  
10 with the Secretary, may reduce the number of days  
11 described in subsection (a)(5) if the Attorney Gen-  
12 eral determines that such reduction will—

13 “(A) reduce the risk of diversion; or

14 “(B) protect the public health.

15 “(2) MODIFICATIONS AFTER SUBMISSION OF  
16 REPORT.—After the date on which the report de-  
17 scribed in subsection (c) is submitted, the Attorney  
18 General, in coordination with the Secretary, may  
19 modify the number of days described in subsection  
20 (a)(5).

21 “(3) MINIMUM NUMBER OF DAYS.—Any modi-  
22 fication under this subsection shall be for a period  
23 of not less than 7 days.”.

24 (b) STUDY AND REPORT.—Not later than 2 years  
25 after the date of enactment of this section, the Comp-



1 troller General of the United States shall conduct a study  
2 and submit to Congress a report on access to and potential  
3 diversion of controlled substances administered by injec-  
4 tion or implantation.

5 (c) TECHNICAL AND CONFORMING AMENDMENT.—

6 The table of contents for the Comprehensive Drug Abuse  
7 Prevention and Control Act of 1970 is amended by insert-  
8 ing after the item relating to section 309 the following:

“Sec. 309A. Delivery of a controlled substance by a pharmacy to an admin-  
istering practitioner.”.

9 **Subtitle D—Treatment and**  
10 **Recovery**

11 **SEC. 1401. COMPREHENSIVE OPIOID RECOVERY CENTERS.**

12 (a) IN GENERAL.—The Secretary shall award grants  
13 on a competitive basis to eligible entities to establish or  
14 operate a comprehensive opioid recovery center (referred  
15 to in this section as a “Center”). A Center may be a single  
16 entity or an integrated delivery network.

17 (b) GRANT PERIOD.—

18 (1) IN GENERAL.—A grant awarded under sub-  
19 section (a) shall be for a period not more than 5  
20 years.

21 (2) RENEWAL.—A grant awarded under sub-  
22 section (a) may be renewed, on a competitive basis,  
23 for additional periods of time, as determined by the  
24 Secretary. In determining whether to renew a grant

1 under this paragraph, the Secretary shall consider  
2 the data submitted under subsection (h).

3 (c) MINIMUM NUMBER OF GRANTS.—The Secretary  
4 shall allocate the amounts made available under sub-  
5 section (j) such that not fewer than 10 grants may be  
6 awarded. Not more than one grant shall be made to enti-  
7 ties in a single State for any one period.

8 (d) APPLICATION.—

9 (1) ELIGIBLE ENTITY.—An entity is eligible for  
10 a grant under this section if the entity offers treat-  
11 ment and other services for individuals with a sub-  
12 stance use disorder.

13 (2) SUBMISSION OF APPLICATION.—In order to  
14 be eligible for a grant under subsection (a), an enti-  
15 ty shall submit an application to the Secretary at  
16 such time and in such manner as the Secretary may  
17 require. Such application shall include—

18 (A) evidence that such entity carries out,  
19 or is capable of coordinating with other entities  
20 to carry out, the activities described in sub-  
21 section (g); and

22 (B) such other information as the Sec-  
23 retary may require.

24 (e) PRIORITY.—In awarding grants under subsection  
25 (a), the Secretary shall give priority to eligible entities lo-

1 cated in a State or Indian Tribe with an age-adjusted rate  
2 of drug overdose deaths that is above the national over-  
3 dose mortality rate, as determined by the Director of the  
4 Centers for Disease Control and Prevention.

5 (f) PREFERENCE.—In awarding grants under sub-  
6 section (a), the Secretary may give preference to eligible  
7 entities utilizing technology-enabled collaborative learning  
8 and capacity building models, including such models as de-  
9 fined in section 2 of the Expanding Capacity for Health  
10 Outcomes Act (Public Law 114–270; 130 Stat. 1395), to  
11 conduct the activities described in this section.

12 (g) CENTER ACTIVITIES.—Each Center shall, at a  
13 minimum, carry out the following activities directly,  
14 through referral, or through contractual arrangements,  
15 which may include carrying out such activities through  
16 technology-enabled collaborative learning and capacity  
17 building models described in subsection (f):

18 (1) TREATMENT AND RECOVERY SERVICES.—

19 Each Center shall—

20 (A) ensure that intake and evaluations  
21 meet the individualized clinical needs of pa-  
22 tients, including by offering assessments for  
23 services and care recommendations through  
24 independent, evidence-based verification proc-

1           esses for reviewing patient placement in treat-  
2           ment settings;

3                   (B) provide the full continuum of treat-  
4           ment services, including—

5                           (i) all drugs approved by the Food  
6                           and Drug Administration to treat sub-  
7                           stance use disorders, pursuant to Federal  
8                           and State law;

9                           (ii) medically supervised withdrawal  
10                          management that includes patient evalua-  
11                          tion, stabilization, and readiness for and  
12                          entry into treatment;

13                          (iii) counseling provided by a program  
14                          counselor or other certified professional  
15                          who is licensed and qualified by education,  
16                          training, or experience to assess the psy-  
17                          chological and sociological background of  
18                          patients, to contribute to the appropriate  
19                          treatment plan for the patient, and to  
20                          monitor patient progress;

21                          (iv) treatment, as appropriate, for pa-  
22                          tients with co-occurring substance use and  
23                          mental disorders;

1 (v) testing, as appropriate, for infec-  
2 tions commonly associated with illicit drug  
3 use;

4 (vi) residential rehabilitation, and out-  
5 patient and intensive outpatient programs;

6 (vii) recovery housing;

7 (viii) community-based and peer re-  
8 covery support services;

9 (ix) job training, job placement assist-  
10 ance, and continuing education assistance  
11 to support reintegration into the work-  
12 force; and

13 (x) other best practices to provide the  
14 full continuum of treatment and services,  
15 as determined by the Secretary;

16 (C) ensure that all programs covered by  
17 the Center include medication-assisted treat-  
18 ment, as appropriate, and do not exclude indi-  
19 viduals receiving medication-assisted treatment  
20 from any service;

21 (D) periodically conduct patient assess-  
22 ments to support sustained and clinically sig-  
23 nificant recovery, as defined by the Assistant  
24 Secretary for Mental Health and Substance  
25 Use;

1 (E) administer an onsite pharmacy and  
2 provide toxicology services, for purposes of car-  
3 rying out this section; and

4 (F) operate a secure, confidential, and  
5 interoperable electronic health information sys-  
6 tem.

7 (2) OUTREACH.—Each Center shall carry out  
8 outreach activities to publicize the services offered  
9 through the Centers, which may include—

10 (A) training and supervising outreach  
11 staff, as appropriate, to work with State and  
12 local health departments, health care providers,  
13 the Indian Health Service, State and local edu-  
14 cational agencies, schools funded by the Indian  
15 Bureau of Education, institutions of higher  
16 education, State and local workforce develop-  
17 ment boards, State and local community action  
18 agencies, public safety officials, first respond-  
19 ers, Indian Tribes, child welfare agencies, as  
20 appropriate, and other community partners and  
21 the public, including patients, to identify and  
22 respond to community needs;

23 (B) ensuring that the entities described in  
24 subparagraph (A) are aware of the services of  
25 the Center; and

1           (C) disseminating and making publicly  
2           available, including through the internet, evi-  
3           dence-based resources that educate profes-  
4           sionals and the public on opioid use disorder  
5           and other substance use disorders, including co-  
6           occurring substance use and mental disorders.

7           (h) DATA REPORTING AND PROGRAM OVERSIGHT.—  
8           With respect to a grant awarded under subsection (a), not  
9           later than 90 days after the end of the first year of the  
10          grant period, and annually thereafter for the duration of  
11          the grant period (including the duration of any renewal  
12          period for such grant), the entity shall submit data, as  
13          appropriate, to the Secretary regarding—

14               (1) the programs and activities funded by the  
15               grant;

16               (2) health outcomes of the population of indi-  
17               viduals with a substance use disorder who received  
18               services from the Center, evaluated by an inde-  
19               pendent program evaluator through the use of out-  
20               comes measures, as determined by the Secretary;

21               (3) the retention rate of program participants;  
22               and

23               (4) any other information that the Secretary  
24               may require for the purpose of ensuring that the  
25               Center is complying with all the requirements of the

1 grant, including providing the full continuum of  
2 services described in subsection (g)(1)(B).

3 (i) PRIVACY.—The provisions of this section, includ-  
4 ing with respect to data reporting and program oversight,  
5 shall be subject to all applicable Federal and State privacy  
6 laws.

7 (j) AUTHORIZATION OF APPROPRIATIONS.—There is  
8 authorized to be appropriated \$10,000,000 for each of fis-  
9 cal years 2019 through 2023 for purposes of carrying out  
10 this section.

11 (k) REPORTS TO CONGRESS.—

12 (1) PRELIMINARY REPORT.—Not later than 3  
13 years after the date of the enactment of this Act, the  
14 Secretary shall submit to Congress a preliminary re-  
15 port that analyzes data submitted under subsection  
16 (h).

17 (2) FINAL REPORT.—Not later than 2 years  
18 after submitting the preliminary report required  
19 under paragraph (1), the Secretary shall submit to  
20 Congress a final report that includes—

21 (A) an evaluation of the effectiveness of  
22 the comprehensive services provided by the Cen-  
23 ters established or operated pursuant to this  
24 section with respect to health outcomes of the  
25 population of individuals with substance use



1 disorder who receive services from the Center,  
2 which shall include an evaluation of the effec-  
3 tiveness of services for treatment and recovery  
4 support and to reduce relapse, recidivism, and  
5 overdose; and

6 (B) recommendations, as appropriate, re-  
7 garding ways to improve Federal programs re-  
8 lated to substance use disorders, which may in-  
9 clude dissemination of best practices for the  
10 treatment of substance use disorders to health  
11 care professionals.

12 **SEC. 1402. PROGRAM TO SUPPORT COORDINATION AND**  
13 **CONTINUATION OF CARE FOR DRUG OVER-**  
14 **DOSE PATIENTS.**

15 (a) IN GENERAL.—The Secretary shall identify or fa-  
16 cilitate the development of best practices for—

17 (1) emergency treatment of known or suspected  
18 drug overdose;

19 (2) the use of recovery coaches, as appropriate,  
20 to encourage individuals who experience a non-fatal  
21 overdose to seek treatment for substance use dis-  
22 order and to support coordination and continuation  
23 of care;

1           (3) coordination and continuation of care and  
2 treatment, including, as appropriate, through refer-  
3 rals, of individuals after an opioid overdose; and

4           (4) the provision of overdose reversal medica-  
5 tion, as appropriate.

6           (b) GRANT ESTABLISHMENT AND PARTICIPATION.—

7           (1) IN GENERAL.—The Secretary shall award  
8 grants on a competitive basis to eligible entities to  
9 support implementation of voluntary programs for  
10 care and treatment of individuals after an opioid  
11 overdose, as appropriate, which may include imple-  
12 mentation of the best practices described in sub-  
13 section (a).

14           (2) ELIGIBLE ENTITY.—In this section, the  
15 term “eligible entity” means—

16                   (A) a State alcohol or drug agency;

17                   (B) an Indian Tribe or tribal organization;

18                   or

19                   (C) an entity that offers treatment or  
20 other services for individuals in response to, or  
21 following, drug overdoses or a drug overdose, in  
22 consultation with a State alcohol and drug  
23 agency.

24           (3) APPLICATION.—An eligible entity desiring a  
25 grant under this section shall submit an application

1 to the Secretary, at such time and in such manner  
2 as the Secretary may require, that includes—

3 (A) evidence that such eligible entity car-  
4 ries out, or is capable of contracting and coordi-  
5 nating with other community entities to carry  
6 out, the activities described in paragraph (4);

7 (B) evidence that such eligible entity will  
8 work with a recovery community organization to  
9 recruit, train, hire, mentor, and supervise recov-  
10 ery coaches and fulfill the requirements de-  
11 scribed in paragraph (4)(A); and

12 (C) such additional information as the Sec-  
13 retary may require.

14 (4) USE OF GRANT FUNDS.—An eligible entity  
15 awarded a grant under this section shall use such  
16 grant funds to—

17 (A) hire or utilize recovery coaches to help  
18 support recovery, including by—

19 (i) connecting patients to a continuum  
20 of care services, such as—

21 (I) treatment and recovery sup-  
22 port programs;

23 (II) programs that provide non-  
24 clinical recovery support services;

25 (III) peer support networks;

1 (IV) recovery community organi-  
2 zations;

3 (V) health care providers, includ-  
4 ing physicians and other providers of  
5 behavioral health and primary care;

6 (VI) education and training pro-  
7 viders;

8 (VII) employers;

9 (VIII) housing services; and

10 (IX) child welfare agencies;

11 (ii) providing education on overdose  
12 prevention and overdose reversal to pa-  
13 tients and families, as appropriate;

14 (iii) providing follow-up services for  
15 patients after an overdose to ensure con-  
16 tinued recovery and connection to support  
17 services;

18 (iv) collecting and evaluating outcome  
19 data for patients receiving recovery coach-  
20 ing services; and

21 (v) providing other services the Sec-  
22 retary determines necessary to help ensure  
23 continued connection with recovery support  
24 services, including culturally appropriate  
25 services, as applicable;

1 (B) establish policies and procedures, pur-  
2 suant to Federal and State law, that address  
3 the provision of overdose reversal medication,  
4 the administration of all drugs approved by the  
5 Food and Drug Administration to treat sub-  
6 stance use disorder, and subsequent continu-  
7 ation of, or referral to, evidence-based treat-  
8 ment for patients with a substance use disorder  
9 who have experienced a non-fatal drug over-  
10 dose, in order to support long-term treatment,  
11 prevent relapse, and reduce recidivism and fu-  
12 ture overdose; and

13 (C) establish integrated models of care for  
14 individuals who have experienced a non-fatal  
15 drug overdose which may include patient as-  
16 sessment, follow up, and transportation to and  
17 from treatment facilities.

18 (5) ADDITIONAL PERMISSIBLE USES.—In addi-  
19 tion to the uses described in paragraph (4), a grant  
20 awarded under this section may be used, directly or  
21 through contractual arrangements, to provide—

22 (A) all drugs approved by the Food and  
23 Drug Administration to treat substance use dis-  
24 orders, pursuant to Federal and State law;

1 (B) withdrawal and detoxification services  
2 that include patient evaluation, stabilization,  
3 and preparation for treatment of substance use  
4 disorder, including treatment described in sub-  
5 paragraph (A), as appropriate; or

6 (C) mental health services provided by a  
7 program counselor, social worker, therapist, or  
8 other certified professional who is licensed and  
9 qualified by education, training, or experience  
10 to assess the psychosocial background of pa-  
11 tients, to contribute to the appropriate treat-  
12 ment plan for patients with substance use dis-  
13 order, and to monitor patient progress.

14 (6) PREFERENCE.—In awarding grants under  
15 this section, the Secretary shall give preference to el-  
16 igible entities that meet any or all of the following  
17 criteria:

18 (A) The eligible entity is a critical access  
19 hospital (as defined in section 1861(mm)(1) of  
20 the Social Security Act (42 U.S.C.  
21 1395x(mm)(1))), a low volume hospital (as de-  
22 fined in section 1886(d)(12)(C)(i) of such Act  
23 (42 U.S.C. 1395ww(d)(12)(C)(i))), or a sole  
24 community hospital (as defined in section

1 1886(d)(5)(D)(iii) of such Act (42 U.S.C.  
2 1395ww(d)(5)(D)(iii)).

3 (B) The eligible entity is located in a  
4 State, or under the jurisdiction of an Indian  
5 Tribe, with an age-adjusted rate of drug over-  
6 dose deaths that is above the national overdose  
7 mortality rate, as determined by the Director of  
8 the Centers for Disease Control and Prevention.

9 (C) The eligible entity demonstrates that  
10 recovery coaches will be placed in both health  
11 care settings and community settings.

12 (7) PERIOD OF GRANT.—A grant awarded to an  
13 eligible entity under this section shall be for a period  
14 of not more than 5 years.

15 (c) DEFINITIONS.—In this section:

16 (1) RECOVERY COACH.—the term “recovery  
17 coach” means an individual—

18 (A) with knowledge of, or experience with,  
19 recovery from a substance use disorder; and

20 (B) who has completed training from, and  
21 is determined to be in good standing by, a re-  
22 covery services organization capable of con-  
23 ducting such training and making such deter-  
24 mination.

1           (2) RECOVERY COMMUNITY ORGANIZATION.—

2           The term “recovery community organization” has  
3           the meaning given such term in section 547(a) of  
4           the Public Health Service Act (42 U.S.C. 290ee–  
5           2(a)).

6           (3) STATE ALCOHOL AND DRUG AGENCY.—The  
7           term “State alcohol and drug agency” means the  
8           principal agency of a State that is responsible for  
9           carrying out the block grant for prevention and  
10          treatment of substance abuse under subpart II of  
11          part B of title XIX of the Public Health Service Act  
12          (42 U.S.C. 300x–21 et seq.)

13          (d) REPORTING REQUIREMENTS.—

14               (1) REPORTS BY GRANTEEES.—Each eligible en-  
15               tity awarded a grant under this section shall submit  
16               to the Secretary an annual report for each year for  
17               which the entity has received such grant that in-  
18               cludes information on—

19                       (A) the number of individuals treated by  
20                       the entity for non-fatal overdoses, including the  
21                       number of non-fatal overdoses where overdose  
22                       reversal medication was administered;

23                       (B) the number of individuals administered  
24                       medication-assisted treatment by the entity;



1 (C) the number of individuals referred by  
2 the entity to other treatment facilities after a  
3 non-fatal overdose, the types of such other fa-  
4 cilities, and the number of such individuals ad-  
5 mitted to such other facilities pursuant to such  
6 referrals; and

7 (D) the frequency and number of patients  
8 with reoccurrences, including readmissions for  
9 non-fatal overdoses and evidence of relapse re-  
10 lated to substance use disorder.

11 (2) REPORT BY SECRETARY.—Not later than 5  
12 years after the date of enactment of this Act, the  
13 Secretary shall submit to Congress a report that in-  
14 cludes an evaluation of the effectiveness of the grant  
15 program carried out under this section with respect  
16 to long term health outcomes of the population of in-  
17 dividuals who have experienced a drug overdose, the  
18 percentage of patients treated or referred to treat-  
19 ment by grantees, and the frequency and number of  
20 patients who experienced relapse, were readmitted  
21 for treatment, or experienced another overdose.

22 (e) PRIVACY.—The requirements of this section, in-  
23 cluding with respect to data reporting and program over-  
24 sight, shall be subject to all applicable Federal and State  
25 privacy laws.

1 (f) AUTHORIZATION OF APPROPRIATIONS.—There is  
2 authorized to be appropriated to carry out this section  
3 such sums as may be necessary for each of fiscal years  
4 2019 through 2023.

5 **SEC. 1403. ALTERNATIVES TO OPIOIDS.**

6 (a) IN GENERAL.—The Secretary shall, directly or  
7 through grants to, or contracts with, public and private  
8 entities, provide technical assistance to hospitals and other  
9 acute care settings on alternatives to opioids for pain man-  
10 agement. The technical assistance provided shall be for the  
11 purpose of—

12 (1) utilizing information from acute care pro-  
13 viders including emergency departments and other  
14 providers that have successfully implemented alter-  
15 natives to opioids programs, promoting non-addictive  
16 protocols and medications while appropriately lim-  
17 iting the use of opioids;

18 (2) identifying or facilitating the development of  
19 best practices on the use of alternatives to opioids,  
20 which may include pain-management strategies that  
21 involve non-addictive medical products, non-pharma-  
22 cologic treatments, and technologies or techniques to  
23 identify patients at risk for opioid use disorder;

24 (3) identifying or facilitating the development of  
25 best practices on the use of alternatives to opioids

1 that target common painful conditions and include  
2 certain patient populations, such as geriatric pa-  
3 tients, pregnant women, and children;

4 (4) disseminating information on the use of al-  
5 ternatives to opioids to providers in acute care set-  
6 tings, which may include emergency departments,  
7 outpatient clinics, critical access hospitals, Federally  
8 qualified health centers, Indian Health Service  
9 health facilities, and tribal hospitals; and

10 (5) collecting data and reporting on health out-  
11 comes associated with the use of alternatives to  
12 opioids.

13 (b) PAIN MANAGEMENT AND FUNDING.—

14 (1) IN GENERAL.—The Secretary shall award  
15 grants to hospitals and other acute care settings re-  
16 lating to alternatives to opioids for pain manage-  
17 ment.

18 (2) AUTHORIZATION OF APPROPRIATIONS.—

19 There is authorized to be appropriated \$5,000,000  
20 for each of fiscal years 2019 through 2023 for pur-  
21 poses of carrying out this section.

22 **SEC. 1404. BUILDING COMMUNITIES OF RECOVERY.**

23 Section 547 of the Public Health Service Act (42  
24 U.S.C. 290ee-2) is amended to read as follows:

1 **“SEC. 547. BUILDING COMMUNITIES OF RECOVERY.**

2 “(a) DEFINITION.—In this section, the term ‘recov-  
3 ery community organization’ means an independent non-  
4 profit organization that—

5 “(1) mobilizes resources within and outside of  
6 the recovery community, which may include through  
7 a peer support network, to increase the prevalence  
8 and quality of long-term recovery from substance  
9 use disorders; and

10 “(2) is wholly or principally governed by people  
11 in recovery for substance use disorders who reflect  
12 the community served.

13 “(b) GRANTS AUTHORIZED.—The Secretary shall  
14 award grants to recovery community organizations to en-  
15 able such organizations to develop, expand, and enhance  
16 recovery services.

17 “(c) FEDERAL SHARE.—The Federal share of the  
18 costs of a program funded by a grant under this section  
19 may not exceed 85 percent.

20 “(d) USE OF FUNDS.—Grants awarded under sub-  
21 section (b)—

22 “(1) shall be used to develop, expand, and en-  
23 hance community and statewide recovery support  
24 services; and

25 “(2) may be used to—

1           “(A) build connections between recovery  
2 networks, including between recovery commu-  
3 nity organizations and peer support networks,  
4 and with other recovery support services, in-  
5 cluding—

6                   “(i) behavioral health providers;

7                   “(ii) primary care providers and phy-  
8 sicians;

9                   “(iii) educational and vocational  
10 schools;

11                   “(iv) employers;

12                   “(v) housing services;

13                   “(vi) child welfare agencies; and

14                   “(vii) other recovery support services  
15 that facilitate recovery from substance use  
16 disorders, including non-clinical community  
17 services;

18           “(B) reduce the stigma associated with  
19 substance use disorders; and

20           “(C) conduct outreach on issues relating to  
21 substance use disorders and recovery, includ-  
22 ing—

23                   “(i) identifying the signs of substance  
24 use disorder;

1                   “(ii) the resources available to individ-  
2                   uals with substance use disorder and to  
3                   families of an individual with a substance  
4                   use disorder, including programs that men-  
5                   tor and provide support services to chil-  
6                   dren;

7                   “(iii) the resources available to help  
8                   support individuals in recovery; and

9                   “(iv) related medical outcomes of sub-  
10                  stance use disorders, the potential of ac-  
11                  quiring an infection commonly associated  
12                  with illicit drug use, and neonatal absti-  
13                  nence syndrome among infants exposed to  
14                  opioids during pregnancy.

15               “(e) SPECIAL CONSIDERATION.—In carrying out this  
16               section, the Secretary shall give special consideration to  
17               the unique needs of rural areas, including areas with an  
18               age-adjusted rate of drug overdose deaths that is above  
19               the national average and areas with a shortage of preven-  
20               tion and treatment services.

21               “(f) AUTHORIZATION OF APPROPRIATIONS.—There  
22               is authorized to be appropriated to carry out this section  
23               \$5,000,000 for each of fiscal years 2019 through 2023.”.

1 **SEC. 1405. PEER SUPPORT TECHNICAL ASSISTANCE CEN-**  
2 **TER.**

3 (a) ESTABLISHMENT.—The Secretary, acting  
4 through the Assistant Secretary for Mental Health and  
5 Substance Abuse, shall establish or operate a National  
6 Peer-Run Training and Technical Assistance Center for  
7 Addiction Recovery Support (referred to in this subsection  
8 as the “Center”).

9 (b) FUNCTIONS.—The Center established under sub-  
10 section (a) shall provide technical assistance and support  
11 to recovery community organizations and peer support  
12 networks, including such assistance and support related  
13 to—

14 (1) training on identifying—

15 (A) signs of substance use disorder;

16 (B) resources to assist individuals with a  
17 substance use disorder, or resources for families  
18 of an individual with a substance use disorder;  
19 and

20 (C) best practices for the delivery of recov-  
21 ery support services;

22 (2) the provision of translation services, inter-  
23 pretation, or other such services for clients with lim-  
24 ited English speaking proficiency;

25 (3) data collection to support research, includ-  
26 ing for translational research;

1 (4) capacity building; and

2 (5) evaluation and improvement, as necessary,  
3 of the effectiveness of such services provided by re-  
4 covery community organizations (as defined in sec-  
5 tion 547 of the Public Health Service Act).

6 (c) **BEST PRACTICES.**—The Center established under  
7 subsection (a) shall periodically issue best practices for use  
8 by recovery community organizations and peer support  
9 networks.

10 (d) **RECOVERY COMMUNITY ORGANIZATION.**—In this  
11 section, the term “recovery community organization” has  
12 the meaning given such term in section 547 of the Public  
13 Health Service Act.

14 (e) **AUTHORIZATION OF APPROPRIATIONS.**—There is  
15 authorized to be appropriated to carry out this section  
16 such sums as may be necessary for each of fiscal years  
17 2019 through 2023.

18 **SEC. 1406. MEDICATION-ASSISTED TREATMENT FOR RE-**  
19 **COVERY FROM ADDICTION.**

20 (a) **WAIVERS FOR MAINTENANCE TREATMENT OR**  
21 **DETOXIFICATION.**—Section 303(g)(2)(G)(ii) of the Con-  
22 trolled Substances Act (21 U.S.C. 823(g)(2)(G)(ii)) is  
23 amended by adding at the end the following:

24 “(VIII) The physician graduated in good  
25 standing from an accredited school of allopathic



1 medicine or osteopathic medicine in the United  
2 States during the 5-year period immediately  
3 preceding the date on which the physician sub-  
4 mits to the Secretary a written notification  
5 under subparagraph (B) and successfully com-  
6 pleted a comprehensive allopathic or osteopathic  
7 medicine curriculum or accredited medical resi-  
8 dency that—

9 “(aa) included not less than 24 hours  
10 of training on treating and managing  
11 opioid-dependent patients; and

12 “(bb) included, at a minimum—

13 “(AA) the training described in  
14 items (aa) through (gg) of subclause  
15 (IV); and

16 “(BB) training with respect to  
17 any other best practice the Secretary  
18 determines should be included in the  
19 curriculum, which may include train-  
20 ing on pain management, including  
21 assessment and appropriate use of  
22 opioid and non-opioid alternatives.”.

23 (b) TREATMENT FOR CHILDREN.—The Secretary  
24 shall consider ways to ensure that an adequate number  
25 of physicians who meet the requirements under the

1 amendment made by subsection (a) and have a specialty  
2 in pediatrics, or the treatment of children or of adoles-  
3 cents, are granted a waiver under section 303(g)(2) of the  
4 Controlled Substances Act (21 U.S.C. 823(g)(2)) to treat  
5 children and adolescents with substance use disorders.

6 (c) TECHNICAL AMENDMENT.—Section 102(24) of  
7 the Controlled Substances Act (21 U.S.C. 802(24)) is  
8 amended by striking “Health, Education, and Welfare”  
9 and inserting “Health and Human Services”.

10 **SEC. 1407. GRANT PROGRAM.**

11 (a) IN GENERAL.—The Secretary shall establish a  
12 grant program under which the Secretary may make  
13 grants to accredited schools of allopathic medicine or os-  
14 teopathic medicine and teaching hospitals located in the  
15 United States to support the development of curricula that  
16 meet the requirements under subclause (VIII) of section  
17 303(g)(2)(G)(ii) of the Controlled Substances Act, as  
18 added by section 1406(a) of this Act.

19 (b) AUTHORIZATION OF APPROPRIATIONS.—There is  
20 authorized to be appropriated for grants under subsection  
21 (a), \$4,000,000 for each of fiscal years 2019 through  
22 2023.

1 **SEC. 1408. ALLOWING FOR MORE FLEXIBILITY WITH RE-**  
2 **SPECT TO MEDICATION-ASSISTED TREAT-**  
3 **MENT FOR OPIOID USE DISORDERS.**

4 Subclause (II) of section 303(g)(2)(B)(iii) of the  
5 Controlled Substances Act (21 U.S.C. 823(g)(2)(B)(iii))  
6 is amended to read as follows:

7 “(II) The applicable number is—

8 “(aa) 100 if, not sooner than 1 year after  
9 the date on which the practitioner submitted  
10 the initial notification, the practitioner submits  
11 a second notification to the Secretary of the  
12 need and intent of the practitioner to treat up  
13 to 100 patients; or

14 “(bb) 275 if the practitioner meets the re-  
15 quirements specified in section 8.610 of title  
16 42, Code of Federal Regulations (or successor  
17 regulations).”.

18 **SEC. 1409. NATIONAL RECOVERY HOUSING BEST PRAC-**  
19 **TICES.**

20 (a) **BEST PRACTICES FOR OPERATING RECOVERY**  
21 **HOUSING.—**

22 (1) **IN GENERAL.—**The Secretary, in consulta-  
23 tion with the individuals and entities described in  
24 paragraph (2), shall identify or facilitate the devel-  
25 opment of best practices, which may include model

1 laws for implementing suggested minimum stand-  
2 ards, for operating recovery housing.

3 (2) CONSULTATION.—In carrying out the activi-  
4 ties described in paragraph (1) the Secretary shall  
5 consult with, as appropriate—

6 (A) relevant divisions of the Department of  
7 Health and Human Services, including the Sub-  
8 stance Abuse and Mental Health Services Ad-  
9 ministration, the Office of Inspector General,  
10 the Indian Health Service, and the Centers for  
11 Medicare & Medicaid Services;

12 (B) the Secretary of Housing and Urban  
13 Development;

14 (C) directors or commissioners, as applica-  
15 ble, of State health departments, tribal health  
16 departments, State Medicaid programs, and  
17 State insurance agencies;

18 (D) representatives of health insurance  
19 issuers;

20 (E) national accrediting entities and rep-  
21 utable providers of, and analysts of, recovery  
22 housing services, including Indian Tribes, tribal  
23 organizations, and tribally designated housing  
24 entities that provide recovery housing services,  
25 as applicable;

1 (F) individuals with a history of substance  
2 use disorder; and

3 (G) other stakeholders identified by the  
4 Secretary.

5 (b) IDENTIFICATION OF FRAUDULENT RECOVERY  
6 HOUSING OPERATORS.—

7 (1) IN GENERAL.—The Secretary, in consulta-  
8 tion with the individuals and entities described in  
9 paragraph (2), shall identify or facilitate the devel-  
10 opment of common indicators that could be used to  
11 identify potentially fraudulent recovery housing oper-  
12 ators.

13 (2) CONSULTATION.—In carrying out the activi-  
14 ties described in paragraph (1), the Secretary shall  
15 consult with, as appropriate—

16 (A) relevant divisions of the Department of  
17 Health and Human Services, including the Sub-  
18 stance Abuse and Mental Health Services Ad-  
19 ministration, the Office of Inspector General,  
20 the Indian Health Service, and the Centers for  
21 Medicare & Medicaid Services;

22 (B) the Attorney General;

23 (C) the Secretary of Housing and Urban  
24 Development;

1 (D) directors or commissioners, as applica-  
2 ble, of State health departments, tribal health  
3 departments, State Medicaid programs, and  
4 State insurance agencies;

5 (E) representatives of health insurance  
6 issuers;

7 (F) national accrediting entities and rep-  
8 utable providers of, and analysts of, recovery  
9 housing services, including Indian Tribes, tribal  
10 organizations, and tribally designated housing  
11 entities that provide recovery housing services,  
12 as applicable;

13 (G) individuals with a history of substance  
14 use disorder; and

15 (H) other stakeholders identified by the  
16 Secretary.

17 (3) REQUIREMENTS.—

18 (A) PRACTICES FOR IDENTIFICATION AND  
19 REPORTING.—In carrying out the activities de-  
20 scribed in this subsection, the Secretary shall  
21 consider how law enforcement, public and pri-  
22 vate payers, and the public can best identify  
23 and report fraudulent recovery housing opera-  
24 tors.

1 (B) FACTORS TO BE CONSIDERED.—In  
2 carrying out the activities described in this sub-  
3 section, the Secretary shall consider identifying  
4 or developing indicators regarding—

- 5 (i) unusual billing practices;  
6 (ii) average lengths of stays;  
7 (iii) excessive levels of drug testing (in  
8 terms of cost or frequency);  
9 (iv) unusually high levels of recidi-  
10 vism; and  
11 (v) any other factors identified by the  
12 Secretary.

13 (c) DISSEMINATION.—The Secretary shall, as appro-  
14 priate, disseminate the best practices identified or devel-  
15 oped under subsection (a), and the common indicators  
16 identified or developed under subsection (b), to—

- 17 (1) State agencies, which may include the provi-  
18 sion of technical assistance to State agencies seeking  
19 to adopt or implement such best practices;  
20 (2) Indian Tribes, tribal organizations, and  
21 tribally designated housing entities;  
22 (3) the Attorney General;  
23 (4) the Secretary of Labor;  
24 (5) the Secretary of Housing and Urban Devel-  
25 opment;

- 1 (6) State and local law enforcement agencies;
- 2 (7) health insurance issuers;
- 3 (8) recovery housing entities; and
- 4 (9) the public.

5 (d) REQUIREMENTS.—In carrying out the activities  
6 under subsections (a) and (b), the Secretary, in consulta-  
7 tion with appropriate stakeholders as described in each  
8 such subsection, shall consider how recovery housing is  
9 able to support recovery and prevent relapse, recidivism,  
10 or overdose (including overdose death), including by im-  
11 proving access and adherence to treatment, including  
12 medication-assisted treatment.

13 (e) RULE OF CONSTRUCTION.—Nothing in this sec-  
14 tion shall be construed to provide the Secretary with the  
15 authority to require States to adhere to minimum stand-  
16 ards in the State oversight of recovery housing.

17 (f) DEFINITIONS.—In this section—

18 (1) the term “recovery housing” means a  
19 shared living environment free from alcohol and il-  
20 licit drug use and centered on peer support and con-  
21 nection to services that promote sustained recovery  
22 from substance use disorders; and

23 (2) the term “tribally designated housing enti-  
24 ty” has the meaning given such term in section 4 of



1 the Native American Housing Assistance and Self-  
2 Determination Act of 1996 (25 U.S.C. 4103).

3 **SEC. 1410. ADDRESSING ECONOMIC AND WORKFORCE IM-**  
4 **PACTS OF THE OPIOID CRISIS.**

5 (a) DEFINITIONS.—Except as otherwise expressly  
6 provided, in this section:

7 (1) WIOA DEFINITIONS.—The terms “core pro-  
8 gram”, “individual with a barrier to employment”,  
9 “local area”, “local board”, “one-stop operator”,  
10 “outlying area”, “State”, “State board”, and “sup-  
11 portive services” have the meanings given the terms  
12 in section 3 of the Workforce Innovation and Oppor-  
13 tunity Act (29 U.S.C. 3102).

14 (2) EDUCATION PROVIDER.—The term “edu-  
15 cation provider” means—

16 (A) an institution of higher education, as  
17 defined in section 101 of the Higher Education  
18 Act of 1965 (20 U.S.C. 1001); or

19 (B) a postsecondary vocational institution,  
20 as defined in section 102(e) of such Act (20  
21 U.S.C. 1002(e)).

22 (3) ELIGIBLE ENTITY.—The term “eligible enti-  
23 ty” means—

24 (A) a State workforce agency;

25 (B) an outlying area; or

1 (C) a Tribal entity.

2 (4) PARTICIPATING PARTNERSHIP.—The term  
3 “participating partnership” means a partnership—

4 (A) evidenced by a written contract or  
5 agreement; and

6 (B) including, as members of the partner-  
7 ship, a local board receiving a subgrant under  
8 subsection (d) and 1 or more of the following:

9 (i) The eligible entity.

10 (ii) A treatment provider.

11 (iii) An employer or industry organi-  
12 zation.

13 (iv) An education provider.

14 (v) A legal service or law enforcement  
15 organization.

16 (vi) A faith-based or community-based  
17 organization.

18 (vii) Other State or local agencies, in-  
19 cluding counties or local governments.

20 (viii) Other organizations, as deter-  
21 mined to be necessary by the local board.

22 (ix) Indian Tribes or tribal organiza-  
23 tions.

24 (5) PROGRAM PARTICIPANT.—The term “pro-  
25 gram participant” means an individual who—

1 (A) is a member of a population of workers  
2 described in subsection (e)(2) that is served by  
3 a participating partnership through the pilot  
4 program under this section; and

5 (B) enrolls with the applicable partici-  
6 pating partnership to receive any of the services  
7 described in subsection (e)(3).

8 (6) PROVIDER OF PEER RECOVERY SUPPORT  
9 SERVICES.—The term “provider of peer recovery  
10 support services” means a provider that delivers  
11 peer recovery support services through an organiza-  
12 tion described in section 547(a) of the Public Health  
13 Service Act (42 U.S.C. 290ee–2(a)).

14 (7) SECRETARY.—The term “Secretary” means  
15 the Secretary of Labor.

16 (8) STATE WORKFORCE AGENCY.—The term  
17 “State workforce agency” means the lead State  
18 agency with responsibility for the administration of  
19 a program under chapter 2 or 3 of subtitle B of title  
20 I of the Workforce Innovation and Opportunity Act  
21 (29 U.S.C. 3161 et seq., 3171 et seq.).

22 (9) SUBSTANCE USE DISORDER.—The term  
23 “substance use disorder” has the meaning given  
24 such term by the Assistant Secretary for Mental  
25 Health and Substance Use.

1           (10) TREATMENT PROVIDER.—The term “treat-  
2           ment provider”—

3                   (A) means a health care provider that—

4                           (i) offers services for treating sub-  
5                           stance use disorders and is licensed in ac-  
6                           cordance with applicable State law to pro-  
7                           vide such services; and

8                           (ii) accepts health insurance for such  
9                           services, including coverage under title  
10                          XIX of the Social Security Act (42 U.S.C.  
11                          1396 et seq.); and

12                   (B) may include—

13                           (i) a nonprofit provider of peer recov-  
14                           ery support services;

15                           (ii) a community health care provider;

16                           (iii) a Federally qualified health cen-  
17                           ter (as defined in section 1861(aa) of the  
18                           Social Security Act (42 U.S.C. 1395x));

19                           (iv) an Indian health program (as de-  
20                           fined in section 3 of the Indian Health  
21                           Care Improvement Act (25 U.S.C. 1603)),  
22                           including an Indian health program that  
23                           serves an urban center (as defined in such  
24                           section); and

1 (v) a Native Hawaiian health center  
2 (as defined in section 12 of the Native Ha-  
3 waiian Health Care Improvement Act (42  
4 U.S.C. 11711)).

5 (11) TRIBAL ENTITY.—The term “Tribal enti-  
6 ty” includes any Indian Tribe, tribal organization,  
7 Indian-controlled organization serving Indians, Na-  
8 tive Hawaiian organization, or Alaska Native entity,  
9 as such terms are defined or used in section 166 of  
10 the Workforce Innovation and Opportunity Act (29  
11 U.S.C. 3221).

12 (b) PILOT PROGRAM AND GRANTS AUTHORIZED.—

13 (1) IN GENERAL.—The Secretary, in consulta-  
14 tion with the Secretary of Health and Human Serv-  
15 ices, shall carry out a pilot program to address eco-  
16 nomic and workforce impacts associated with a high  
17 rate of a substance use disorder. In carrying out the  
18 pilot program, the Secretary shall make grants, on  
19 a competitive basis, to eligible entities to enable such  
20 entities to make subgrants to local boards to address  
21 the economic and workforce impacts associated with  
22 a high rate of a substance use disorder.

23 (2) GRANT AMOUNTS.—The Secretary shall  
24 make each such grant in an amount that is not less

1 than \$500,000, and not more than \$5,000,000, for  
2 a fiscal year.

3 (c) GRANT APPLICATIONS.—

4 (1) IN GENERAL.—An eligible entity applying  
5 for a grant under this section shall submit an appli-  
6 cation to the Secretary at such time and in such  
7 form and manner as the Secretary may reasonably  
8 require, including the information described in this  
9 subsection.

10 (2) SIGNIFICANT IMPACT ON COMMUNITY BY  
11 OPIOID AND SUBSTANCE USE DISORDER-RELATED  
12 PROBLEMS.—

13 (A) DEMONSTRATION.—An eligible entity  
14 shall include in the application—

15 (i) information that demonstrates sig-  
16 nificant impact on the community by prob-  
17 lems related to opioid abuse or another  
18 substance use disorder, by—

19 (I) identifying the counties, com-  
20 munities, regions, or local areas that  
21 have been significantly impacted and  
22 will be served through the grant (each  
23 referred to in this section as a “serv-  
24 ice area”); and

1 (II) demonstrating for each such  
2 service area, an increase equal to or  
3 greater than the national increase in  
4 such problems, between—

5 (aa) 1999; and

6 (bb) 2016 or the latest year  
7 for which data are available; and

8 (ii) a description of how the eligible  
9 entity will prioritize support for signifi-  
10 cantly impacted service areas described in  
11 clause (i)(I).

12 (B) INFORMATION.—To meet the require-  
13 ments described in subparagraph (A)(i)(II), the  
14 eligible entity may use information including  
15 data on—

16 (i) the incidence or prevalence of  
17 opioid abuse and other substance use dis-  
18 orders;

19 (ii) the age-adjusted rate of drug  
20 overdose deaths, as determined by the Di-  
21 rector of the Centers for Disease Control  
22 and Prevention;

23 (iii) the rate of non-fatal hospitaliza-  
24 tions related to opioid abuse or other sub-  
25 stance use disorders;

1 (iv) the number of arrests or convic-  
2 tions, or a relevant law enforcement sta-  
3 tistic, that reasonably shows an increase in  
4 opioid abuse or another substance use dis-  
5 order; or

6 (v) in the case of an eligible entity de-  
7 scribed in subsection (a)(3)(C), other alter-  
8 native relevant data as determined appro-  
9 priate by the Secretary.

10 (C) SUPPORT FOR STATE STRATEGY.—The  
11 eligible entity may include in the application in-  
12 formation describing how the proposed services  
13 and activities are aligned with the State, out-  
14 lying area, or Tribal strategy, as applicable, for  
15 addressing problems described in subparagraph  
16 (A) in specific service areas or across the State,  
17 outlying area, or Tribal land.

18 (3) ECONOMIC AND EMPLOYMENT CONDITIONS  
19 DEMONSTRATE ADDITIONAL FEDERAL SUPPORT  
20 NEEDED.—

21 (A) DEMONSTRATION.—An eligible entity  
22 shall include in the application information that  
23 demonstrates that a high rate of a substance  
24 use disorder has caused, or is coincident to—



1 (i) an economic or employment down-  
2 turn in the service area; or

3 (ii) persistent economically depressed  
4 conditions in such service area.

5 (B) INFORMATION.—To meet the require-  
6 ments of subparagraph (A), an eligible entity  
7 may use information including—

8 (i) documentation of any layoff, an-  
9 nounced future layoff, legacy industry de-  
10 cline, decrease in an employment or labor  
11 market participation rate, or economic im-  
12 pact, whether or not the result described in  
13 this clause is overtly related to a high rate  
14 of a substance use disorder;

15 (ii) documentation showing decreased  
16 economic activity related to, caused by, or  
17 contributing to a high rate of a substance  
18 use disorder, including a description of  
19 how the service area has been impacted, or  
20 will be impacted, by such a decrease;

21 (iii) information on economic indica-  
22 tors, labor market analyses, information  
23 from public announcements, and demo-  
24 graphic and industry data;

1 (iv) information on rapid response ac-  
2 tivities (as defined in section 3 of the  
3 Workforce Innovation and Opportunity Act  
4 (29 U.S.C. 3102)) that have been or will  
5 be conducted, including demographic data  
6 gathered by employer or worker surveys or  
7 through other methods;

8 (v) data or documentation, beyond an-  
9 ecdotal evidence, showing that employers  
10 face challenges filling job vacancies due to  
11 a lack of skilled workers able to pass a  
12 drug test; or

13 (vi) any additional relevant data or in-  
14 formation on the economy, workforce, or  
15 another aspect of the service area to sup-  
16 port the application.

17 (d) SUBGRANT AUTHORIZATION AND APPLICATION  
18 PROCESS.—

19 (1) SUBGRANTS AUTHORIZED.—

20 (A) IN GENERAL.—An eligible entity re-  
21 ceiving a grant under subsection (b)—

22 (i) may use not more than 5 percent  
23 of the grant funds for the administrative  
24 costs of carrying out the grant;

1 (ii) in the case of an eligible entity de-  
2 scribed in subparagraph (A) or (B) of sub-  
3 section (a)(3), shall use the remaining  
4 grant funds to make subgrants to local en-  
5 tities in the service area to carry out the  
6 services and activities described in sub-  
7 section (e); and

8 (iii) in the case of an eligible entity  
9 described in subsection (a)(3)(C), shall use  
10 the remaining grant funds to carry out the  
11 services and activities described in sub-  
12 section (e).

13 (B) **EQUITABLE DISTRIBUTION.**—In mak-  
14 ing subgrants under this subsection, an eligible  
15 entity shall ensure, to the extent practicable,  
16 the equitable distribution of subgrants, based  
17 on—

18 (i) geography (such as urban and  
19 rural distribution); and

20 (ii) significantly impacted service  
21 areas as described in subsection (c)(2).

22 (C) **TIMING OF SUBGRANT FUNDS DIS-**  
23 **TRIBUTION.**—An eligible entity making sub-  
24 grants under this subsection shall disburse  
25 subgrant funds to a local board receiving a

1 subgrant from the eligible entity by the later  
2 of—

3 (i) the date that is 90 days after the  
4 date on which the Secretary makes the  
5 funds available to the eligible entity; or

6 (ii) the date that is 15 days after the  
7 date that the eligible entity makes the  
8 subgrant under subparagraph (A)(ii).

9 (2) SUBGRANT APPLICATION.—

10 (A) IN GENERAL.—A local board desiring  
11 to receive a subgrant under this subsection  
12 from an eligible entity shall submit an applica-  
13 tion at such time and in such manner as the el-  
14 igible entity may reasonably require, including  
15 the information described in this paragraph.

16 (B) CONTENTS.—Each application de-  
17 scribed in subparagraph (A) shall include—

18 (i) an analysis of the estimated per-  
19 formance of the local board in carrying out  
20 the proposed services and activities under  
21 the subgrant—

22 (I) based on—

23 (aa) primary indicators of  
24 performance described in section  
25 116(c)(1)(A)(i) of the Workforce

1 Innovation and Opportunity Act  
2 (29 U.S.C. 3141(c)(1)(A)(i), to  
3 assess estimated effectiveness of  
4 the proposed services and activi-  
5 ties, including the estimated  
6 number of individuals with a sub-  
7 stance use disorder who may be  
8 served by the proposed services  
9 and activities;

10 (bb) the record of the local  
11 board in serving individuals with  
12 a barrier to employment; and

13 (cc) the ability of the local  
14 board to establish a participating  
15 partnership; and

16 (II) which may include or uti-  
17 lize—

18 (aa) data from the National  
19 Center for Health Statistics of  
20 the Centers for Disease Control  
21 and Prevention;

22 (bb) data from the Center  
23 for Behavioral Health Statistics  
24 and Quality of the Substance

1 Abuse and Mental Health Serv-  
2 ices Administration;  
3 (cc) State vital statistics;  
4 (dd) municipal police depart-  
5 ment records;  
6 (ee) reports from local coro-  
7 ners; or  
8 (ff) other relevant data; and  
9 (ii) in the case of a local board pro-  
10 posing to serve a population described in  
11 subsection (e)(2)(B), a demonstration of  
12 the workforce shortage in the professional  
13 area to be addressed under the subgrant  
14 (which may include substance use disorder  
15 treatment and related services, non-addict-  
16 ive pain therapy and pain management  
17 services, mental health care treatment  
18 services, emergency response services, or  
19 mental health care), which shall include in-  
20 formation that can demonstrate such a  
21 shortage, such as—  
22 (I) the distance between—  
23 (aa) communities affected by  
24 opioid abuse or another sub-  
25 stance use disorder; and

1 (bb) facilities or profes-  
2 sionals offering services in the  
3 professional area; or

4 (II) the maximum capacity of fa-  
5 cilities or professionals to serve indi-  
6 viduals in an affected community, or  
7 increases in arrests related to opioid  
8 or another substance use disorder,  
9 overdose deaths, or nonfatal overdose  
10 emergencies in the community.

11 (e) SUBGRANT SERVICES AND ACTIVITIES.—

12 (1) IN GENERAL.—Each local board that re-  
13 ceives a subgrant under subsection (d) shall carry  
14 out the services and activities described in this sub-  
15 section through a participating partnership.

16 (2) SELECTION OF POPULATION TO BE  
17 SERVED.—A participating partnership shall elect to  
18 provide services and activities under the subgrant to  
19 one or both of the following populations of workers:

20 (A) Workers, including dislocated workers,  
21 individuals with barriers to employment, new  
22 entrants in the workforce, or incumbent work-  
23 ers (employed or underemployed), each of  
24 whom—

1 (i) is directly or indirectly affected by  
2 a high rate of a substance use disorder;  
3 and

4 (ii) voluntarily confirms that the  
5 worker, or a friend or family member of  
6 the worker, has a history of opioid abuse  
7 or another substance use disorder.

8 (B) Workers, including dislocated workers,  
9 individuals with barriers to employment, new  
10 entrants in the workforce, or incumbent work-  
11 ers (employed or underemployed), who—

12 (i) seek to transition to professions  
13 that support individuals with a substance  
14 use disorder or at risk for developing such  
15 disorder, such as professions that pro-  
16 vide—

17 (I) substance use disorder treat-  
18 ment and related services;

19 (II) services offered through pro-  
20 viders of peer recovery support serv-  
21 ices;

22 (III) non-addictive pain therapy  
23 and pain management services;

24 (IV) emergency response services;

25 or



1 (V) mental health care; and  
2 (ii) need new or upgraded skills to  
3 better serve such a population of strug-  
4 gling or at-risk individuals.

5 (3) SERVICES AND ACTIVITIES.—Each partici-  
6 pating partnership shall use funds available through  
7 a subgrant under this subsection to carry out 1 or  
8 more of the following:

9 (A) ENGAGING EMPLOYERS.—Engaging  
10 with employers to—

11 (i) learn about the skill and hiring re-  
12 quirements of employers;

13 (ii) learn about the support needed by  
14 employers to hire and retain program par-  
15 ticipants, and other individuals with a sub-  
16 stance use disorder, and the support need-  
17 ed by such employers to obtain their com-  
18 mitment to testing creative solutions to  
19 employing program participants and such  
20 individuals;

21 (iii) connect employers and workers to  
22 on-the-job or customized training programs  
23 before or after layoff to help facilitate re-  
24 employment;

1 (iv) connect employers with an edu-  
2 cation provider to develop classroom in-  
3 struction to complement on-the-job learn-  
4 ing for program participants and such in-  
5 dividuals;

6 (v) help employers develop the cur-  
7 riculum design of a work-based learning  
8 program for program participants and  
9 such individuals;

10 (vi) help employers employ program  
11 participants or such individuals engaging  
12 in a work-based learning program for a  
13 transitional period before hiring such a  
14 program participant or individual for full-  
15 time employment of not less than 30 hours  
16 a week; or

17 (vii) connect employers to program  
18 participants receiving concurrent out-  
19 patient treatment and job training services.

20 (B) SCREENING SERVICES.—Providing  
21 screening services, which may include—

22 (i) using an evidence-based screening  
23 method to screen each individual seeking  
24 participation in the pilot program to deter-

1 mine whether the individual has a sub-  
2 stance use disorder;

3 (ii) conducting an assessment of each  
4 such individual to determine the services  
5 needed for such individual to obtain or re-  
6 tain employment, including an assessment  
7 of strengths and general work readiness; or

8 (iii) accepting walk-ins or referrals  
9 from employers, labor organizations, or  
10 other entities recommending individuals to  
11 participate in such program.

12 (C) INDIVIDUAL TREATMENT AND EM-  
13 PLOYMENT PLAN.—Developing an individual  
14 treatment and employment plan for each pro-  
15 gram participant—

16 (i) in coordination, as appropriate,  
17 with other programs serving the partici-  
18 pant such as the core programs within the  
19 workforce development system under the  
20 Workforce Innovation and Opportunity Act  
21 (29 U.S.C. 3101 et seq.); and

22 (ii) which shall include providing a  
23 case manager to work with each partici-  
24 pant to develop the plan, which may in-  
25 clude—

1 (I) identifying employment and  
2 career goals;

3 (II) exploring career pathways  
4 that lead to in-demand industries and  
5 sectors, as determined by the State  
6 board and the head of the State work-  
7 force agency or, as applicable, the  
8 Tribal entity;

9 (III) setting appropriate achieve-  
10 ment objectives to attain the employ-  
11 ment and career goals identified  
12 under subclause (I); or

13 (IV) developing the appropriate  
14 combination of services to enable the  
15 participant to achieve the employment  
16 and career goals identified under sub-  
17 clause (I).

18 (D) OUTPATIENT TREATMENT AND RECOV-  
19 ERY CARE.—In the case of a participating part-  
20 nership serving program participants described  
21 in paragraph (2)(A) with a substance use dis-  
22 order, providing individualized and group out-  
23 patient treatment and recovery services for such  
24 program participants that are offered during

1 the day and evening, and on weekends. Such  
2 treatment and recovery services—

3 (i) shall be based on a model that uti-  
4 lizes combined behavioral interventions and  
5 other evidence-based or evidence-informed  
6 interventions; and

7 (ii) may include additional services  
8 such as—

9 (I) health, mental health, addic-  
10 tion, or other forms of outpatient  
11 treatment that may impact a sub-  
12 stance use disorder and co-occurring  
13 conditions;

14 (II) drug testing for a current  
15 substance use disorder prior to enroll-  
16 ment in career or training services or  
17 prior to employment;

18 (III) linkages to community serv-  
19 ices, including services offered by  
20 partner organizations designed to sup-  
21 port program participants; or

22 (IV) referrals to health care, in-  
23 cluding referrals to substance use dis-  
24 order treatment and mental health  
25 services.

1           (E) SUPPORTIVE SERVICES.—Providing  
2           supportive services, which shall include services  
3           such as—

4                   (i) coordinated wraparound services to  
5                   provide maximum support for program  
6                   participants to assist the program partici-  
7                   pants in maintaining employment and re-  
8                   covery for not less than 12 months, as ap-  
9                   propriate;

10                   (ii) assistance in establishing eligi-  
11                   bility for assistance under Federal, State,  
12                   Tribal, and local programs providing  
13                   health services, mental health services, vo-  
14                   cational services, housing services, trans-  
15                   portation services, social services, or serv-  
16                   ices through early childhood education pro-  
17                   grams (as defined in section 103 of the  
18                   Higher Education Act of 1965 (20 U.S.C.  
19                   1003));

20                   (iii) services offered through providers  
21                   of peer recovery support services;

22                   (iv) networking and mentorship op-  
23                   portunities; or

24                   (v) any supportive services determined  
25                   necessary by the local board.

1                   (F) CAREER AND JOB TRAINING SERV-  
2 ICES.—Offering career services and training  
3 services, and related services, concurrently or  
4 sequentially with the services provided under  
5 subparagraphs (B) through (E). Such services  
6 shall include the following:

7                   (i) Services provided to program par-  
8 ticipants who are in a pre-employment  
9 stage of the program, which may include—

10                   (I) initial education and skills as-  
11 sements;

12                   (II) traditional classroom train-  
13 ing funded through individual training  
14 accounts under chapter 3 of subtitle B  
15 of title I of the Workforce Innovation  
16 and Opportunity Act (29 U.S.C. 3171  
17 et seq.);

18                   (III) services to promote employ-  
19 ability skills such as punctuality, per-  
20 sonal maintenance skills, and profes-  
21 sional conduct;

22                   (IV) in-depth interviewing and  
23 evaluation to identify employment bar-  
24 riers and to develop individual em-  
25 ployment plans;

1 (V) career planning that in-  
2 cludes—

3 (aa) career pathways leading  
4 to in-demand, high-wage jobs;  
5 and

6 (bb) job coaching, job  
7 matching, and job placement  
8 services;

9 (VI) provision of payments and  
10 fees for employment and training-re-  
11 lated applications, tests, and certifi-  
12 cations; or

13 (VII) any other appropriate ca-  
14 reer service or training service de-  
15 scribed in section 134(c) of the Work-  
16 force Innovation and Opportunity Act  
17 (29 U.S.C. 3174(c)).

18 (ii) Services provided to program par-  
19 ticipants during their first 6 months of  
20 employment to ensure job retention, which  
21 may include—

22 (I) case management and support  
23 services, including a continuation of  
24 the services described in clause (i);



1 (II) a continuation of skills train-  
2 ing, and career and technical edu-  
3 cation, described in clause (i) that is  
4 conducted in collaboration with the  
5 employers of such participants;

6 (III) mentorship services and job  
7 retention support for such partici-  
8 pants; or

9 (IV) targeted training for man-  
10 agers and workers working with such  
11 participants (such as mentors), and  
12 human resource representatives in the  
13 business in which such participants  
14 are employed.

15 (iii) Services to assist program partici-  
16 pants in maintaining employment for not  
17 less than 12 months, as appropriate.

18 (G) PROVEN AND PROMISING PRAC-  
19 TICES.—Leading efforts in the service area to  
20 identify and promote proven and promising  
21 strategies and initiatives for meeting the needs  
22 of employers and program participants.

23 (4) LIMITATIONS.—A participating partnership  
24 may not use—

1 (A) more than 10 percent of the funds re-  
2 ceived under a subgrant under subsection (d)  
3 for the administrative costs of the partnership;

4 (B) more than 10 percent of the funds re-  
5 ceived under such subgrant for the provision of  
6 treatment and recovery services, as described in  
7 paragraph (3)(D); and

8 (C) more than 10 percent of the funds re-  
9 ceived under such subgrant for the provision of  
10 supportive services described in paragraph  
11 (3)(E) to program participants.

12 (f) PERFORMANCE ACCOUNTABILITY.—

13 (1) REPORTS.—The Secretary shall establish  
14 quarterly reporting requirements for recipients of  
15 grants and subgrants under this section that, to the  
16 extent practicable, are based on the performance ac-  
17 countability system under section 116 of the Work-  
18 force Innovation and Opportunity Act (29 U.S.C.  
19 3141) and, in the case of a grant awarded to an eli-  
20 gible entity described in subsection (a)(3)(C), section  
21 166(h) of such Act (29 U.S.C. 3221(h)), including  
22 the indicators described in subsection (c)(1)(A)(i) of  
23 such section 116 and the requirements for local area  
24 performance reports under subsection (d) of such  
25 section 116.

1 (2) EVALUATIONS.—

2 (A) AUTHORITY TO ENTER INTO AGREE-  
3 MENTS.—The Secretary shall ensure that an  
4 independent evaluation is conducted on the pilot  
5 program carried out under this section to deter-  
6 mine the impact of the program on employment  
7 of individuals with substance use disorders. The  
8 Secretary shall enter into an agreement with el-  
9 igible entities receiving grants under this sec-  
10 tion to pay for all or part of such evaluation.

11 (B) METHODOLOGIES TO BE USED.—The  
12 independent evaluation required under this  
13 paragraph shall use experimental designs using  
14 random assignment or, when random assign-  
15 ment is not feasible, other reliable, evidence-  
16 based research methodologies that allow for the  
17 strongest possible causal inferences.

18 (g) FUNDING.—

19 (1) COVERED FISCAL YEAR.—In this sub-  
20 section, the term “covered fiscal year” means any of  
21 fiscal years 2018 through 2023.

22 (2) USING FUNDING FOR NATIONAL DIS-  
23 LOCATED WORKER GRANTS.—Subject to paragraph  
24 (4) and notwithstanding section 132(a)(2)(A) and  
25 subtitle D of the Workforce Innovation and Oppor-

1 tunity Act (29 U.S.C. 3172(a)(2)(A), 3221 et seq.),  
2 the Secretary may use, to carry out the pilot pro-  
3 gram under this section for a covered fiscal year—

4 (A) funds made available to carry out sec-  
5 tion 170 of such Act (29 U.S.C. 3225) for that  
6 fiscal year;

7 (B) funds made available to carry out sec-  
8 tion 170 of such Act that remain available for  
9 that fiscal year; and

10 (C) funds that remain available under sec-  
11 tion 172(f) of such Act (29 U.S.C. 3227(f)).

12 (3) AVAILABILITY OF FUNDS.—Funds appro-  
13 priated under section 136(c) of such Act (29 U.S.C.  
14 3181(e)) and made available to carry out section  
15 170 of such Act for a fiscal year shall remain avail-  
16 able for use under paragraph (2) for a subsequent  
17 fiscal year until expended.

18 (4) LIMITATION.—The Secretary may not use  
19 more than \$100,000,000 of the funds described in  
20 paragraph (2) for any covered fiscal year under this  
21 section.

22 **SEC. 1411. CAREER ACT.**

23 (a) IN GENERAL.—The Secretary, in consultation  
24 with the Secretary of Labor, shall continue or establish  
25 a program to support individuals in treatment for, or re-

1 recovery from, a substance use disorder to transition to inde-  
2 pendent living and the workforce.

3 (b) GRANTS AUTHORIZED.—In carrying out the ac-  
4 tivities under this section, the Secretary shall, on a com-  
5 petitive basis, award grants for a period of not more than  
6 5 years to entities to enable such entities to carry out evi-  
7 dence-based programs to help individuals in recovery from  
8 a substance use disorder transition from treatment to  
9 independent living and the workforce. Such entities shall  
10 coordinate, as applicable, with Indian tribes or tribal orga-  
11 nizations (as applicable), State boards and local boards  
12 (as defined in section 3 of the Workforce Innovation and  
13 Opportunity Act (29 U.S.C. 3102), lead State agencies  
14 with responsibility for a workforce investment activity (as  
15 defined in such section 3), and State agencies responsible  
16 for carrying out substance use disorder prevention and  
17 treatment programs.

18 (c) PRIORITY.—

19 (1) IN GENERAL.—In awarding grants under  
20 this section, the Secretary shall give priority based  
21 on the State in which the entity is located. Priority  
22 shall be given among States according to a formula  
23 based on the rates described in paragraph (2) and  
24 weighted as described in paragraph (3).

1           (2) RATES.—The rates described in this para-  
2 graph are the following:

3           (A) The amount by which the rate of drug  
4 overdose deaths in the State, adjusted for age,  
5 is above the national overdose mortality rate, as  
6 determined by the Director of the Centers for  
7 Disease Control and Prevention.

8           (B) The amount by which the rate of un-  
9 employment for the State, based on data pro-  
10 vided by the Bureau of Labor Statistics for cal-  
11 endar years 2013 through 2017, is above the  
12 national average.

13           (C) The amount by which rate of labor  
14 force participation in the State, based on data  
15 provided by the Bureau of Labor Statistics for  
16 calendar years 2013 through 2017, is below the  
17 national average.

18           (3) WEIGHTING.—The rates described in para-  
19 graph (2) shall be weighted as follows:

20           (A) The rate described in paragraph  
21 (2)(A) shall be weighted 70 percent.

22           (B) The rate described in paragraph  
23 (2)(B) shall be weighted 15 percent.

24           (C) The rate described in paragraph (2)(C)  
25 shall be weighted 15 percent.

1 (d) PREFERENCE.—In awarding grants under this  
2 section, the Secretary shall give preference to entities lo-  
3 cated in areas with the greatest need, as such need is de-  
4 termined by the Secretary based on the highest mortality  
5 rate related to substance use disorder.

6 (e) APPLICATIONS.—An eligible entity shall submit  
7 an application at such time and in such manner as the  
8 Secretary may require. In submitting an application, the  
9 entity shall demonstrate the ability to partner with local  
10 stakeholders, which may include local employers, commu-  
11 nity stakeholders, the local workforce development board,  
12 local and State governments, and Indian Tribes or tribal  
13 organizations, as applicable, to—

14 (1) identify gaps in the workforce due to the  
15 prevalence of substance use disorders;

16 (2) in coordination with statewide employment  
17 and training activities, including coordination and  
18 alignment of activities carried out by entities pro-  
19 vided grant funds under section 1410, help individ-  
20 uals in recovery from a substance use disorder tran-  
21 sition into the workforce, including by providing ca-  
22 reer services, training services as described in para-  
23 graph (2) of section 134(c) of the Workforce Innova-  
24 tion and Opportunity Act (29 U.S.C. 3174(c)), and

1 related services described in section 134(a)(3) of  
2 such Act (42 U.S.C. 3174(a)); and

3 (3) assist employers with informing their em-  
4 ployees of the resources, such as resources related to  
5 substance use disorders that are available to their  
6 employees.

7 (f) USE OF FUNDS.—An entity receiving a grant  
8 under this section shall use the funds to conduct one or  
9 more of the following activities:

10 (1) Hire case managers, care coordinators, pro-  
11 viders of peer recovery support services, as described  
12 in section 547(a) of the Public Health Service Act  
13 (42 U.S.C. 290ee-2(a)), or other professionals, as  
14 appropriate, to provide services that support treat-  
15 ment, recovery, and rehabilitation, and prevent re-  
16 lapse, recidivism, and overdose, including by encour-  
17 aging—

18 (A) the development of daily living skills;

19 and

20 (B) the use of counseling, care coordina-  
21 tion, and other services, as appropriate, to sup-  
22 port recovery from substance use disorders.

23 (2) Implement or utilize innovative technologies,  
24 which may include the use of telemedicine.



1           (3) In coordination with the lead State agency  
2           with responsibility for a workforce investment activ-  
3           ity or local board described in subsection (b), pro-  
4           vide—

5                   (A) short-term prevocational training serv-  
6           ices; and

7                   (B) training services that are directly  
8           linked to the employment opportunities in the  
9           local area or the planning region.

10          (g) SUPPORT FOR STATE STRATEGY.—An eligible en-  
11       tity shall include in its application under subsection (e)  
12       information describing how the services and activities pro-  
13       posed in such application are aligned with the State, out-  
14       lying area, or Tribal strategy, as applicable, for addressing  
15       issues described in such application and how such entity  
16       will coordinate with existing systems to deliver services as  
17       described in such application.

18          (h) DATA REPORTING AND PROGRAM OVERSIGHT.—  
19       Each eligible entity awarded a grant under this section  
20       shall submit to the Secretary a report at such time and  
21       in such manner as the Secretary may require. Such report  
22       shall include a description of—

23                   (1) the programs and activities funded by the  
24       grant;

1           (2) outcomes of the population of individuals  
2 with a substance use disorder the grantee served  
3 through activities described in subsection (f); and

4           (3) any other information that the Secretary  
5 may require for the purpose of ensuring that the  
6 grantee is complying with all of the requirements of  
7 the grant.

8           (i) REPORTS TO CONGRESS.—

9           (1) PRELIMINARY REPORT.—Not later than 2  
10 years after the end of the first year of the grant pe-  
11 riod under this section, the Secretary shall submit to  
12 Congress a preliminary report that analyzes reports  
13 submitted under subsection (h).

14           (2) FINAL REPORT.—Not later than 2 years  
15 after submitting the preliminary report required  
16 under paragraph (1), the Secretary shall submit to  
17 Congress a final report that includes—

18           (A) an evaluation of the effectiveness of  
19 the activities conducted by the grantee with re-  
20 spect to outcomes of the population of individ-  
21 uals with substance use disorder who receive  
22 services from the grantee; and

23           (B) recommendations, as appropriate, re-  
24 garding ways to improve Federal programs re-  
25 lated to substance use disorders, which may in-

1           clude dissemination of best practices for sup-  
2           porting health care professionals.

3           (j) AUTHORIZATION OF APPROPRIATIONS.—There is  
4 authorized to be appropriated such sums as may be nec-  
5 essary for each of fiscal years 2019 through 2023 for pur-  
6 poses of carrying out this section.

7 **SEC. 1412. PILOT PROGRAM TO HELP INDIVIDUALS IN RE-**  
8                                   **COVERY FROM A SUBSTANCE USE DISORDER**  
9                                   **BECOME STABLY HOUSED.**

10          (a) AUTHORIZATION OF APPROPRIATIONS.—There is  
11 authorized to be appropriated under this section such  
12 sums as may be necessary for each of fiscal years 2019  
13 through 2023 for assistance to States to provide individ-  
14 uals in recovery from a substance use disorder stable, tem-  
15 porary housing for a period of not more than 2 years or  
16 until the individual secures permanent housing, whichever  
17 is earlier.

18          (b) ALLOCATION OF APPROPRIATED AMOUNTS.—

19               (1) IN GENERAL.—The amounts appropriated  
20 or otherwise made available to States under this sec-  
21 tion shall be allocated based on a funding formula  
22 established by the Secretary of Housing and Urban  
23 Development (referred to in this section as the “Sec-  
24 retary”) not later than 60 days after the date of en-  
25 actment of this Act.

## 1 (2) CRITERIA.—

2 (A) IN GENERAL.—The funding formula  
3 required under paragraph (1) shall ensure that  
4 any amounts appropriated or otherwise made  
5 available under this section are allocated to  
6 States with an age-adjusted rate of drug over-  
7 dose deaths that is above the national overdose  
8 mortality rate, according to the Centers for Dis-  
9 ease Control and Prevention.

## 10 (B) PRIORITY.—

11 (i) IN GENERAL.—Among such States,  
12 priority shall be given to States with the  
13 greatest need, as such need is determined  
14 by the Secretary based on the following  
15 factors, and weighting such factors as de-  
16 scribed in clause (ii):

17 (I) The highest average rates of  
18 unemployment based on data provided  
19 by the Bureau of Labor Statistics for  
20 calendar years 2013 through 2017.

21 (II) The lowest average labor  
22 force participation rates based on data  
23 provided by the Bureau of Labor Sta-  
24 tistics for calendar years 2013  
25 through 2017.

1 (III) The highest age-adjusted  
2 rates of drug overdose deaths based  
3 on data from the Centers for Disease  
4 Control and Prevention.

5 (ii) WEIGHTING.—The factors de-  
6 scribed in clause (i) shall be weighted as  
7 follows:

8 (I) The rate described in clause  
9 (i)(I) shall be weighted at 15 percent.

10 (II) The rate described in clause  
11 (i)(II) shall be weighted at 15 percent.

12 (III) The rate described in clause  
13 (i)(III) shall be weighted at 70 per-  
14 cent.

15 (3) DISTRIBUTION.—Amounts appropriated or  
16 otherwise made available under this section shall be  
17 distributed according to the funding formula estab-  
18 lished by the Secretary under paragraph (1) not  
19 later than 30 days after the establishment of such  
20 formula.

21 (c) USE OF FUNDS.—

22 (1) IN GENERAL.—Any State that receives  
23 amounts pursuant to this section shall expend at  
24 least 30 percent of such funds within one year of the

1 date funds become available to the grantee for obli-  
2 gation.

3 (2) PRIORITY.—Any State that receives  
4 amounts pursuant to this section shall distribute  
5 such amounts giving priority to entities with the  
6 greatest need and ability to deliver effective assist-  
7 ance in a timely manner.

8 (3) ADMINISTRATIVE COSTS.—Any State that  
9 receives amounts pursuant to this section may use  
10 up to 5 percent of any grant for administrative  
11 costs.

12 (d) RULES OF CONSTRUCTION.—

13 (1) IN GENERAL.—Except as otherwise pro-  
14 vided by this section, amounts appropriated, or  
15 amounts otherwise made available to States under  
16 this section shall be treated as though such funds  
17 were community development block grant funds  
18 under title I of the Housing and Community Devel-  
19 opment Act of 1974 (42 U.S.C. 5301 et seq.).

20 (2) NO MATCH.—No matching funds shall be  
21 required in order for a State to receive any amounts  
22 under this section.

23 (e) AUTHORITY TO WAIVE OR SPECIFY ALTER-  
24 NATIVE REQUIREMENTS.—

1           (1) IN GENERAL.—In administering any  
2 amounts appropriated or otherwise made available  
3 under this section, the Secretary may waive or speci-  
4 fy alternative requirements to any provision under  
5 title I of the Housing and Community Development  
6 Act of 1974 (42 U.S.C. 5301 et seq.) except for re-  
7 quirements related to fair housing, nondiscrimina-  
8 tion, labor standards, the environment, and require-  
9 ments that activities benefit persons of low- and  
10 moderate-income, upon a finding that such a waiver  
11 is necessary to expedite or facilitate the use of such  
12 funds.

13           (2) NOTICE OF INTENT.—The Secretary shall  
14 provide written notice of its intent to exercise the  
15 authority to specify alternative requirements under  
16 paragraph (1) to the Committee on Banking, Hous-  
17 ing, and Urban Affairs of the Senate and the Com-  
18 mittee on Financial Services of the House of Rep-  
19 resentatives not later than 15 business days before  
20 such exercise of authority occurs.

21           (3) NOTICE TO THE PUBLIC.—The Secretary  
22 shall provide written notice of its intent to exercise  
23 the authority to specify alternative requirements  
24 under paragraph (1) to the public via notice, on the  
25 internet website of the Department of Housing and

1 Urban Development, and by other appropriate  
2 means, not later than 15 business days before such  
3 exercise of authority occurs.

4 (f) TECHNICAL ASSISTANCE.—For the 2-year period  
5 following the date of enactment of this Act, the Secretary  
6 may use not more than 2 percent of the funds made avail-  
7 able under this section for technical assistance to grantees.

8 (g) STATE.—For purposes of this section the term  
9 “State” includes any State as defined in section 102 of  
10 the Housing and Community Development Act of 1974  
11 (42 U.S.C. 5302) and the District of Columbia.

12 **SEC. 1413. YOUTH PREVENTION AND RECOVERY.**

13 (a) SUBSTANCE ABUSE TREATMENT SERVICES FOR  
14 CHILDREN, ADOLESCENTS, AND YOUNG ADULTS.—Sec-  
15 tion 514 of the Public Health Service Act (42 U.S.C.  
16 290bb–7) is amended—

17 (1) in the section heading, by striking “**CHIL-**  
18 **DREN AND ADOLESCENTS**” and inserting “**CHIL-**  
19 **DREN, ADOLESCENTS, AND YOUNG ADULTS**”;

20 (2) in subsection (a)(2), by striking “children,  
21 including” and inserting “children, adolescents, and  
22 young adults, including”; and

23 (3) by striking “children and adolescents” each  
24 place it appears and inserting “children, adolescents,  
25 and young adults”.



1           (b) RESOURCE CENTER.—The Secretary, in consulta-  
2 tion with the Secretary of Education and other heads of  
3 agencies, including the Assistant Secretary of Mental  
4 Health and Substance Use and the Administrator of  
5 Health Resources and Services Administration, as appro-  
6 priate, shall establish a resource center to provide tech-  
7 nical support to recipients of grants under subsection (c).

8           (c) YOUTH PREVENTION AND RECOVERY INITIA-  
9 TIVE.—

10           (1) IN GENERAL.—The Secretary, in consulta-  
11 tion with the Secretary of Education, shall admin-  
12 ister a program to provide support for communities  
13 to support the prevention of, treatment of, and re-  
14 covery from, substance use disorders for children,  
15 adolescents, and young adults.

16           (2) DEFINITIONS.—In this subsection:

17           (A) ELIGIBLE ENTITY.—The term “eligible  
18 entity” means—

19                   (i) a local educational agency that is  
20 seeking to establish or expand substance  
21 use prevention or recovery support services  
22 at one or more high schools;

23                   (ii) a State educational agency;

24                   (iii) an institution of higher education  
25 (or consortia of such institutions), which

1 may include a recovery program at an in-  
2 stitution of higher education;

3 (iv) a local board or one-stop oper-  
4 ator;

5 (v) a nonprofit organization with ap-  
6 propriate expertise in providing services or  
7 programs for children, adolescents, or  
8 young adults, excluding a school;

9 (vi) a State, political subdivision of a  
10 State, Indian Tribe, or tribal organization;

11 or

12 (vii) a high school or dormitory serv-  
13 ing high school students that receives  
14 funding from the Bureau of Indian Edu-  
15 cation.

16 (B) EVIDENCE-BASED.—The term “evi-  
17 dence-based” has the meaning given such term  
18 in section 8101 of the Elementary and Sec-  
19 ondary Education Act (20 U.S.C. 7801).

20 (C) FOSTER CARE.—The term “foster  
21 care” has the meaning given such term in sec-  
22 tion 1355.20(a) of title 45, Code of Federal  
23 Regulations (or any successor regulations).

24 (D) HIGH SCHOOL.—The term “high  
25 school” has the meaning given such term in

1 section 8101 of the Elementary and Secondary  
2 Education Act of 1965 (20 U.S.C. 7801).

3 (E) HOMELESS YOUTH.—The term “home-  
4 less youth” has the meaning given the term  
5 “homeless children or youths” in section 725 of  
6 the McKinney-Vento Homeless Assistance Act  
7 (42 U.S.C. 11434a);

8 (F) INSTITUTION OF HIGHER EDU-  
9 CATION.—The term “institution of higher edu-  
10 cation” has the meaning given such term in  
11 section 101 of the Higher Education Act of  
12 1965 (20 U.S.C. 1001) and includes a “post-  
13 secondary vocational institution” as defined in  
14 section 102(c) of such Act (20 U.S.C. 1002(c)).

15 (G) LOCAL EDUCATIONAL AGENCY.—The  
16 term “local educational agency” has the mean-  
17 ing given the term in section 8101 of the Ele-  
18 mentary and Secondary Education Act of 1965  
19 (20 U.S.C. 7801).

20 (H) LOCAL BOARD; ONE-STOP OPER-  
21 ATOR.—The terms “local board” and “one-stop  
22 operator” have the meanings given such terms  
23 in section 3 of the Workforce Innovation and  
24 Opportunity Act (29 U.S.C. 3102).

1 (I) OUT OF SCHOOL YOUTH.—The term  
2 “out-of-school youth” has the meaning given  
3 such term in section 129(a)(1)(B) of the Work-  
4 force Innovation and Opportunity Act (29  
5 U.S.C. 3164(a)(1)(B)).

6 (J) RECOVERY PROGRAM.—The term “re-  
7 covery program” means a program—

8 (i) to help children, adolescents, or  
9 young adults who are recovering from sub-  
10 stance use disorders to initiate, stabilize,  
11 and maintain healthy and productive lives  
12 in the community; and

13 (ii) that includes peer-to-peer support  
14 delivered by individuals with lived experi-  
15 ence in recovery, and communal activities  
16 to build recovery skills and supportive so-  
17 cial networks.

18 (K) STATE EDUCATIONAL AGENCY.—The  
19 term “State educational agency” has the mean-  
20 ing given the term in section 8101 of the Ele-  
21 mentary and Secondary Education Act (20  
22 U.S.C. 7801).

23 (3) BEST PRACTICES.—The Secretary, in con-  
24 sultation with the Secretary of Education, shall—

1 (A) identify or facilitate the development of  
2 evidence-based best practices for prevention of  
3 substance misuse and abuse by children, adoles-  
4 cents, and young adults, including for specific  
5 populations such as youth in foster care, home-  
6 less youth, out-of-school youth, and youth who  
7 are at risk of or have experienced trafficking  
8 that address—

9 (i) primary prevention;

10 (ii) appropriate recovery support serv-  
11 ices;

12 (iii) appropriate use of medication-as-  
13 sisted treatment for such individuals, if ap-  
14 plicable, and ways of overcoming barriers  
15 to the use of medication-assisted treatment  
16 in such population; and

17 (iv) efficient and effective communica-  
18 tion, which may include the use of social  
19 media, to maximize outreach efforts;

20 (B) disseminate such best practices to  
21 State educational agencies, local educational  
22 agencies, schools and dormitories funded by the  
23 Bureau of Indian Education, institutions of  
24 higher education, recovery programs at institu-  
25 tions of higher education, local boards, one-stop

1 operators, family and youth homeless providers,  
2 and nonprofit organizations, as appropriate;

3 (C) conduct a rigorous evaluation of each  
4 grant funded under this subsection, particularly  
5 its impact on the indicators described in para-  
6 graph (8)(B); and

7 (D) provide technical assistance for grant-  
8 ees under this subsection.

9 (4) GRANTS AUTHORIZED.—The Secretary, in  
10 consultation with the Secretary of Education, shall  
11 award 3-year grants, on a competitive basis, to eligi-  
12 ble entities to enable such entities, in coordination  
13 with Indian Tribes, if applicable, and State agencies  
14 responsible for carrying out substance use disorder  
15 prevention and treatment programs, to carry out evi-  
16 dence-based programs for—

17 (A) prevention of substance misuse and  
18 abuse by children, adolescents, and young  
19 adults, which may include primary prevention;

20 (B) recovery support services for children,  
21 adolescents, and young adults, which may in-  
22 clude counseling, job training, linkages to com-  
23 munity-based services, family support groups,  
24 peer mentoring, and recovery coaching; or

1 (C) treatment or referrals for treatment of  
2 substance use disorders, which may include the  
3 use of medication-assisted treatment, as appro-  
4 priate.

5 (5) SPECIAL CONSIDERATION.—In awarding  
6 grants under this subsection, the Secretary shall give  
7 special consideration to the unique needs of tribal,  
8 urban, suburban, and rural populations.

9 (6) APPLICATION.—To be eligible for a grant  
10 under this subsection, an entity shall submit to the  
11 Secretary an application at such time, in such man-  
12 ner, and containing such information as the Sec-  
13 retary may require. Such application shall include—

14 (A) a description of—

15 (i) the impact of substance use dis-  
16 orders in the population that will be served  
17 by the grant program;

18 (ii) how the eligible entity has solici-  
19 ted input from relevant stakeholders,  
20 which may include faculty, teachers, staff,  
21 families, students, and experts in sub-  
22 stance use prevention and treatment in de-  
23 veloping such application;

24 (iii) the goals of the proposed project,  
25 including the intended outcomes;

1 (iv) how the eligible entity plans to  
2 use grant funds for evidence-based activi-  
3 ties, in accordance with this subsection to  
4 prevent, provide recovery support for, or  
5 treat substance use disorders amongst  
6 such individuals, or a combination of such  
7 activities; and

8 (v) how the eligible entity will collabo-  
9 rate with relevant partners, which may in-  
10 clude State educational agencies, local edu-  
11 cational agencies, institutions of higher  
12 education, juvenile justice agencies, preven-  
13 tion and recovery support providers, local  
14 service providers, including substance use  
15 disorder treatment programs, providers of  
16 mental health services, youth serving orga-  
17 nizations, family and youth homeless pro-  
18 viders, child welfare agencies, and primary  
19 care providers, in carrying out the grant  
20 program; and

21 (B) an assurance that the eligible entity  
22 will participate in the evaluation described in  
23 paragraph (3)(C).

24 (7) PRIORITY.—In awarding grants under this  
25 subsection, the Secretary shall give priority to eligi-



1 ble entities that propose to use grant funds for ac-  
2 tivities that meet the criteria described in subclauses  
3 (I) and (II) of section 8101(21)(A)(i) of the Elemen-  
4 tary and Secondary Education Act (20 U.S.C.  
5 7801(21)(A)(i)).

6 (8) REPORTS TO THE SECRETARY.—Each eligi-  
7 ble entity awarded a grant under this subsection  
8 shall submit to the Secretary a report at such time  
9 and in such manner as the Secretary may require.  
10 Such report shall include—

11 (A) a description of how the eligible entity  
12 used grant funds, in accordance with this sub-  
13 section, including the number of children, ado-  
14 lescents, and young adults reached through pro-  
15 gramming; and

16 (B) a description, including relevant data,  
17 of how the grant program has made an impact  
18 on the intended outcomes described in para-  
19 graph (6)(A)(iii), including—

20 (i) indicators of student success,  
21 which, if the eligible entity is an edu-  
22 cational institution, shall include student  
23 well-being and academic achievement;

24 (ii) substance use disorders amongst  
25 children, adolescents, and young adults, in-

1 cluding the number of overdoses and  
2 deaths amongst children, adolescents, and  
3 young adults during the grant period; and  
4 (iii) other indicators, as the Secretary  
5 determines appropriate.

6 (9) REPORT TO CONGRESS.—The Secretary  
7 shall, not later than October 1, 2022, submit a re-  
8 port to the Committee on Health, Education, Labor,  
9 and Pensions of the Senate, and the Committee on  
10 Energy and Commerce and the Committee on Edu-  
11 cation and the Workforce of the House of Rep-  
12 resentatives, a report summarizing the effectiveness  
13 of the grant program under this subsection, based  
14 on the information submitted in reports required  
15 under paragraph (8).

16 (10) AUTHORIZATION OF APPROPRIATIONS.—  
17 There is authorized to be appropriated such sums as  
18 may be necessary to carry out this subsection for  
19 each of fiscal years 2019 through 2023.

20 **SEC. 1414. PLANS OF SAFE CARE.**

21 Section 105(a) of the Child Abuse Prevention and  
22 Treatment Act (42 U.S.C. 5106(a)) is amended by adding  
23 at the end the following:

24 “(7) GRANTS TO STATES TO IMPROVE AND CO-  
25 ORDINATE THEIR RESPONSE TO ENSURE THE SAFE-

1 TY, PERMANENCY, AND WELL-BEING OF INFANTS  
2 AFFECTED BY SUBSTANCE USE.—

3 “(A) PROGRAM AUTHORIZED.—The Sec-  
4 retary shall make grants to States for the pur-  
5 pose of assisting child welfare agencies, social  
6 services agencies, substance use disorder treat-  
7 ment agencies, hospitals with labor and delivery  
8 units, medical staff, public health and mental  
9 health agencies, and maternal and child health  
10 agencies to facilitate collaboration in developing,  
11 updating, implementing, and monitoring plans  
12 of safe care described in section  
13 106(b)(2)(B)(iii).

14 “(B) DISTRIBUTION OF FUNDS.—

15 “(i) RESERVATIONS.—Of the amounts  
16 appropriated under subparagraph (H), the  
17 Secretary shall reserve—

18 “(I) no more than 3 percent for  
19 the purposes described in subpara-  
20 graph (G); and

21 “(II) up to 3 percent for grants  
22 to Indian Tribes and tribal organiza-  
23 tions to address the needs of infants  
24 born with, and identified as being af-  
25 fected by, substance abuse or with-

1 drawal symptoms resulting from pre-  
2 natal drug exposure or a fetal alcohol  
3 spectrum disorder and their families  
4 or caregivers, which to the extent  
5 practicable, shall be consistent with  
6 the uses of funds described under sub-  
7 paragraph (D).

8 “(ii) ALLOTMENTS TO STATES AND  
9 TERRITORIES.—The Secretary shall allot  
10 the amount appropriated under subpara-  
11 graph (H) that remains after application  
12 of clause (i) to each State that applies for  
13 such a grant, in an amount equal to the  
14 sum of—

15 “(I) \$500,000; and

16 “(II) an amount that bears the  
17 same relationship to any funds appro-  
18 priated under subparagraph (H) and  
19 remaining after application of clause  
20 (i), as the number of live births in the  
21 State in the previous calendar year  
22 bears to the number of live births in  
23 all States in such year.

24 “(iii) RATABLE REDUCTION.—If the  
25 amount appropriated under subparagraph

1 (H) is insufficient to satisfy the require-  
2 ments of clause (ii), the Secretary shall  
3 ratably reduce each allotment to a State.

4 “(C) APPLICATION.—A State desiring a  
5 grant under this paragraph shall submit an ap-  
6 plication to the Secretary at such time and in  
7 such manner as the Secretary may require.  
8 Such application shall include—

9 “(i) a description of—

10 “(I) the impact of substance use  
11 disorder in such State, including with  
12 respect to the substance or class of  
13 substances with the highest incidence  
14 of abuse in the previous year in such  
15 State, including—

16 “(aa) the prevalence of sub-  
17 stance use disorder in such State;

18 “(bb) the aggregate rate of  
19 births in the State of infants af-  
20 fected by substance abuse or  
21 withdrawal symptoms or a fetal  
22 alcohol spectrum disorder (as de-  
23 termined by hospitals, insurance  
24 claims, claims submitted to the  
25 State Medicaid program, or other

1 records), if available and to the  
2 extent practicable; and

3 “(cc) the number of infants  
4 identified, for whom a plan of  
5 safe care was developed, and for  
6 whom a referral was made for  
7 appropriate services, as reported  
8 under section 106(d)(18);

9 “(II) the challenges the State  
10 faces in developing, implementing, and  
11 monitoring plans of safe care in ac-  
12 cordance with section  
13 106(b)(2)(B)(iii);

14 “(III) the State’s lead agency for  
15 the grant program and how that agen-  
16 cy will coordinate with relevant State  
17 entities and programs, including the  
18 child welfare agency, the substance  
19 use disorder treatment agency, hos-  
20 pitals with labor and delivery units,  
21 health care providers, the public  
22 health and mental health agencies,  
23 programs funded by the Substance  
24 Abuse and Mental Health Services  
25 Administration that provide substance

1 use disorder treatment for women, the  
2 State Medicaid program, the State  
3 agency administering the block grant  
4 program under title V of the Social  
5 Security Act (42 U.S.C. 701 et seq.),  
6 the State agency administering the  
7 programs funded under part C of the  
8 Individuals with Disabilities Edu-  
9 cation Act (20 U.S.C. 1431 et seq.),  
10 the maternal, infant, and early child-  
11 hood home visiting program under  
12 section 511 of the Social Security Act  
13 (42 U.S.C. 711), the State judicial  
14 system, and other agencies, as deter-  
15 mined by the Secretary, and Indian  
16 Tribes and tribal organizations, as ap-  
17 propriate;

18 “(IV) how the State will monitor  
19 local development and implementation  
20 of plans of safe care, in accordance  
21 with section 106(b)(2)(B)(iii)(II), in-  
22 cluding how the State will monitor to  
23 ensure plans of safe care address dif-  
24 ferences between substance use dis-  
25 order and medically supervised sub-

1                   stance use, including for the treat-  
2                   ment of a substance use disorder;

3                   “(V) how the State meets the re-  
4                   quirements of section 1927 of the  
5                   Public Health Service Act (42 U.S.C.  
6                   300x-27);

7                   “(VI) how the State plans to uti-  
8                   lize funding authorized under part E  
9                   of title IV of the Social Security Act  
10                  (42 U.S.C. 670 et seq.) to assist in  
11                  carrying out any plan of safe care, in-  
12                  cluding such funding authorized under  
13                  section 471(e) of such Act (as in ef-  
14                  fect on October 1, 2018) for mental  
15                  health and substance abuse prevention  
16                  and treatment services and in-home  
17                  parent skill-based programs and fund-  
18                  ing authorized under such section  
19                  472(j) (as in effect on October 1,  
20                  2018) for children with a parent in a  
21                  licensed residential family-based treat-  
22                  ment facility for substance abuse; and

23                  “(VII) an assessment of the  
24                  treatment and other services and pro-  
25                  grams available in the State, to effec-



1           tively carry out any plan of safe care  
2           developed, including identification of  
3           needed treatment, and other services  
4           and programs to ensure the well-being  
5           of young children and their families  
6           affected by substance use disorder,  
7           such as programs carried out under  
8           part C of the Individuals with Disabil-  
9           ities Education Act and comprehen-  
10          sive early childhood development serv-  
11          ices and programs such as Head Start  
12          programs;

13           “(ii) a description of how the State  
14          plans to use funds for activities described  
15          in subparagraph (D) for the purposes of  
16          ensuring State compliance with require-  
17          ments under clauses (ii) and (iii) of section  
18          106(b)(2)(B); and

19           “(iii) an assurance that the State  
20          will—

21                   “(I) comply with this Act and  
22                   parts B and E of title IV of the Social  
23                   Security Act (42 U.S.C. 621 et seq.,  
24                   670 et seq.); and

1                   “(II) comply with requirements  
2                   to refer a child identified as sub-  
3                   stance-exposed to early intervention  
4                   services as required pursuant to a  
5                   grant under part C of the Individuals  
6                   with Disabilities Education Act (20  
7                   U.S.C. 1431 et seq.).

8                   “(D) USES OF FUNDS.—Funds awarded to  
9                   a State under this paragraph may be used for  
10                  the following activities, which may be carried  
11                  out by the State directly, or through grants or  
12                  subgrants, contracts, or cooperative agreements:

13                  “(i) Improving State and local sys-  
14                  tems with respect to the development and  
15                  implementation of plans of safe care,  
16                  which—

17                  “(I) shall include parent and  
18                  caregiver engagement, as required  
19                  under section 106(b)(2)(B)(iii)(I), re-  
20                  garding available treatment and serv-  
21                  ice options, which may include re-  
22                  sources available for pregnant,  
23                  perinatal, and postnatal women; and

24                  “(II) may include activities such  
25                  as—

1           “(aa) developing policies,  
2           procedures, or protocols for the  
3           administration or development of  
4           evidence-based and validated  
5           screening tools for infants who  
6           may be affected by substance use  
7           withdrawal symptoms or a fetal  
8           alcohol spectrum disorder and  
9           pregnant, perinatal, and post-  
10          natal women whose infants may  
11          be affected by substance use  
12          withdrawal symptoms or a fetal  
13          alcohol spectrum disorder;

14           “(bb) improving assessments  
15          used to determine the needs of  
16          the infant and family;

17           “(cc) improving ongoing  
18          case management services; and

19           “(dd) improving access to  
20          treatment services, which may be  
21          prior to the pregnant woman’s  
22          delivery date.

23           “(ii) Developing policies, procedures,  
24          or protocols in consultation and coordina-  
25          tion with health professionals, public and

1 private health facilities, and substance use  
2 disorder treatment agencies to ensure  
3 that—

4 “(I) appropriate notification to  
5 child protective services is made in a  
6 timely manner;

7 “(II) a plan of safe care is in  
8 place, in accordance with section  
9 106(b)(2)(B)(iii), before the infant is  
10 discharged from the birth or health  
11 care facility; and

12 “(III) such health and related  
13 agency professionals are trained on  
14 how to follow such protocols and are  
15 aware of the supports that may be  
16 provided under a plan of safe care.

17 “(iii) Training health professionals  
18 and health system leaders, child welfare  
19 workers, substance use disorder treatment  
20 agencies, and other related professionals  
21 such as home visiting agency staff and law  
22 enforcement in relevant topics including—

23 “(I) State mandatory reporting  
24 laws and the referral and process re-  
25 quirements for notification to child

1 protective services when child abuse or  
2 neglect reporting is not mandated;

3 “(II) the co-occurrence of preg-  
4 nancy and substance use disorder, and  
5 implications of prenatal exposure;

6 “(III) the clinical guidance about  
7 treating substance use disorder in  
8 pregnant and postpartum women;

9 “(IV) appropriate screening and  
10 interventions for infants affected by  
11 substance use disorder, withdrawal  
12 symptoms, or a fetal alcohol spectrum  
13 disorder and the requirements under  
14 section 106(b)(2)(B)(iii); and

15 “(V) appropriate  
16 multigenerational strategies to ad-  
17 dress the mental health needs of the  
18 parent and child together.

19 “(iv) Establishing partnerships, agree-  
20 ments, or memoranda of understanding be-  
21 tween the lead agency and health profes-  
22 sionals, health facilities, child welfare pro-  
23 fessionals, juvenile and family court  
24 judges, substance use and mental disorder  
25 treatment programs, early childhood edu-

1 cation programs, and maternal and child  
2 health and early intervention professionals,  
3 including home visiting providers, peer-to-  
4 peer recovery programs such as parent  
5 mentoring programs, and housing agencies  
6 to facilitate the implementation of, and  
7 compliance with section 106(b)(2) and  
8 clause (ii) of this subparagraph, in areas  
9 which may include—

10 “(I) developing a comprehensive,  
11 multi-disciplinary assessment and  
12 intervention process for infants, preg-  
13 nant women, and their families who  
14 are affected by substance use dis-  
15 order, withdrawal symptoms, or a  
16 fetal alcohol spectrum disorder, that  
17 includes meaningful engagement with  
18 and takes into account the unique  
19 needs of each family and addresses  
20 differences between medically super-  
21 vised substance use, including for the  
22 treatment of substance use disorder,  
23 and substance use disorder;

24 “(II) ensuring that treatment ap-  
25 proaches for serving infants, pregnant

1 women, and perinatal and postnatal  
2 women whose infants may be affected  
3 by substance use, withdrawal symp-  
4 toms, or a fetal alcohol spectrum dis-  
5 order, are designed to, where appro-  
6 priate, keep infants with their moth-  
7 ers during both inpatient and out-  
8 patient treatment; and

9 “(III) increasing access to all evi-  
10 dence-based medication-assisted treat-  
11 ment approved by the Food and Drug  
12 Administration, behavioral therapy,  
13 and counseling services for the treat-  
14 ment of substance use disorders, as  
15 appropriate.

16 “(v) Developing and updating systems  
17 of technology for improved data collection  
18 and monitoring under section  
19 106(b)(2)(B)(iii), including existing elec-  
20 tronic medical records, to measure the out-  
21 comes achieved through the plans of safe  
22 care, including monitoring systems to meet  
23 the requirements of this Act and submis-  
24 sion of performance measures.

1           “(E) REPORTING.—Each State that re-  
2 ceives funds under this paragraph, for each  
3 year such funds are received, shall submit a re-  
4 port to the Secretary, disaggregated by geo-  
5 graphic location, economic status, and major  
6 racial and ethnic groups, except that such  
7 disaggregation shall not be required if the re-  
8 sults would reveal personally identifiable infor-  
9 mation on, with respect to infants identified  
10 under section 106(b)(2)(B)(ii)—

11                   “(i) the number who experienced re-  
12 moval associated with parental substance  
13 use;

14                   “(ii) the number who experienced re-  
15 moval and subsequently are reunified with  
16 parents, and the length of time between  
17 such removal and reunification;

18                   “(iii) the number who are referred to  
19 community providers without a child pro-  
20 tection case;

21                   “(iv) the number who receive services  
22 while in the care of their birth parents;

23                   “(v) the number who receive post-re-  
24 unification services within 1 year after a  
25 reunification has occurred; and



1                   “(vi) the number who experienced a  
2                   return to out-of-home care within 1 year  
3                   after reunification.

4                   “(F) SECRETARY’S REPORT TO CON-  
5                   GRESS.—The Secretary shall submit an annual  
6                   report to the Committee on Health, Education,  
7                   Labor, and Pensions and the Committee on Ap-  
8                   propriations of the Senate and the Committee  
9                   on Education and the Workforce and the Com-  
10                  mittee on Appropriations of the House of Rep-  
11                  resentatives that includes the information de-  
12                  scribed in subparagraph (E) and recommenda-  
13                  tions or observations on the challenges, suc-  
14                  cesses, and lessons derived from implementation  
15                  of the grant program.

16                  “(G) RESERVATION OF FUNDS.—The Sec-  
17                  retary shall use the amount reserved under sub-  
18                  paragraph (B)(i)(I) for the purposes of—

19                         “(i) providing technical assistance, in-  
20                         cluding programs of in-depth technical as-  
21                         sistance, to additional States, territories,  
22                         and Indian Tribes and tribal organizations  
23                         in accordance with the substance-exposed  
24                         infant initiative developed by the National

1 Center on Substance Abuse and Child Wel-  
2 fare;

3 “(ii) issuing guidance on the require-  
4 ments of this Act with respect to infants  
5 born with and identified as being affected  
6 by substance use or withdrawal symptoms  
7 or fetal alcohol spectrum disorder, as de-  
8 scribed in clauses (ii) and (iii) of section  
9 106(b)(2)(B), including by—

10 “(I) clarifying key terms; and

11 “(II) disseminating best practices  
12 on implementation of plans of safe  
13 care, on such topics as differential re-  
14 sponse, collaboration and coordina-  
15 tion, and identification and delivery of  
16 services for different populations;

17 “(iii) supporting State efforts to de-  
18 velop information technology systems to  
19 manage plans of safe care; and

20 “(iv) preparing the Secretary’s report  
21 to Congress described in subparagraph  
22 (F).

23 “(H) AUTHORIZATION OF APPROPRIA-  
24 TIONS.—To carry out the program under this  
25 paragraph, there is authorized to be appro-

1            priedated \$60,000,000 for each of fiscal years  
2            2019 through 2023.”.

3 **SEC. 1415. REGULATIONS RELATING TO SPECIAL REG-**  
4 **ISTRATION FOR TELEMEDICINE.**

5            Section 311(h) of the Controlled Substances Act (21  
6 U.S.C. 831(h)) is amended by striking paragraph (2) and  
7 inserting the following:

8            “(2) REGULATIONS.—

9            “(A) IN GENERAL.—Not later than 1 year  
10            after the date of enactment of the Opioid Crisis  
11            Response Act of 2018, in consultation with the  
12            Secretary, and in accordance with the procedure  
13            described in subparagraph (B), the Attorney  
14            General shall promulgate final regulations  
15            specifying—

16            “(i) the limited circumstances in  
17            which a special registration under this sub-  
18            section may be issued; and

19            “(ii) the procedure for obtaining a  
20            special registration under this subsection.

21            “(B) PROCEDURE.—In promulgating final  
22            regulations under subparagraph (A), the Attor-  
23            ney General shall—

1 “(i) issue a notice of proposed rule-  
2 making that includes a copy of the pro-  
3 posed regulations;

4 “(ii) provide a period of not less than  
5 60 days for comments on the proposed reg-  
6 ulations;

7 “(iii) finalize the proposed regulation  
8 not later than 6 months after the close of  
9 the comment period; and

10 “(iv) publish the final regulations not  
11 later than 30 days before the effective date  
12 of the final regulations.”.

13 **SEC. 1416. NATIONAL HEALTH SERVICE CORPS BEHAV-**  
14 **IORAL AND MENTAL HEALTH PROFES-**  
15 **SIONALS PROVIDING OBLIGATED SERVICE IN**  
16 **SCHOOLS AND OTHER COMMUNITY-BASED**  
17 **SETTINGS.**

18 Subpart III of part D of title III of the Public Health  
19 Service Act (42 U.S.C. 254*l* et seq.) is amended by adding  
20 at the end the following:

1 **“SEC. 338N. BEHAVIORAL AND MENTAL HEALTH PROFES-**  
2 **SIONALS PROVIDING OBLIGATED SERVICE IN**  
3 **SCHOOLS AND OTHER COMMUNITY-BASED**  
4 **SETTINGS.**

5 “(a) SCHOOLS AND COMMUNITY-BASED SETTINGS.—  
6 An entity to which a participant in the Scholarship Pro-  
7 gram or the Loan Repayment Program (referred to in this  
8 section as a ‘participant’) is assigned under section 333  
9 may direct such participant to provide service as a behav-  
10 ioral or mental health professional at a school or other  
11 community-based setting located in a health professional  
12 shortage area.

13 “(b) OBLIGATED SERVICE.—

14 “(1) IN GENERAL.—Any service described in  
15 subsection (a) that a participant provides may count  
16 towards such participant’s completion of any obli-  
17 gated service requirements under the Scholarship  
18 Program or the Loan Repayment Program, subject  
19 to any limitation imposed under paragraph (2).

20 “(2) LIMITATION.—The Secretary may impose  
21 a limitation on the number of hours of service de-  
22 scribed in subsection (a) that a participant may  
23 credit towards completing obligated service require-  
24 ments, provided that the limitation allows a member  
25 to credit service described in subsection (a) for not

1 less than 50 percent of the total hours required to  
2 complete such obligated service requirements.

3 “(c) **RULE OF CONSTRUCTION.**—The authorization  
4 under subsection (a) shall be notwithstanding any other  
5 provision of this subpart or subpart II.”.

6 **SEC. 1417. LOAN REPAYMENT FOR SUBSTANCE USE DIS-**  
7 **ORDER TREATMENT PROVIDERS.**

8 (a) **LOAN REPAYMENT FOR SUBSTANCE USE TREAT-**  
9 **MENT PROVIDERS.**—The Secretary shall enter into con-  
10 tracts under section 338B of the Public Health Service  
11 Act (42 U.S.C. 254l–1) with eligible health professionals  
12 providing substance use disorder treatment services in  
13 substance use disorder treatment facilities, as defined by  
14 the Secretary.

15 (b) **PROVISION OF SUBSTANCE USE DISORDER**  
16 **TREATMENT.**—In carrying out the activities described in  
17 subsection (a)—

18 (1) each such facility shall be located in or serv-  
19 ing a mental health professional shortage area des-  
20 ignated under section 332 of the Public Health Serv-  
21 ice Act (42 U.S.C. 254e), or, as the Secretary deter-  
22 mines appropriate, an area with an age-adjusted  
23 rate of drug overdose deaths that is above the na-  
24 tional overdose mortality rate;

1           (2) section 331(a)(3)(D) of such Act (42 U.S.C.  
2           254d(a)(3)(D)) shall be applied as if the term “pri-  
3           mary health services” includes health services re-  
4           garding substance use disorder treatment and infec-  
5           tions associated with illicit drug use;

6           (3) section 331(a)(3)(E)(i) of such Act (42  
7           U.S.C. 254d(a)(3)(E)(i)) shall be applied as if the  
8           term “behavioral and mental health professionals”  
9           includes master’s level, licensed substance use dis-  
10          order treatment counselors, and other relevant pro-  
11          fessionals or paraprofessionals, as the Secretary de-  
12          termines appropriate; and

13          (4) such professionals and facilities shall pro-  
14          vide—

15                (A) directly, or through the use of tele-  
16                health technology, and pursuant to Federal and  
17                State law, counseling by a program counselor or  
18                other certified professional who is licensed and  
19                qualified by education, training, or experience  
20                to assess the psychological and sociological  
21                background of patients, to contribute to the ap-  
22                propriate treatment plan for the patient, and to  
23                monitor progress; and

24                (B) medication-assisted treatment, includ-  
25                ing, to the extent practicable, all drugs ap-

1           proved by the Food and Drug Administration to  
2           treat substance use disorders, pursuant to Fed-  
3           eral and State law.

4           (c) AUTHORIZATION OF APPROPRIATIONS.—There is  
5 authorized to be appropriated to carry out this section  
6 \$25,000,000 for each of fiscal years 2019 through 2023.

7 **SEC. 1418. PROTECTING MOMS AND INFANTS.**

8           (a) REPORT.—

9           (1) IN GENERAL.—Not later than 60 days after  
10 the date of enactment of this Act, the Secretary  
11 shall submit to the appropriate committees of Con-  
12 gress and make available to the public on the inter-  
13 net website of the Department of Health and  
14 Human Services a report regarding the implementa-  
15 tion of the recommendations in the strategy relating  
16 to prenatal opioid use, including neonatal abstinence  
17 syndrome, developed pursuant to section 2 of the  
18 Protecting Our Infants Act of 2015 (Public Law  
19 114–91). Such report shall include—

20           (A) an update on the implementation of  
21 the recommendations in the strategy, including  
22 information regarding the agencies involved in  
23 the implementation; and

24           (B) information on additional funding or  
25 authority the Secretary requires, if any, to im-





1 and Prevention, develop educational materials for  
2 clinicians to use with pregnant women for shared de-  
3 cisionmaking regarding pain management during  
4 pregnancy.”.

5 (b) GUIDELINES AND RECOMMENDATIONS BY CEN-  
6 TER FOR SUBSTANCE ABUSE TREATMENT.—Section  
7 507(b) of the Public Health Service Act (42 U.S.C.  
8 290bb(b)) is amended—

9 (1) in paragraph (13), by striking “and” at the  
10 end;

11 (2) in paragraph (14), by striking the period at  
12 the end and inserting a semicolon; and

13 (3) by adding at the end the following:

14 “(15) in cooperation with the Secretary, imple-  
15 ment and disseminate, as appropriate, the rec-  
16 ommendations in the report entitled ‘Protecting Our  
17 Infants Act: Final Strategy’ issued by the Depart-  
18 ment of Health and Human Services in 2017; and”.

19 (c) SUPPORT OF PARTNERSHIPS BY CENTER FOR  
20 SUBSTANCE ABUSE TREATMENT.—Section 507(b) of the  
21 Public Health Service Act (42 U.S.C. 290bb(b)), as  
22 amended by subsection (b), is further amended by adding  
23 at the end the following:

24 “(16) in cooperation with relevant stakeholders,  
25 support public-private partnerships to assist with

1 education about, and support with respect to, sub-  
2 stance use disorder for pregnant women and health  
3 care providers who treat pregnant women and ba-  
4 bies.”.

5 **SEC. 1420. REPORT ON INVESTIGATIONS REGARDING PAR-**  
6 **ITY IN MENTAL HEALTH AND SUBSTANCE**  
7 **USE DISORDER BENEFITS.**

8 (a) IN GENERAL.—Section 13003 of the 21st Cen-  
9 tury Cures Act (Public Law 114–255) is amended—

10 (1) in subsection (a), by striking “with findings  
11 of any serious violation regarding” and inserting  
12 “concerning”; and

13 (2) in subsection (b)(1)—

14 (A) by inserting “complaints received and  
15 number of” before “closed”; and

16 (B) by inserting before the period “, and,  
17 for each such investigation closed, which agency  
18 conducted the investigation, whether the health  
19 plan that is the subject of the investigation is  
20 fully insured or not fully insured and a sum-  
21 mary of any coordination between the applicable  
22 State regulators and the Department of Labor,  
23 the Department of Health and Human Services,  
24 or the Department of the Treasury, and ref-  
25 erences to any guidance provided by the agen-

1           cies addressing the category of violation com-  
2           mitted”.

3           (b) APPLICABILITY.—The amendments made by sub-  
4 section (a) shall apply with respect to the second annual  
5 report required under such section 13003 and each such  
6 annual report thereafter.

## 7                           **Subtitle E—Prevention**

### 8   **SEC. 1501. STUDY ON PRESCRIBING LIMITS.**

9           Not later than 2 years after the date of enactment  
10 of this Act, the Secretary, in consultation with the Attor-  
11 ney General, shall submit to the Committee on Health,  
12 Education, Labor, and Pensions of the Senate and the  
13 Committee on Energy and Commerce of the House of  
14 Representatives a report on the impact of Federal and  
15 State laws and regulations that limit the length, quantity,  
16 or dosage of opioid prescriptions. Such report shall ad-  
17 dress—

18                   (1) the impact of such limits on—

19                           (A) the incidence and prevalence of over-  
20 dose related to prescription opioids;

21                           (B) the incidence and prevalence of over-  
22 dose related to illicit opioids;

23                           (C) the prevalence of opioid use disorders;

24                           (D) medically appropriate use of, and ac-  
25 cess to, opioids, including any impact on travel

1 expenses and pain management outcomes for  
2 patients, whether such limits are associated  
3 with significantly higher rates of negative  
4 health outcomes, including suicide, and whether  
5 the impact of such limits differs based on the  
6 clinical indication for which opioids are pre-  
7 scribed;

8 (2) whether such limits lead to a significant in-  
9 crease in burden for prescribers of opioids or pre-  
10 scribers of treatments for opioid use disorder, in-  
11 cluding any impact on patient access to treatment,  
12 and whether any such burden is mitigated by any  
13 factors such as electronic prescribing or telemedi-  
14 cine; and

15 (3) the impact of such limits on diversion or  
16 misuse of any controlled substance in schedule II,  
17 III, or IV of section 202(c) of the Controlled Sub-  
18 stances Act (21 U.S.C. 812(c)).

19 **SEC. 1502. PROGRAMS FOR HEALTH CARE WORKFORCE.**

20 (a) PROGRAM FOR EDUCATION AND TRAINING IN  
21 PAIN CARE.—Section 759 of the Public Health Service  
22 Act (42 U.S.C. 294i) is amended—

23 (1) in subsection (a), by striking “hospices, and  
24 other public and private entities” and inserting  
25 “hospices, tribal health programs (as defined in sec-

1           tion 4 of the Indian Health Care Improvement Act),  
2           and other public and nonprofit private entities”;

3           (2) in subsection (b)—

4                   (A) in the matter preceding paragraph (1),  
5                   by striking “award may be made under sub-  
6                   section (a) only if the applicant for the award  
7                   agrees that the program carried out with the  
8                   award will include” and inserting “entity receiv-  
9                   ing an award under this section shall develop a  
10                  comprehensive education and training plan that  
11                  includes”;

12                  (B) in paragraph (1)—

13                          (i) by inserting “preventing,” after  
14                          “diagnosing,”; and

15                          (ii) by inserting “non-addictive med-  
16                          ical products and non-pharmacologic treat-  
17                          ments and” after “including”;

18                  (C) in paragraph (2)—

19                          (i) by inserting “Federal, State, and  
20                          local” after “applicable”; and

21                          (ii) by striking “the degree to which”  
22                          and all that follows through “effective pain  
23                          care” and inserting “opioids”;

24                  (D) in paragraph (3), by inserting “, inte-  
25                  grated, evidence-based pain management, and,

1 as appropriate, non-pharmacotherapy” before  
2 the semicolon;

3 (E) in paragraph (4), by striking “; and”  
4 and inserting “;”; and

5 (F) by striking paragraph (5) and insert-  
6 ing the following:

7 “(5) recent findings, developments, and ad-  
8 vancements in pain care research and the provision  
9 of pain care, which may include non-addictive med-  
10 ical products and non-pharmacologic treatments in-  
11 tended to treat pain; and

12 “(6) the dangers of opioid abuse and misuse,  
13 detection of early warning signs of opioid use dis-  
14 orders (which may include best practices related to  
15 screening for opioid use disorders, training on  
16 screening, brief intervention, and referral to treat-  
17 ment), and safe disposal options for prescription  
18 medications (including such options provided by law  
19 enforcement or other innovative deactivation mecha-  
20 nisms).”;

21 (3) in subsection (d), by inserting “prevention,”  
22 after “diagnosis,”; and

23 (4) in subsection (e), by striking “2010 through  
24 2012” and inserting “2019 through 2023”.

1 (b) MENTAL AND BEHAVIORAL HEALTH EDUCATION  
2 AND TRAINING PROGRAM.—Section 756(a) of the Public  
3 Health Service Act (42 U.S.C. 294e–1(a)) is amended—

4 (1) in paragraph (1), by inserting “, trauma,”  
5 after “focus on child and adolescent mental health”;  
6 and

7 (2) in paragraphs (2) and (3), by inserting  
8 “trauma-informed care and” before “substance use  
9 disorder prevention and treatment services”.

10 **SEC. 1503. EDUCATION AND AWARENESS CAMPAIGNS.**

11 Section 102 of the Comprehensive Addiction and Re-  
12 covery Act of 2016 (Public Law 114–198) is amended—

13 (1) by amending subsection (a) to read as fol-  
14 lows:

15 “(a) IN GENERAL.—The Secretary of Health and  
16 Human Services, acting through the Director of the Cen-  
17 ters for Disease Control and Prevention and in coordina-  
18 tion with the heads of other departments and agencies,  
19 shall advance education and awareness regarding the risks  
20 related to misuse and abuse of opioids, as appropriate,  
21 which may include developing or improving existing pro-  
22 grams, conducting activities, and awarding grants that ad-  
23 vance the education and awareness of—

24 “(1) the public, including patients and con-  
25 sumers;



1           “(2) patients, consumers, and other appropriate  
2 members of the public, regarding such risks related  
3 to unused opioids and the dispensing options under  
4 section 309(f) of the Controlled Substances Act, as  
5 applicable;

6           “(3) providers, which may include—

7               “(A) providing for continuing education on  
8 appropriate prescribing practices;

9               “(B) education related to applicable State  
10 or local prescriber limit laws, information on  
11 the use of non-addictive alternatives for pain  
12 management, and the use of overdose reversal  
13 drugs, as appropriate;

14               “(C) disseminating and improving the use  
15 of evidence-based opioid prescribing guidelines  
16 across relevant health care settings, as appro-  
17 priate, and updating guidelines as necessary;

18               “(D) implementing strategies, such as best  
19 practices, to encourage and facilitate the use of  
20 prescriber guidelines, in accordance with State  
21 and local law;

22               “(E) disseminating information to pro-  
23 viders about prescribing options for controlled  
24 substances, including such options under sec-

1 tion 309(f) of the Controlled Substances Act, as  
2 applicable; and

3 “(F) disseminating information, as appro-  
4 priate, on the National Pain Strategy developed  
5 by or in consultation with the Assistant Sec-  
6 retary for Health; and

7 “(4) other appropriate entities.”; and  
8 (2) in subsection (b)—

9 (A) by striking “opioid abuse” each place  
10 such term appears and inserting “opioid misuse  
11 and abuse”; and

12 (B) in paragraph (2), by striking “safe dis-  
13 posal of prescription medications and other”  
14 and inserting “non-addictive treatment options,  
15 safe disposal options for prescription medica-  
16 tions, and other applicable”.

17 **SEC. 1504. ENHANCED CONTROLLED SUBSTANCE**  
18 **OVERDOSES DATA COLLECTION, ANALYSIS,**  
19 **AND DISSEMINATION.**

20 Part J of title III of the Public Health Service Act  
21 is amended by inserting after section 392 (42 U.S.C.  
22 280b-1) the following:

1 **“SEC. 392A. ENHANCED CONTROLLED SUBSTANCE**  
2 **OVERDOSES DATA COLLECTION, ANALYSIS,**  
3 **AND DISSEMINATION.**

4 “(a) IN GENERAL.—The Director of the Centers for  
5 Disease Control and Prevention, using the authority pro-  
6 vided to the Director under section 392, may—

7 “(1) to the extent practicable, carry out and ex-  
8 pand any controlled substance overdose data collec-  
9 tion, analysis, and dissemination activity described  
10 in subsection (b);

11 “(2) provide training and technical assistance  
12 to States, localities, and Indian Tribes for the pur-  
13 pose of carrying out any such activity; and

14 “(3) award grants to States, localities, and In-  
15 dian Tribes for the purpose of carrying out any such  
16 activity.

17 “(b) CONTROLLED SUBSTANCE OVERDOSE DATA  
18 COLLECTION AND ANALYSIS ACTIVITIES.—A controlled  
19 substance overdose data collection, analysis, and dissemi-  
20 nation activity described in this subsection is any of the  
21 following activities:

22 “(1) Improving the timeliness of reporting ag-  
23 gregate data to the public, including data on fatal  
24 and nonfatal controlled substance overdoses.

25 “(2) Enhancing the comprehensiveness of con-  
26 trolled substance overdose data by collecting infor-

1       mation on such overdoses from appropriate sources  
2       such as toxicology reports, autopsy reports, death  
3       scene investigations, and emergency department  
4       services.

5               “(3) Modernizing the system for coding causes  
6       of death related to controlled substance overdoses to  
7       use an electronic-based system.

8               “(4) Using data to help identify risk factors as-  
9       sociated with controlled substance overdoses, includ-  
10      ing the delivery of certain health care services.

11              “(5) Supporting entities involved in reporting  
12      information on controlled substance overdoses, such  
13      as coroners and medical examiners, to improve accu-  
14      rate testing and standardized reporting of causes  
15      and contributing factors of such overdoses, and anal-  
16      ysis of various opioid analogues to controlled sub-  
17      stance overdoses.

18              “(6) Working to enable and encourage the ac-  
19      cess, exchange, and use of data regarding controlled  
20      substances overdoses among data sources and enti-  
21      ties.

22      “(c) DEFINITIONS.—In this section—

23              “(1) the term ‘controlled substance’ has the  
24      meaning given that term in section 102 of the Con-  
25      trolled Substances Act; and

1           “(2) the term ‘Indian Tribe’ has the meaning  
2           given the term ‘Indian tribe’ in section 4 of the In-  
3           dian Self-Determination and Education Assistance  
4           Act.”.

5   **SEC. 1505. PREVENTING OVERDOSES OF CONTROLLED SUB-**  
6                           **STANCES.**

7           Part J of title III of the Public Health Service Act  
8           (42 U.S.C. 280b et seq.), as amended by section 504, is  
9           further amended by inserting after section 392A the fol-  
10          lowing:

11   **“SEC. 392B. PREVENTING OVERDOSES OF CONTROLLED**  
12                           **SUBSTANCES.**

13          “(a) PREVENTION ACTIVITIES.—

14               “(1) IN GENERAL.—The Director of the Cen-  
15               ters for Disease Control and Prevention (referred to  
16               in this section as the ‘Director’), using the authority  
17               provided to the Director under section 392, may—

18                       “(A) to the extent practicable, carry out  
19                       and expand any prevention activity described in  
20                       paragraph (2);

21                       “(B) provide training and technical assist-  
22                       ance to States, localities, and Indian Tribes to  
23                       carry out any such activity; and

1           “(C) award grants to States, localities, and  
2           Indian Tribes for the purpose of carrying out  
3           any such activity.

4           “(2) PREVENTION ACTIVITIES.—A prevention  
5           activity described in this paragraph is an activity to  
6           improve the efficiency and use of a new or currently  
7           operating prescription drug monitoring program,  
8           such as—

9           “(A) encouraging all authorized users (as  
10           specified by the State or other entity) to reg-  
11           ister with and use the program;

12           “(B) enabling such users to access any  
13           data updates in as close to real-time as prac-  
14           ticable;

15           “(C) providing for a mechanism for the  
16           program to notify authorized users of any po-  
17           tential misuse or abuse of controlled substances  
18           and any detection of inappropriate prescribing  
19           or dispensing practices relating to such sub-  
20           stances;

21           “(D) encouraging the analysis of prescrip-  
22           tion drug monitoring data for purposes of pro-  
23           viding de-identified, aggregate reports based on  
24           such analysis to State public health agencies,  
25           State alcohol and drug agencies, State licensing

1 boards, and other appropriate State agencies,  
2 as permitted under applicable Federal and  
3 State law and the policies of the prescription  
4 drug monitoring program and not containing  
5 any protected health information, to prevent in-  
6 appropriate prescribing, drug diversion, or  
7 abuse and misuse of controlled substances, and  
8 to facilitate better coordination among agencies;

9 “(E) enhancing interoperability between  
10 the program and any health information tech-  
11 nology (including certified health information  
12 technology), including by integrating program  
13 data into such technology;

14 “(F) updating program capabilities to re-  
15 spond to technological innovation for purposes  
16 of appropriately addressing the occurrence and  
17 evolution of controlled substance overdoses;

18 “(G) developing or enhancing data ex-  
19 change with other sources such as the Medicaid  
20 agency, the Medicare program, pharmacy ben-  
21 efit managers, coroners’ reports, and workers’  
22 compensation data;

23 “(H) facilitating and encouraging data ex-  
24 change between the program and the prescrip-  
25 tion drug monitoring programs of other States;

1           “(I) enhancing data collection and quality,  
2           including improving patient matching and  
3           proactively monitoring data quality; and

4           “(J) providing prescriber and dispenser  
5           practice tools, including prescriber practice in-  
6           sight reports for practitioners to review their  
7           prescribing patterns in comparison to such pat-  
8           terns of other practitioners in the specialty.

9           “(b) ADDITIONAL GRANTS.—The Director may  
10          award grants to States, localities, and Indian Tribes—

11           “(1) to carry out innovative projects for grant-  
12           ees to rapidly respond to controlled substance mis-  
13           use, abuse, and overdoses, including changes in pat-  
14           terns of controlled substance use; and

15           “(2) for any other evidence-based activity for  
16           preventing controlled substance misuse, abuse, and  
17           overdoses as the Director determines appropriate.

18           “(c) RESEARCH.—The Director, in coordination with  
19          the Assistant Secretary for Mental Health and Substance  
20          Use and the National Mental Health and Substance Use  
21          Policy Laboratory established under section 501A, as ap-  
22          propriate and applicable, may conduct studies and evalua-  
23          tions to address substance use disorders, including pre-  
24          venting substance use disorders or other related topics the  
25          Director determines appropriate.



1       “(d) PUBLIC AND PRESCRIBER EDUCATION.—Pursu-  
2 ant to section 102 of the Comprehensive Addiction and  
3 Recovery Act of 2016, the Director may advance the edu-  
4 cation and awareness of prescribers and the public regard-  
5 ing the risk of abuse and misuse of prescription opioids.

6       “(e) DEFINITIONS.—In this section—

7           “(1) the term ‘controlled substance’ has the  
8 meaning given that term in section 102 of the Con-  
9 trolled Substances Act; and

10          “(2) the term ‘Indian Tribe’ has the meaning  
11 given the term ‘Indian tribe’ in section 4 of the In-  
12 dian Self-Determination and Education Assistance  
13 Act.

14       “(f) AUTHORIZATION OF APPROPRIATIONS.—For  
15 purposes of carrying out this section, section 392A of this  
16 Act, and section 102 of the Comprehensive Addiction and  
17 Recovery Act of 2016, there is authorized to be appro-  
18 priated \$486,000,000 for each of fiscal years 2019  
19 through 2024.”.

20 **SEC. 1506. CDC SURVEILLANCE AND DATA COLLECTION**  
21 **FOR CHILD, YOUTH, AND ADULT TRAUMA.**

22       (a) DATA COLLECTION.—The Director of the Centers  
23 for Disease Control and Prevention (referred to in this  
24 section as the “Director”) may, in cooperation with the  
25 States, collect and report data on adverse childhood expe-

1 riences through the Behavioral Risk Factor Surveillance  
2 System, the Youth Risk Behavior Surveillance System,  
3 and other relevant public health surveys or questionnaires.

4 (b) TIMING.—The collection of data under subsection  
5 (a) may occur in fiscal year 2019 and every 2 years there-  
6 after.

7 (c) DATA FROM RURAL AREAS.—The Director shall  
8 encourage each State that participates in collecting and  
9 reporting data under subsection (a) to collect and report  
10 data from tribal and rural areas within such State, in  
11 order to generate a statistically reliable representation of  
12 such areas.

13 (d) DATA FROM TRIBAL AREAS.—The Director may,  
14 in cooperation with Indian Tribes and pursuant to a writ-  
15 ten request from an Indian Tribe, provide technical assist-  
16 ance to such Indian Tribe to collect and report data on  
17 adverse childhood experiences through the Behavioral Risk  
18 Factor Surveillance System, the Youth Risk Behavior Sur-  
19 veillance System, or another relevant public health survey  
20 or questionnaire.

21 (e) AUTHORIZATION OF APPROPRIATIONS.—To carry  
22 out this section, there is authorized to be appropriated  
23 such sums as may be necessary for the period of fiscal  
24 years 2019 through 2021.

1 **SEC. 1507. REAUTHORIZATION OF NASPER.**

2 Section 3990 of the Public Health Service Act (42  
3 U.S.C. 280g-3) is amended—

4 (1) in subsection (a)—

5 (A) in paragraph (1), in the matter pre-  
6 ceding subparagraph (A), by striking “in con-  
7 sultation with the Administrator of the Sub-  
8 stance Abuse and Mental Health Services Ad-  
9 ministration and Director of the Centers for  
10 Disease Control and Prevention” and inserting  
11 “in coordination with the Director of the Cen-  
12 ters for Disease Control and the heads of other  
13 departments and agencies as appropriate”; and

14 (B) by adding at the end the following:

15 “(4) STATES AND LOCAL GOVERNMENTS.—

16 “(A) IN GENERAL.—In the case of a State  
17 that does not have a prescription drug moni-  
18 toring program, a county or other unit of local  
19 government within the State that has a pre-  
20 scription drug monitoring program shall be  
21 treated as a State for purposes of this section,  
22 including for purposes of eligibility for grants  
23 under paragraph (1).

24 “(B) PLAN FOR INTEROPERABILITY.—For  
25 purposes of meeting the interoperability re-  
26 quirements under subsection (c)(3), a county or

1 other unit of local government shall submit a  
2 plan outlining the methods such county or unit  
3 of local government will use to ensure the capa-  
4 bility of data sharing with other counties and  
5 units of local government within the State and  
6 with other States, as applicable.”;

7 (2) in subsection (c)—

8 (A) in paragraph (1)(A)(iii)—

9 (i) by inserting “as such standards  
10 become available,” after “interoperability  
11 standards,”; and

12 (ii) by striking “generated or identi-  
13 fied by the Secretary or his or her des-  
14 ignee” and inserting “recognized by the  
15 Office of the National Coordinator for  
16 Health Information Technology”; and

17 (B) in paragraph (3)(A), by inserting “in-  
18 cluding electronic health records,” after “tech-  
19 nology systems,”;

20 (3) in subsection (d)(1), by striking “not later  
21 than 1 week after the date of such dispensing” and  
22 inserting “in as close to real time as practicable”;

23 (4) in subsection (f)—

24 (A) in paragraph (1)(D), by striking “med-  
25 icaid” and inserting “Medicaid”; and

1 (B) in paragraph (2)—

2 (i) in subparagraph (A), by striking

3 “and” at the end;

4 (ii) in subparagraph (B), by striking  
5 the period and inserting a semicolon; and

6 (iii) by adding at the end the fol-  
7 lowing:

8 “(C) may conduct analyses of controlled  
9 substance program data for purposes of pro-  
10 viding appropriate State agencies with aggreg-  
11 ate reports based on such analyses in as close  
12 to real-time as practicable, regarding prescrip-  
13 tion patterns flagged as potentially presenting a  
14 risk of misuse, abuse, addiction, overdose, and  
15 other aggregate information, as appropriate and  
16 in compliance with applicable Federal and State  
17 laws and provided that such reports shall not  
18 include protected health information; and

19 “(D) may access information about pre-  
20 scriptions, such as claims data, to ensure that  
21 such prescribing and dispensing history is up-  
22 dated in as close to real-time as practicable, in  
23 compliance with applicable Federal and State  
24 laws and provided that such information shall  
25 not include protected health information.”;

1           (5) in subsection (i), by inserting “, in collabo-  
2           ration with the National Coordinator for Health In-  
3           formation Technology and the Director of the Na-  
4           tional Institute of Standards and Technology,” after  
5           “The Secretary”; and

6           (6) in subsection (n), by striking “2021” and  
7           inserting “2026”.

8 **SEC. 1508. JESSIE’S LAW.**

9           (a) BEST PRACTICES.—

10           (1) IN GENERAL.—Not later than 1 year after  
11           the date of enactment of this Act, the Secretary, in  
12           consultation with appropriate stakeholders, including  
13           a patient with a history of opioid use disorder, an  
14           expert in electronic health records, an expert in the  
15           confidentiality of patient health information and  
16           records, and a health care provider, shall identify or  
17           facilitate the development of best practices regard-  
18           ing—

19                   (A) the circumstances under which infor-  
20                   mation that a patient has provided to a health  
21                   care provider regarding such patient’s history of  
22                   opioid use disorder should, only at the patient’s  
23                   request, be prominently displayed in the med-  
24                   ical records (including electronic health records)  
25                   of such patient;

1 (B) what constitutes the patient's request  
2 for the purpose described in subparagraph (A);  
3 and

4 (C) the process and methods by which the  
5 information should be so displayed.

6 (2) DISSEMINATION.—The Secretary shall dis-  
7 seminate the best practices developed under para-  
8 graph (1) to health care providers and State agen-  
9 cies.

10 (b) REQUIREMENTS.—In identifying or facilitating  
11 the development of best practices under subsection (a), as  
12 applicable, the Secretary, in consultation with appropriate  
13 stakeholders, shall consider the following:

14 (1) The potential for addiction relapse or over-  
15 dose, including overdose death, when opioid medica-  
16 tions are prescribed to a patient recovering from  
17 opioid use disorder.

18 (2) The benefits of displaying information  
19 about a patient's opioid use disorder history in a  
20 manner similar to other potentially lethal medical  
21 concerns, including drug allergies and contraindica-  
22 tions.

23 (3) The importance of prominently displaying  
24 information about a patient's opioid use disorder  
25 when a physician or medical professional is pre-

1       scribing medication, including methods for avoiding  
2       alert fatigue in providers.

3           (4) The importance of a variety of appropriate  
4       medical professionals, including physicians, nurses,  
5       and pharmacists, having access to information de-  
6       scribed in this section when prescribing or dis-  
7       pensing opioid medication, consistent with Federal  
8       and State laws and regulations.

9           (5) The importance of protecting patient pri-  
10      vacy, including the requirements related to consent  
11      for disclosure of substance use disorder information  
12      under all applicable laws and regulations.

13           (6) All applicable Federal and State laws and  
14      regulations.

15 **SEC. 1509. DEVELOPMENT AND DISSEMINATION OF MODEL**  
16                   **TRAINING PROGRAMS FOR SUBSTANCE USE**  
17                   **DISORDER PATIENT RECORDS.**

18       (a) INITIAL PROGRAMS AND MATERIALS.—Not later  
19      than 1 year after the date of the enactment of this Act,  
20      the Secretary, in consultation with appropriate experts,  
21      shall identify the following model programs and materials  
22      (or if no such programs or materials exist, recognize pri-  
23      vate or public entities to develop and disseminate such  
24      programs and materials):



1           (1) Model programs and materials for training  
2 health care providers (including physicians, emer-  
3 gency medical personnel, psychiatrists, psychologists,  
4 counselors, therapists, nurse practitioners, physician  
5 assistants, behavioral health facilities and clinics,  
6 care managers, and hospitals, including individuals  
7 such as general counsels or regulatory compliance  
8 staff who are responsible for establishing provider  
9 privacy policies) concerning the permitted uses and  
10 disclosures, consistent with the standards and regu-  
11 lations governing the privacy and security of sub-  
12 stance use disorder patient records promulgated by  
13 the Secretary under section 543 of the Public  
14 Health Service Act (42 U.S.C. 290dd-2) for the  
15 confidentiality of patient records.

16           (2) Model programs and materials for training  
17 patients and their families regarding their rights to  
18 protect and obtain information under the standards  
19 and regulations described in paragraph (1).

20           (b) REQUIREMENTS.—The model programs and ma-  
21 terials described in paragraphs (1) and (2) of subsection  
22 (a) shall address circumstances under which disclosure of  
23 substance use disorder patient records is needed to—

24           (1) facilitate communication between substance  
25 use disorder treatment providers and other health

1 care providers to promote and provide the best possible integrated care;

2 (2) avoid inappropriate prescribing that can  
3 lead to dangerous drug interactions, overdose, or re-  
4 lapse; and

5 (3) notify and involve families and caregivers  
6 when individuals experience an overdose.

7 (c) PERIODIC UPDATES.—The Secretary shall—

8 (1) periodically review and update the model  
9 program and materials identified or developed under  
10 subsection (a); and

11 (2) disseminate such updated programs and  
12 materials to the individuals described in subsection  
13 (a)(1).

14 (d) INPUT OF CERTAIN ENTITIES.—In identifying,  
15 reviewing, or updating the model programs and materials  
16 under this section, the Secretary shall solicit the input of  
17 relevant stakeholders.

18 (e) AUTHORIZATION OF APPROPRIATIONS.—There is  
19 authorized to be appropriated to carry out this section,  
20 such sums as may be necessary for each of fiscal years  
21 2019 through 2023.

1 **SEC. 1510. COMMUNICATION WITH FAMILIES DURING**  
2 **EMERGENCIES.**

3 (a) PROMOTING AWARENESS OF AUTHORIZED DIS-  
4 CLOSURES DURING EMERGENCIES.—The Secretary shall  
5 annually notify health care providers regarding permitted  
6 disclosures during emergencies, including overdoses, of  
7 certain health information to families and caregivers  
8 under Federal health care privacy laws and regulations.

9 (b) USE OF MATERIAL.—For the purposes of car-  
10 rying out subsection (a), the Secretary may use material  
11 produced under section 1509 of this Act or under section  
12 11004 of the 21st Century Cures Act (42 U.S.C. 1320d-  
13 2 note).

14 **SEC. 1511. PRENATAL AND POSTNATAL HEALTH.**

15 Section 317L of the Public Health Service Act (42  
16 U.S.C. 247b-13) is amended—

17 (1) in subsection (a)—

18 (A) by amending paragraph (1) to read as  
19 follows:

20 “(1) to collect, analyze, and make available data  
21 on prenatal smoking and alcohol and substance  
22 abuse and misuse, including—

23 “(A) data on—

24 “(i) the incidence, prevalence, and im-  
25 plications of such activities; and

1                   “(ii) the incidence and prevalence of  
2                   implications and outcomes, including neo-  
3                   natal abstinence syndrome and other ma-  
4                   ternal and child health outcomes associated  
5                   with such activities; and

6                   “(B) to inform such analysis, additional in-  
7                   formation or data on family health history,  
8                   medication exposures during pregnancy, demo-  
9                   graphic information, such as race, ethnicity, ge-  
10                  ographic location, and family history, and other  
11                  relevant information, as appropriate;”;

12                  (B) in paragraph (2)—

13                         (i) by striking “prevention of” and in-  
14                         serting “prevention and long-term out-  
15                         comes associated with”; and

16                         (ii) by striking “illegal drug use” and  
17                         inserting “substance abuse and misuse”;

18                  (C) in paragraph (3), by striking “and ces-  
19                  sation programs; and” and inserting “, treat-  
20                  ment, and cessation programs;”;

21                  (D) in paragraph (4), by striking “illegal  
22                  drug use.” and inserting “substance abuse and  
23                  misuse; and”; and

24                  (E) by adding at the end the following:

1           “(5) to issue public reports on the analysis of  
2 data described in paragraph (1), including analysis  
3 of—

4                   “(A) long-term outcomes of children af-  
5 fected by neonatal abstinence syndrome;

6                   “(B) health outcomes associated with pre-  
7 natal smoking, alcohol, and substance abuse  
8 and misuse; and

9                   “(C) relevant studies, evaluations, or infor-  
10 mation the Secretary determines to be appro-  
11 priate.”;

12           (2) in subsection (b), by inserting “tribal enti-  
13 ties,” after “local governments,”;

14           (3) by redesignating subsection (c) as sub-  
15 section (d);

16           (4) by inserting after subsection (b) the fol-  
17 lowing:

18           “(c) COORDINATING ACTIVITIES.—To carry out this  
19 section, the Secretary may—

20                   “(1) provide technical and consultative assist-  
21 ance to entities receiving grants under subsection  
22 (b);

23                   “(2) ensure a pathway for data sharing between  
24 States, tribal entities, and the Centers for Disease  
25 Control and Prevention;

1           “(3) ensure data collection under this section is  
2 consistent with applicable State, Federal, and Tribal  
3 privacy laws; and

4           “(4) coordinate with the National Coordinator  
5 for Health Information Technology, as appropriate,  
6 to assist States and Tribes in implementing systems  
7 that use standards recognized by such National Co-  
8 ordinator, as such recognized standards are avail-  
9 able, in order to facilitate interoperability between  
10 such systems and health information technology sys-  
11 tems, including certified health information tech-  
12 nology.”; and

13           (5) in subsection (d), as so redesignated, by  
14 striking “2001 through 2005” and inserting “2019  
15 through 2023”.

16 **SEC. 1512. SURVEILLANCE AND EDUCATION REGARDING**  
17 **INFECTIONS ASSOCIATED WITH ILLICIT**  
18 **DRUG USE AND OTHER RISK FACTORS.**

19           Section 317N of the Public Health Service Act (42  
20 U.S.C. 247b-15) is amended—

21           (1) by amending the section heading to read as  
22 follows: “**SURVEILLANCE AND EDUCATION RE-**  
23 **GARDING INFECTIONS ASSOCIATED WITH IL-**  
24 **LICIT DRUG USE AND OTHER RISK FACTORS**”;

25           (2) in subsection (a)—

1 (A) in the matter preceding paragraph (1),  
2 by inserting “activities” before the colon;

3 (B) in paragraph (1)—

4 (i) by inserting “or maintaining” after  
5 “implementing”;

6 (ii) by striking “hepatitis C virus in-  
7 fection (in this section referred to as ‘HCV  
8 infection’)” and inserting “infections com-  
9 monly associated with illicit drug use,  
10 which may include viral hepatitis, human  
11 immunodeficiency virus, and infective en-  
12 docarditis,”; and

13 (iii) by striking “such infection” and  
14 all that follows through the period at the  
15 end and inserting “such infections, which  
16 may include the reporting of cases of such  
17 infections.”;

18 (C) in paragraph (2), by striking “HCV  
19 infection” and all that follows through the pe-  
20 riod at the end and inserting “infections as a  
21 result of illicit drug use, receiving blood trans-  
22 fusions prior to July 1992, or other risk fac-  
23 tors.”;

24 (D) in paragraphs (4) and (5), by striking  
25 “HCV infection” each place such term appears

1 and inserting “infections described in para-  
2 graph (1)”; and

3 (E) in paragraph (5), by striking “pedia-  
4 tricians and other primary care physicians, and  
5 obstetricians and gynecologists” and inserting  
6 “substance use disorder treatment providers,  
7 pediatricians, other primary care providers, and  
8 obstetrician-gynecologists”;

9 (3) in subsection (b)—

10 (A) by striking “directly and” and insert-  
11 ing “directly or”; and

12 (B) by striking “hepatitis C,” and all that  
13 follows through the period at the end and in-  
14 serting “infections described in subsection  
15 (a)(1).”; and

16 (4) in subsection (c), by striking “such sums as  
17 may be necessary for each of the fiscal years 2001  
18 through 2005” and inserting “\$40,000,000 for each  
19 of fiscal years 2019 through 2023”.

20 **SEC. 1513. TASK FORCE TO DEVELOP BEST PRACTICES FOR**  
21 **TRAUMA-INFORMED IDENTIFICATION, RE-**  
22 **FERRAL, AND SUPPORT.**

23 (a) **ESTABLISHMENT.**—There is established a task  
24 force, to be known as the Interagency Task Force on  
25 Trauma-Informed Care (in this section referred to as the



1 “task force”) that shall identify, evaluate, and make rec-  
2 ommendations regarding best practices with respect to  
3 children and youth, and their families as appropriate, who  
4 have experienced or are at risk of experiencing trauma.

5 (b) MEMBERSHIP.—

6 (1) COMPOSITION.—The task force shall be  
7 composed of the heads of the following Federal de-  
8 partments and agencies, or their designees:

9 (A) The Centers for Medicare & Medicaid  
10 Services.

11 (B) The Substance Abuse and Mental  
12 Health Services Administration.

13 (C) The Agency for Healthcare Research  
14 and Quality.

15 (D) The Centers for Disease Control and  
16 Prevention.

17 (E) The Indian Health Service.

18 (F) The Department of Veterans Affairs.

19 (G) The National Institutes of Health.

20 (H) The Food and Drug Administration.

21 (I) The Health Resources and Services Ad-  
22 ministration.

23 (J) The Department of Defense.

24 (K) The Office of Minority Health.

1           (L) The Administration for Children and  
2 Families.

3           (M) The Office of the Assistant Secretary  
4 for Planning and Evaluation.

5           (N) The Office for Civil Rights of the De-  
6 partment of Health and Human Services.

7           (O) The Office of Juvenile Justice and De-  
8 linquency Prevention of the Department of Jus-  
9 tice.

10          (P) The Office of Community Oriented Po-  
11 licing Services of the Department of Justice.

12          (Q) The Office on Violence Against  
13 Women of the Department of Justice.

14          (R) The National Center for Education  
15 Evaluation and Regional Assistance of the De-  
16 partment of Education.

17          (S) The National Center for Special Edu-  
18 cation Research of the Institute of Education  
19 Science.

20          (T) The Office of Elementary and Sec-  
21 ondary Education of the Department of Edu-  
22 cation.

23          (U) The Office for Civil Rights of the De-  
24 partment of Education.

1                   (V) The Office of Special Education and  
2                   Rehabilitative Services of the Department of  
3                   Education.

4                   (W) The Bureau of Indian Affairs of the  
5                   Department of the Interior.

6                   (X) The Veterans Health Administration  
7                   of the Department of Veterans Affairs.

8                   (Y) The Office of Special Needs Assistance  
9                   Programs of the Department of Housing and  
10                  Urban Development.

11                  (Z) The Office of Head Start of the Ad-  
12                  ministration for Children and Families.

13                  (AA) The Children's Bureau of the Admin-  
14                  istration for Children and Families.

15                  (BB) The Bureau of Indian Education of  
16                  the Department of the Interior.

17                  (CC) Such other Federal agencies as the  
18                  Secretaries determine to be appropriate.

19                  (2) DATE OF APPOINTMENTS.—The heads of  
20                  Federal departments and agencies shall appoint the  
21                  corresponding members of the task force not later  
22                  than 6 months after the date of enactment of this  
23                  Act.

1           (3) CHAIRPERSON.—The task force shall be  
2           chaired by the Assistant Secretary for Mental  
3           Health and Substance Use.

4           (c) TASK FORCE DUTIES.—The task force shall—

5           (1) solicit input from stakeholders, including  
6           frontline service providers, educators, mental health  
7           professionals, researchers, experts in infant, child,  
8           and youth trauma, child welfare professionals, and  
9           the public, in order to inform the activities under  
10          paragraph (2); and

11          (2) identify, evaluate, make recommendations,  
12          and update such recommendations not less than an-  
13          nually, to the general public, the Secretary of Edu-  
14          cation, the Secretary of Health and Human Services,  
15          the Secretary of Labor, the Secretary of the Inte-  
16          rior, the Attorney General, and other relevant cabi-  
17          net Secretaries, and Congress regarding—

18                (A) a set of evidence-based, evidence-in-  
19                formed, and promising best practices with re-  
20                spect to—

21                   (i) the identification of infants, chil-  
22                   dren and youth, and their families as ap-  
23                   propriate, who have experienced or are at  
24                   risk of experiencing trauma; and



1                   where appropriate, for trauma-informed  
2                   practices; and

3                   (ii) to the general public through the  
4                   internet website of the task force.

5           (d) BEST PRACTICES.—In identifying, evaluating,  
6 and recommending the set of best practices under sub-  
7 section (c), the task force shall—

8                   (1) include guidelines for providing professional  
9                   development for front-line services providers, includ-  
10                  ing school personnel, early childhood education pro-  
11                  gram providers, providers from child- or youth-serv-  
12                  ing organizations, housing and homeless providers,  
13                  primary and behavioral health care providers, child  
14                  welfare and social services providers, juvenile and  
15                  family court personnel, health care providers, indi-  
16                  viduals who are mandatory reporters of child abuse  
17                  or neglect, trained nonclinical providers (including  
18                  peer mentors and clergy), and first responders, in—

19                           (A) understanding and identifying early  
20                           signs and risk factors of trauma in infants,  
21                           children, and youth, and their families as ap-  
22                           propriate, including through screening proc-  
23                           esses;

24                           (B) providing practices to prevent and  
25                           mitigate the impact of trauma, including by fos-

1           tering safe and stable environments and rela-  
2           tionships; and

3                   (C) developing and implementing policies,  
4           procedures, or systems that—

5                   (i) are designed to quickly refer in-  
6           fants, children, youth, and their families as  
7           appropriate, who have experienced or are  
8           at risk of experiencing trauma to the ap-  
9           propriate trauma-informed screening and  
10          support, including age-appropriate treat-  
11          ment, and to ensure such infants, children,  
12          youth, and family members receive such  
13          support;

14                   (ii) utilize and develop partnerships  
15          with early childhood education programs,  
16          local social services organizations, such as  
17          organizations serving youth, and clinical  
18          mental health or health care service pro-  
19          viders with expertise in providing support  
20          services (including age-appropriate trauma-  
21          informed and evidence-based treatment)  
22          aimed at preventing or mitigating the ef-  
23          fects of trauma;

24                   (iii) educate children and youth to—

1 (I) understand and identify the  
2 signs, effects, or symptoms of trauma;  
3 and

4 (II) build the resilience and cop-  
5 ing skills to mitigate the effects of ex-  
6 periencing trauma;

7 (iv) promote and support multi-  
8 generational practices that assist parents,  
9 foster parents, and kinship and other care-  
10 givers in accessing resources related to,  
11 and developing environments conducive to,  
12 the prevention and mitigation of trauma;  
13 and

14 (v) collect and utilize data from  
15 screenings, referrals, or the provision of  
16 services and supports to evaluate and im-  
17 prove processes for trauma-informed sup-  
18 port and outcomes that are culturally sen-  
19 sitive, linguistically appropriate, and spe-  
20 cific to age ranges and sex, as applicable;  
21 and

22 (2) recommend best practices that are designed  
23 to avoid unwarranted custody loss or criminal pen-  
24 alties for parents or guardians in connection with in-



1       fants, children, and youth who have experienced or  
2       are at risk of experiencing trauma.

3       (e) OPERATING PLAN.—Not later than 1 year after  
4 the date of enactment of this Act, the task force shall hold  
5 the first meeting. Not later than 2 years after such date  
6 of enactment, the task force shall submit to the Secretary  
7 of Education, Secretary of Health and Human Services,  
8 Secretary of Labor, Secretary of the Interior, the Attorney  
9 General, and Congress an operating plan for carrying out  
10 the activities of the task force described in subsection  
11 (c)(2). Such operating plan shall include—

12           (1) a list of specific activities that the task  
13 force plans to carry out for purposes of carrying out  
14 duties described in subsection (c)(2), which may in-  
15 clude public engagement;

16           (2) a plan for carrying out the activities under  
17 subsection (c)(2);

18           (3) a list of members of the task force and  
19 other individuals who are not members of the task  
20 force that may be consulted to carry out such activi-  
21 ties;

22           (4) an explanation of Federal agency involve-  
23 ment and coordination needed to carry out such ac-  
24 tivities, including any statutory or regulatory bar-  
25 riers to such coordination;

1           (5) a budget for carrying out such activities;  
2           and

3           (6) other information that the task force deter-  
4           mines appropriate.

5           (f) FINAL REPORT.—Not later than 3 years after the  
6           date of the first meeting of the task force, the task force  
7           shall submit to the general public, Secretary of Education,  
8           Secretary of Health and Human Services, Secretary of  
9           Labor, Secretary of the Interior, the Attorney General,  
10          and other relevant cabinet Secretaries, and Congress, a  
11          final report containing all of the findings and rec-  
12          ommendations required under this section.

13          (g) DEFINITION.—In this section, the term “early  
14          childhood education program” has the meaning given such  
15          term in section 103 of the Higher Education Act of 1965  
16          (20 U.S.C. 1003).

17          (h) AUTHORIZATION OF APPROPRIATIONS.—To carry  
18          out this section, there is authorized to be appropriated  
19          such sums as may be necessary for each of fiscal years  
20          2019 through 2022.

21          (i) SUNSET.—The task force shall on the date that  
22          is 60 days after the submission of the final report under  
23          subsection (f), but not later than September 30, 2022.

1 **SEC. 1514. GRANTS TO IMPROVE TRAUMA SUPPORT SERV-**  
2 **ICES AND MENTAL HEALTH CARE FOR CHIL-**  
3 **DREN AND YOUTH IN EDUCATIONAL SET-**  
4 **TINGS.**

5 (a) GRANTS, CONTRACTS, AND COOPERATIVE  
6 AGREEMENTS AUTHORIZED.—The Secretary, in coordina-  
7 tion with the Assistant Secretary for Mental Health and  
8 Substance Use, is authorized to award grants to, or enter  
9 into contracts or cooperative agreements with, State edu-  
10 cational agencies, local educational agencies, Head Start  
11 agencies (including Early Head Start agencies), State or  
12 local agencies that administer public preschool programs,  
13 Indian Tribes or their tribal educational agencies, a school  
14 operated by the Bureau of Indian Education, a Regional  
15 Corporation (as defined in section 3 of the Alaska Native  
16 Claims Settlement Act (43 U.S.C. 1602)), or a Native Ha-  
17 waiian educational organization (as defined in section  
18 6207 of the Elementary and Secondary Education Act of  
19 1965 (20 U.S.C. 7517)), for the purpose of increasing stu-  
20 dent access to evidence-based trauma support services and  
21 mental health care by developing innovative initiatives, ac-  
22 tivities, or programs to link local school systems with local  
23 trauma-informed support and mental health systems, in-  
24 cluding those under the Indian Health Service.

25 (b) DURATION.—With respect to a grant, contract,  
26 or cooperative agreement awarded or entered into under

1 this section, the period during which payments under such  
2 grant, contract or agreement are made to the recipient  
3 may not exceed 4 years.

4 (c) USE OF FUNDS.—An entity that receives a grant,  
5 contract, or cooperative agreement under this section shall  
6 use amounts made available through such grant, contract,  
7 or cooperative agreement for evidence-based activities,  
8 which shall include any of the following:

9 (1) Collaborative efforts between school-based  
10 service systems and trauma-informed support and  
11 mental health service systems to provide, develop, or  
12 improve prevention, screening, referral, and treat-  
13 ment and support services to students, such as by  
14 providing universal trauma screenings to identify  
15 students in need of specialized support.

16 (2) To implement schoolwide multi-tiered posi-  
17 tive behavioral interventions and supports, or other  
18 trauma-informed models of support.

19 (3) To provide professional development to  
20 teachers, teacher assistants, school leaders, special-  
21 ized instructional support personnel, and mental  
22 health professionals that—

23 (A) fosters safe and stable learning envi-  
24 ronments that prevent and mitigate the effects

1 of trauma, including through social and emo-  
2 tional learning;

3 (B) improves school capacity to identify,  
4 refer, and provide services to students in need  
5 of trauma support or behavioral health services;  
6 or

7 (C) reflects the best practices developed by  
8 the Interagency Task Force on Trauma-In-  
9 formed Care established under section 513.

10 (4) To create or enhance services at a full-serv-  
11 ice community school that focuses on trauma-in-  
12 formed supports, which may include establishing a  
13 school-site advisory team, managing, coordinating,  
14 or delivering pipeline services, hiring a full-time site  
15 coordinator, or other activities consistent with sec-  
16 tion 4625 of the Elementary and Secondary Edu-  
17 cation Act of 1965 (20 U.S.C. 7275).

18 (5) Engaging families and communities in ef-  
19 forts to increase awareness of child and youth trau-  
20 ma, which may include sharing best practices with  
21 law enforcement regarding trauma-informed care  
22 and working with mental health professionals to pro-  
23 vide interventions, as well as longer term coordi-  
24 nated care within the community for children and

1 youth who have experienced trauma and their fami-  
2 lies.

3 (6) To provide technical assistance to school  
4 systems and mental health agencies.

5 (7) To evaluate the effectiveness of the program  
6 carried out under this section in increasing student  
7 access to evidence-based trauma support services  
8 and mental health care.

9 (d) APPLICATIONS.—To be eligible to receive a grant,  
10 contract, or cooperative agreement under this section, an  
11 entity described in subsection (a) shall submit an applica-  
12 tion to the Secretary at such time, in such manner, and  
13 containing such information as the Secretary may reason-  
14 ably require, which shall include the following:

15 (1) A description of the innovative initiatives,  
16 activities, or programs to be funded under the grant,  
17 contract, or cooperative agreement, including how  
18 such program will increase access to evidence-based  
19 trauma support services and mental health care for  
20 students, and, as applicable, the families of such stu-  
21 dents.

22 (2) A description of how the program will pro-  
23 vide linguistically appropriate and culturally com-  
24 petent services.

1           (3) A description of how the program will sup-  
2           port students and the school in improving the school  
3           climate in order to support an environment condu-  
4           cive to learning.

5           (4) An assurance that—

6                 (A) persons providing services under the  
7                 grant, contract, or cooperative agreement are  
8                 adequately trained to provide such services; and

9                 (B) teachers, school leaders, administra-  
10                tors, specialized instructional support personnel,  
11                representatives of local Indian Tribes or tribal  
12                organizations as appropriate, other school per-  
13                sonnel, and parents or guardians of students  
14                participating in services under this section will  
15                be engaged and involved in the design and im-  
16                plementation of the services.

17           (5) A description of how the applicant will sup-  
18           port and integrate existing school-based services  
19           with the program in order to provide mental health  
20           services for students, as appropriate.

21           (e) INTERAGENCY AGREEMENTS.—

22                 (1) DESIGNATION OF LEAD AGENCY.—A recipi-  
23                 ent of a grant, contract, or cooperative agreement  
24                 under this section shall designate a lead agency to  
25                 direct the establishment of an interagency agreement

1 among local educational agencies, agencies respon-  
2 sible for early childhood education programs, juve-  
3 nile justice authorities, mental health agencies, child  
4 welfare agencies, and other relevant entities in the  
5 State or Indian Tribe, in collaboration with local en-  
6 tities.

7 (2) CONTENTS.—The interagency agreement  
8 shall ensure the provision of the services described  
9 in subsection (c), specifying with respect to each  
10 agency, authority, or entity—

11 (A) the financial responsibility for the serv-  
12 ices;

13 (B) the conditions and terms of responsi-  
14 bility for the services, including quality, ac-  
15 countability, and coordination of the services;  
16 and

17 (C) the conditions and terms of reimburse-  
18 ment among the agencies, authorities, or enti-  
19 ties that are parties to the interagency agree-  
20 ment, including procedures for dispute resolu-  
21 tion.

22 (f) EVALUATION.—The Secretary shall reserve not to  
23 exceed 3 percent of the funds made available under sub-  
24 section (l) for each fiscal year to—



1           (1) conduct a rigorous, independent evaluation  
2 of the activities funded under this section; and

3           (2) disseminate and promote the utilization of  
4 evidence-based practices regarding trauma support  
5 services and mental health care.

6           (g) DISTRIBUTION OF AWARDS.—The Secretary shall  
7 ensure that grants, contracts, and cooperative agreements  
8 awarded or entered into under this section are equitably  
9 distributed among the geographical regions of the United  
10 States and among tribal, urban, suburban, and rural pop-  
11 ulations.

12          (h) RULE OF CONSTRUCTION.—Nothing in this sec-  
13 tion shall be construed—

14           (1) to prohibit an entity involved with a pro-  
15 gram carried out under this section from reporting  
16 a crime that is committed by a student to appro-  
17 priate authorities; or

18           (2) to prevent Federal, State, and tribal law en-  
19 forcement and judicial authorities from exercising  
20 their responsibilities with regard to the application  
21 of Federal, tribal, and State law to crimes com-  
22 mitted by a student.

23          (i) SUPPLEMENT, NOT SUPPLANT.—Any services  
24 provided through programs carried out under this section  
25 shall supplement, and not supplant, existing mental health

1 services, including any special education and related serv-  
2 ices provided under the Individuals with Disabilities Edu-  
3 cation Act (20 U.S.C. 1400 et seq.).

4 (j) CONSULTATION WITH INDIAN TRIBES.—In car-  
5 rying out subsection (a), the Secretary shall, in a timely  
6 manner, meaningfully consult, engage, and cooperate with  
7 Indian Tribes and their representatives to ensure notice  
8 of eligibility.

9 (k) DEFINITIONS.—In this section:

10 (1) ELEMENTARY OR SECONDARY SCHOOL.—

11 The term “elementary or secondary school” means a  
12 public elementary and secondary school as such term  
13 is defined in section 8101 of the Elementary and  
14 Secondary Education Act of 1965 (20 U.S.C. 7801).

15 (2) EVIDENCE-BASED.—The term “evidence-  
16 based” has the meaning given such term in section  
17 8101(21)(A)(i) of the Elementary and Secondary  
18 Education Act of 1965 (20 U.S.C. 7801(21)(A)(i)).

19 (3) NATIVE HAWAIIAN EDUCATIONAL ORGANI-  
20 ZATION.—The term “Native Hawaiian educational  
21 organization” has the meaning given such term in  
22 section 6207 of the Elementary and Secondary Edu-  
23 cation Act of 1965 (20 U.S.C. 7517).

24 (4) PIPELINE SERVICES.—The term “pipeline  
25 services” has the meaning given such term in section

1 4622 of the Elementary and Secondary Education  
2 Act of 1965 (20 U.S.C. 7517).

3 (5) SCHOOL LEADER.—The term “school lead-  
4 er” has the meaning given such term in section  
5 8101 of the Elementary and Secondary Education  
6 Act of 1965 (20 U.S.C. 7801).

7 (6) SECRETARY.—The term “Secretary” means  
8 the Secretary of Education.

9 (7) SPECIALIZED INSTRUCTIONAL SUPPORT  
10 PERSONNEL.—The term “specialized instructional  
11 support personnel” has the meaning given such term  
12 in section 8101 of the Elementary and Secondary  
13 Education Act of 1965 (20 U.S.C. 7801).

14 (I) AUTHORIZATION OF APPROPRIATIONS.—There is  
15 authorized to be appropriated to carry out this section,  
16 such sums as may be necessary for each of fiscal years  
17 2019 through 2023.

18 **SEC. 1515. NATIONAL CHILD TRAUMATIC STRESS INITIA-**  
19 **TIVE.**

20 Section 582(j) of the Public Health Service Act (42  
21 U.S.C. 290hh–1(j)) (relating to grants to address the  
22 problems of persons who experience violence-related  
23 stress) is amended by striking “\$46,887,000 for each of  
24 fiscal years 2018 through 2022” and inserting

1 “\$53,887,000 for each of fiscal years 2019 through  
2 2023”.

3 **SEC. 1516. NATIONAL MILESTONES TO MEASURE SUCCESS**  
4 **IN CURTAILING THE OPIOID CRISIS.**

5 (a) IN GENERAL.—Not later than 180 days after the  
6 date of enactment of this Act, the Secretary, in consulta-  
7 tion with the Administrator of the Drug Enforcement Ad-  
8 ministration and the Director of the Office of National  
9 Drug Control Policy, shall develop or identify existing na-  
10 tional indicators (referred to in this section as the “na-  
11 tional milestones”) to measure success in curtailing the  
12 opioid crisis, with the goal of significantly reversing the  
13 incidence and prevalence of opioid misuse and abuse, and  
14 opioid-related morbidity and mortality in the United  
15 States within 5 years of such date of enactment.

16 (b) NATIONAL MILESTONES TO END THE OPIOID  
17 CRISIS.—The national milestones under subsection (a)  
18 shall include the following:

19 (1) Not fewer than 10 indicators or metrics to  
20 accurately and expediently measure progress in  
21 meeting the goal described in subsection (a), which  
22 shall, as appropriate, include, indicators or metrics  
23 related to—

24 (A) the number of fatal and non-fatal  
25 opioid overdoses;

1 (B) the number of emergency room visits  
2 related to opioid misuse and abuse;

3 (C) the number of individuals in sustained  
4 recovery from opioid use disorder;

5 (D) the number of infections associated  
6 with illicit drug use, such as HIV, viral hepa-  
7 titis, and infective endocarditis, and available  
8 capacity for treating such infections;

9 (E) the number of providers prescribing  
10 medication assisted treatment for opioid use  
11 disorders, including in primary care settings,  
12 community health centers, jails, and prisons;

13 (F) the number of individuals receiving  
14 treatment for opioid use disorder; and

15 (G) additional indicators or metrics, as ap-  
16 propriate, such as metrics pertaining to specific  
17 populations, including women and children,  
18 American Indians and Alaskan Natives, individ-  
19 uals living in rural and non-urban areas, and  
20 justice-involved populations, that would further  
21 clarify the progress made in addressing the  
22 opioid misuse and abuse crisis.

23 (2) A reasonable goal, such as a percentage de-  
24 crease or other specified metric, that signifies

1 progress in meeting the goal described in subsection  
2 (a), and annual targets to help achieve that goal.

3 (c) CONSIDERATION OF OTHER SUBSTANCE USE  
4 DISORDERS.—In developing the national milestones under  
5 subsection (b), the Secretary shall, as appropriate, con-  
6 sider other substance use disorders in addition to opioid  
7 use disorder.

8 (d) EXTENSION OF PERIOD.—If the Secretary deter-  
9 mines that the goal described in subsection (a) will not  
10 be achieved with respect to any indicator or metric estab-  
11 lished under subsection (b)(2) within 5 years of the date  
12 of enactment of this Act, the Secretary may extend the  
13 timeline for meeting such goal with respect to that indi-  
14 cator or metric. The Secretary shall include with any such  
15 extension a rationale for why additional time is needed and  
16 information on whether significant changes are needed in  
17 order to achieve such goal with respect to the indicator  
18 or metric.

19 (e) ANNUAL STATUS UPDATE.—Not later than one  
20 year after the enactment of this Act, the Secretary shall  
21 make available on the internet website of the Department  
22 of Health and Human Services, and submit to the Com-  
23 mittee on Health, Education, Labor, and Pensions of the  
24 Senate and the Committee on Energy and Commerce of  
25 the House of Representatives, an update on the progress,

1 including expected progress in the subsequent year, in  
2 achieving the goals detailed in the national milestones.  
3 Each such update shall include the progress made in the  
4 first year or since the previous report, as applicable, in  
5 meeting each indicator or metric in the national mile-  
6 stones.

## 7 **TITLE II—FINANCE**

### 8 **SEC. 2001. SHORT TITLE.**

9 This title may be cited as the “Helping to End Addic-  
10 tion and Lessen Substance Use Disorders Act of 2018”  
11 or the “HEAL Act of 2018”.

## 12 **Subtitle A—Medicare**

### 13 **SEC. 2101. MEDICARE OPIOID SAFETY EDUCATION.**

14 (a) IN GENERAL.—Section 1804 of the Social Secu-  
15 rity Act (42 U.S.C. 1395b–2) is amended by adding at  
16 the end the following new subsection:

17 “(d) The notice provided under subsection (a) shall  
18 include—

19 “(1) references to educational resources regard-  
20 ing opioid use and pain management;

21 “(2) a description of categories of alternative,  
22 non-opioid pain management treatments covered  
23 under this title; and





1 (B) in clause (ii)(X), by inserting “or tele-  
2 health services described in paragraph (7)” be-  
3 fore the period at the end; and

4 (3) by adding at the end the following new  
5 paragraph:

6 “(7) TREATMENT OF SUBSTANCE USE DIS-  
7 ORDER SERVICES FURNISHED THROUGH TELE-  
8 HEALTH.—The geographic requirements described in  
9 paragraph (4)(C)(i) shall not apply with respect to  
10 telehealth services furnished on or after January 1,  
11 2019, to an eligible telehealth individual with a sub-  
12 stance use disorder diagnosis for purposes of treat-  
13 ment of such disorder, as determined by the Sec-  
14 retary, at an originating site described in paragraph  
15 (4)(C)(ii) (other than an originating site described in  
16 subclause (IX) of such paragraph).”.

17 (b) IMPLEMENTATION.—The Secretary of Health and  
18 Human Services (in this section referred to as the “Sec-  
19 retary”) may implement the amendments made by this  
20 section by interim final rule.

21 (c) REPORT.—Not later than 5 years after the date  
22 of the enactment of this Act, the Secretary shall submit  
23 to Congress a report on the impact of the implementation  
24 of the amendments made by this section with respect to

1 telehealth services under section 1834(m) of the Social Se-  
2 curity Act (42 U.S.C. 1395m(m)) on—

3 (1) the utilization of health care items and serv-  
4 ices under title XVIII of such Act (42 U.S.C. 1395  
5 et seq.) related to substance use disorders, including  
6 emergency department visits; and

7 (2) health outcomes related to substance use  
8 disorders, such as opioid overdose deaths.

9 **SEC. 2103. COMPREHENSIVE SCREENINGS FOR SENIORS.**

10 (a) INITIAL PREVENTIVE PHYSICAL EXAMINA-  
11 TION.—Section 1861(ww) of the Social Security Act (42  
12 U.S.C. 1395x(ww)) is amended—

13 (1) in paragraph (1)—

14 (A) by striking “paragraph (2) and” and  
15 inserting “paragraph (2),”; and

16 (B) by inserting “and the furnishing of a  
17 review of any current opioid prescriptions (as  
18 defined in paragraph (4)),” after “upon the  
19 agreement with the individual,”; and

20 (2) in paragraph (2)—

21 (A) by redesignating subparagraph (N) as  
22 subparagraph (O); and

23 (B) by inserting after subparagraph (M)  
24 the following new subparagraph:

1                   “(N) Screening for potential substance use  
2                   disorders.”; and

3                   (3) by adding at the end the following new  
4                   paragraph:

5                   “(4) For purposes of paragraph (1), the term ‘a re-  
6                   view of any current opioid prescriptions’ means, with re-  
7                   spect to an individual determined to have a current pre-  
8                   scription for opioids—

9                   “(A) a review of the potential risk factors to the  
10                  individual for opioid use disorder;

11                  “(B) an evaluation of the individual’s severity  
12                  of pain and current treatment plan;

13                  “(C) the provision of information on non-opioid  
14                  treatment options; and

15                  “(D) a referral to a pain management spe-  
16                  cialist, as appropriate.”.

17                  (b)     ANNUAL     WELLNESS     VISIT.—Section  
18                  1861(hhh)(2) of the Social Security Act (42 U.S.C.  
19                  1395x(hhh)(2)) is amended—

20                  (1) by redesignating subparagraph (G) as sub-  
21                  paragraph (I); and

22                  (2) by inserting after subparagraph (F) the fol-  
23                  lowing new subparagraphs:

1           “(G) Screening for potential substance use  
2 disorders and referral for treatment as appro-  
3 priate.

4           “(H) The furnishing of a review of any  
5 current opioid prescriptions (as defined in sub-  
6 section (ww)(4)).”.

7           (c) EFFECTIVE DATE.—The amendments made by  
8 this section shall apply to examinations and visits fur-  
9 nished on or after January 1, 2019.

10 **SEC. 2104. EVERY PRESCRIPTION CONVEYED SECURELY.**

11           (a) IN GENERAL.—Section 1860D–4(e) of the Social  
12 Security Act (42 U.S.C. 1395w–104(e)) is amended by  
13 adding at the end the following:

14           “(7) REQUIREMENT OF E-PRESCRIBING FOR  
15 CONTROLLED SUBSTANCES.—

16           “(A) IN GENERAL.—Subject to subpara-  
17 graph (B), a prescription for a covered part D  
18 drug under a prescription drug plan (or under  
19 an MA–PD plan) for a schedule II, III, IV, or  
20 V controlled substance shall be transmitted by  
21 a health care practitioner electronically in ac-  
22 cordance with an electronic prescription drug  
23 program that meets the requirements of para-  
24 graph (2).

1           “(B) EXCEPTION FOR CERTAIN CIR-  
2 CUMSTANCES.—The Secretary shall, through  
3 rulemaking, specify circumstances and proc-  
4 esses by which the Secretary may waive the re-  
5 quirement under subparagraph (A), with re-  
6 spect to a covered part D drug, including in the  
7 case of—

8           “(i) a prescription issued when the  
9 practitioner and dispensing pharmacy are  
10 the same entity;

11           “(ii) a prescription issued that cannot  
12 be transmitted electronically under the  
13 most recently implemented version of the  
14 National Council for Prescription Drug  
15 Programs SCRIPT Standard;

16           “(iii) a prescription issued by a practi-  
17 tioner who received a waiver or a renewal  
18 thereof for a period of time as determined  
19 by the Secretary, not to exceed one year,  
20 from the requirement to use electronic pre-  
21 scribing due to demonstrated economic  
22 hardship, technological limitations that are  
23 not reasonably within the control of the  
24 practitioner, or other exceptional cir-

1           cumstance demonstrated by the practi-  
2           tioner;

3           “(iv) a prescription issued by a practi-  
4           tioner under circumstances in which, not-  
5           withstanding the practitioner’s ability to  
6           submit a prescription electronically as re-  
7           quired by this subsection, such practitioner  
8           reasonably determines that it would be im-  
9           practical for the individual involved to ob-  
10          tain substances prescribed by electronic  
11          prescription in a timely manner, and such  
12          delay would adversely impact the individ-  
13          ual’s medical condition involved;

14          “(v) a prescription issued by a practi-  
15          tioner prescribing a drug under a research  
16          protocol;

17          “(vi) a prescription issued by a practi-  
18          tioner for a drug for which the Food and  
19          Drug Administration requires a prescrip-  
20          tion to contain elements that are not able  
21          to be included in electronic prescribing  
22          such as, a drug with risk evaluation and  
23          mitigation strategies that include elements  
24          to assure safe use;

1                   “(vii) a prescription issued by a prac-  
2                   titioner—

3                   “(I) for an individual who re-  
4                   ceives hospice care under this title;  
5                   and

6                   “(II) that is not covered under  
7                   the hospice benefit under this title;  
8                   and

9                   “(viii) a prescription issued by a prac-  
10                  titioner for an individual who is—

11                  “(I) a resident of a nursing facil-  
12                  ity (as defined in section 1919(a));  
13                  and

14                  “(II) dually eligible for benefits  
15                  under this title and title XIX.

16                  “(C) DISPENSING.—(i) Nothing in this  
17                  paragraph shall be construed as requiring a  
18                  sponsor of a prescription drug plan under this  
19                  part, MA organization offering an MA–PD plan  
20                  under part C, or a pharmacist to verify that a  
21                  practitioner, with respect to a prescription for a  
22                  covered part D drug, has a waiver (or is other-  
23                  wise exempt) under subparagraph (B) from the  
24                  requirement under subparagraph (A).

1           “(ii) Nothing in this paragraph shall be  
2 construed as affecting the ability of the plan to  
3 cover or the pharmacists’ ability to continue to  
4 dispense covered part D drugs from otherwise  
5 valid written, oral or fax prescriptions that are  
6 consistent with laws and regulations.

7           “(iii) Nothing in this paragraph shall be  
8 construed as affecting the ability of an indi-  
9 vidual who is being prescribed a covered part D  
10 drug to designate a particular pharmacy to dis-  
11 pense the covered part D drug to the extent  
12 consistent with the requirements under sub-  
13 section (b)(1) and under this paragraph.

14           “(D) ENFORCEMENT.—The Secretary  
15 shall, through rulemaking, have authority to en-  
16 force and specify appropriate penalties for non-  
17 compliance with the requirement under sub-  
18 paragraph (A).”.

19           (b) EFFECTIVE DATE.—The amendment made by  
20 subsection (a) shall apply to coverage of drugs prescribed  
21 on or after January 1, 2021.



1 **SEC. 2105. STANDARDIZING ELECTRONIC PRIOR AUTHOR-**  
2 **IZATION FOR SAFE PRESCRIBING.**

3 Section 1860D–4(e)(2) of the Social Security Act (42  
4 U.S.C. 1395w–104(e)(2)) is amended by adding at the end  
5 the following new subparagraph:

6 “(E) ELECTRONIC PRIOR AUTHORIZA-  
7 TION.—

8 “(i) IN GENERAL.—Not later than  
9 January 1, 2021, the program shall pro-  
10 vide for the secure electronic transmittal  
11 of—

12 “(I) a prior authorization request  
13 from the prescribing health care pro-  
14 fessional for coverage of a covered  
15 part D drug for a part D eligible indi-  
16 vidual enrolled in a part D plan (as  
17 defined in section 1860D–23(a)(5)) to  
18 the PDP sponsor or Medicare Advan-  
19 tage organization offering such plan;  
20 and

21 “(II) a response, in accordance  
22 with this subparagraph, from such  
23 PDP sponsor or Medicare Advantage  
24 organization, respectively, to such pro-  
25 fessional.

26 “(ii) ELECTRONIC TRANSMISSION.—

1                   “(I) EXCLUSIONS.—For purposes  
2 of this subparagraph, a facsimile, a  
3 proprietary payer portal that does not  
4 meet standards specified by the Sec-  
5 retary, or an electronic form shall not  
6 be treated as an electronic trans-  
7 mission described in clause (i).

8                   “(II) STANDARDS.—In order to  
9 be treated, for purposes of this sub-  
10 paragraph, as an electronic trans-  
11 mission described in clause (i), such  
12 transmission shall comply with tech-  
13 nical standards adopted by the Sec-  
14 retary in consultation with the Na-  
15 tional Council for Prescription Drug  
16 Programs, other standard setting or-  
17 ganizations determined appropriate by  
18 the Secretary, and stakeholders in-  
19 cluding PDP sponsors, Medicare Ad-  
20 vantage organizations, health care  
21 professionals, and health information  
22 technology software vendors.

23                   “(III) APPLICATION.—Notwith-  
24 standing any other provision of law,  
25 for purposes of this subparagraph, the

1 Secretary may require the use of such  
2 standards adopted under subclause  
3 (II) in lieu of any other applicable  
4 standards for an electronic trans-  
5 mission described in clause (i) for a  
6 covered part D drug for a part D eli-  
7 gible individual.”.

8 **SEC. 2106. STRENGTHENING PARTNERSHIPS TO PREVENT**  
9 **OPIOID ABUSE.**

10 (a) IN GENERAL.—Section 1859 of the Social Secu-  
11 rity Act (42 U.S.C. 1395w–28) is amended by adding at  
12 the end the following new subsection:

13 “(i) PROGRAM INTEGRITY TRANSPARENCY MEAS-  
14 URES.—

15 “(1) PROGRAM INTEGRITY PORTAL.—

16 “(A) IN GENERAL.—Not later than 2 years  
17 after the date of the enactment of this sub-  
18 section, the Secretary shall, after consultation  
19 with stakeholders, establish a secure Internet  
20 website portal that would allow a secure path  
21 for communication between the Secretary, MA  
22 plans under this part, prescription drug plans  
23 under part D, and an eligible entity with a con-  
24 tract under section 1893 (such as a Medicare  
25 drug integrity contractor or any successor enti-

1 ty to a Medicare drug integrity contractor), in  
2 accordance with subsection (j)(3) of such sec-  
3 tion, for the purpose of enabling through such  
4 portal—

5 “(i) the referral by such plans of sus-  
6 picious activities of a provider of services  
7 (including a prescriber) or supplier related  
8 to fraud, waste, and abuse for initiating or  
9 assisting investigations conducted by the  
10 eligible entity; and

11 “(ii) data sharing among such MA  
12 plans, prescription drug plans, and the  
13 Secretary.

14 “(B) REQUIRED USES OF PORTAL.—The  
15 Secretary shall disseminate the following infor-  
16 mation to MA plans under this part and pre-  
17 scription drug plans under part D through the  
18 secure Internet website portal established under  
19 subparagraph (A):

20 “(i) Providers of services and sup-  
21 pliers that have been referred pursuant to  
22 subparagraph (A)(i) during the previous  
23 12-month period.

24 “(ii) Providers of services and sup-  
25 pliers who are the subject of an active ex-

1           clusion under section 1128 or who are sub-  
2           ject to a suspension of payment under this  
3           title pursuant to section 1862(o) or other-  
4           wise.

5           “(iii) Providers of services and sup-  
6           pliers who are the subject of an active rev-  
7           ocation of participation under this title, in-  
8           cluding for not satisfying conditions of par-  
9           ticipation.

10          “(iv) In the case of such a plan that  
11          makes a referral under subparagraph  
12          (A)(i) through the portal with respect to  
13          suspicious activities of a provider of serv-  
14          ices (including a prescriber) or supplier, if  
15          such provider (or prescriber) or supplier  
16          has been the subject of an administrative  
17          action under this title or title XI with re-  
18          spect to similar activities, a notification to  
19          such plan of such action so taken.

20          “(C) RULEMAKING.—For purposes of this  
21          paragraph, the Secretary shall, through rule-  
22          making, specify what constitutes suspicious ac-  
23          tivities related to fraud, waste, and abuse, using  
24          guidance such as what is provided in the Medi-  
25          care Program Integrity Manual 4.7.1.

1           “(2) QUARTERLY REPORTS.—Beginning not  
2 later than 2 years after the date of the enactment  
3 of this subsection, the Secretary shall make available  
4 to MA plans under this part and prescription drug  
5 plans under part D in a timely manner (but no less  
6 frequently than quarterly) and using information  
7 submitted to an entity described in paragraph (1)  
8 through the portal described in such paragraph or  
9 pursuant to section 1893, information on fraud,  
10 waste, and abuse schemes and trends in identifying  
11 suspicious activity. Information included in each  
12 such report shall—

13           “(A) include administrative actions, perti-  
14 nent information related to opioid overpre-  
15 scribing, and other data determined appropriate  
16 by the Secretary in consultation with stake-  
17 holders; and

18           “(B) be anonymized information submitted  
19 by plans without identifying the source of such  
20 information.

21           “(3) CLARIFICATION.—Nothing in this sub-  
22 section shall preclude or otherwise affect referrals to  
23 the Inspector General of the Department of Health  
24 and Human Services or other law enforcement enti-  
25 ties.”.

1 (b) CONTRACT REQUIREMENT TO COMMUNICATE  
2 PLAN CORRECTIVE ACTIONS AGAINST OPIOIDS OVER-  
3 PRESCRIBERS.—Section 1857(e)(4)(C) of the Social Secu-  
4 rity Act (42 U.S.C. 1395w–27(e)(4)(C)) is amended by  
5 adding at the end the following new paragraph:

6 “(5) COMMUNICATING PLAN CORRECTIVE AC-  
7 TIONS AGAINST OPIOIDS OVER-PRESCRIBERS.—

8 “(A) IN GENERAL.—Beginning with plan  
9 years beginning on or after January 1, 2021, a  
10 contract under this section with an MA organi-  
11 zation shall require the organization to submit  
12 to the Secretary, through the process estab-  
13 lished under subparagraph (B), information on  
14 credible evidence of suspicious activities of a  
15 provider of services (including a prescriber) or  
16 supplier related to fraud and other actions  
17 taken by such plans related to inappropriate  
18 prescribing of opioids.

19 “(B) PROCESS.—Not later than January  
20 1, 2021, the Secretary shall, in consultation  
21 with stakeholders, establish a process under  
22 which MA plans and prescription drug plans  
23 shall submit to the Secretary information de-  
24 scribed in subparagraph (A).

1                   “(C) REGULATIONS.—For purposes of this  
2                   paragraph, including as applied under section  
3                   1860D–12(b)(3)(D), the Secretary shall, pursu-  
4                   ant to rulemaking—

5                   “(i) specify a definition for the term  
6                   ‘inappropriate prescribing of opioids’ and a  
7                   method for determining if a provider of  
8                   services prescribes such a high volume; and

9                   “(ii) establish the process described in  
10                  subparagraph (B) and the types of infor-  
11                  mation that may be submitted through  
12                  such process.”.

13                  (c) REFERENCE UNDER PART D TO PROGRAM IN-  
14                  TEGRITY TRANSPARENCY MEASURES.—Section 1860D–4  
15                  of the Social Security Act (42 U.S.C. 1395w–104) is  
16                  amended by adding at the end the following new sub-  
17                  section:

18                  “(m) PROGRAM INTEGRITY TRANSPARENCY MEAS-  
19                  URES.—For program integrity transparency measures ap-  
20                  plied with respect to prescription drug plan and MA plans,  
21                  see section 1859(i).”.



1 **SEC. 2107. COMMIT TO OPIOID MEDICAL PRESCRIBER AC-**  
2 **COUNTABILITY AND SAFETY FOR SENIORS.**

3 Section 1860D–4(c)(4) of the Social Security Act (42  
4 U.S.C. 1395w–104(c)(4)) is amended by adding at the end  
5 the following new subparagraph:

6 “(D) NOTIFICATION AND ADDITIONAL RE-  
7 QUIREMENTS WITH RESPECT TO STATISTICAL  
8 OUTLIER PRESCRIBERS OF OPIOIDS.—

9 “(i) NOTIFICATION.—Not later than  
10 January 1, 2021, the Secretary shall, in  
11 the case of a prescriber identified by the  
12 Secretary under clause (ii) to be a statis-  
13 tical outlier prescriber of opioids, provide,  
14 subject to clause (iv), an annual notifica-  
15 tion to such prescriber that such prescriber  
16 has been so identified that includes re-  
17 sources on proper prescribing methods and  
18 other information as specified in accord-  
19 ance with clause (iii).

20 “(ii) IDENTIFICATION OF STATISTICAL  
21 OUTLIER PRESCRIBERS OF OPIOIDS.—

22 “(I) IN GENERAL.—The Sec-  
23 retary shall, subject to subclause (III),  
24 using the valid prescriber National  
25 Provider Identifiers included pursuant  
26 to subparagraph (A) on claims for

1 covered part D drugs for part D eligi-  
2 ble individuals enrolled in prescription  
3 drug plans under this part or MA–PD  
4 plans under part C and based on the  
5 thresholds established under subclause  
6 (II), identify prescribers that are sta-  
7 tistical outlier opioids prescribers for  
8 a period of time specified by the Sec-  
9 retary.

10 “(II) ESTABLISHMENT OF  
11 THRESHOLDS.—For purposes of sub-  
12 clause (I) and subject to subclause  
13 (III), the Secretary shall, after con-  
14 sultation with stakeholders, establish  
15 thresholds, based on prescriber spe-  
16 cialty and, as determined appropriate  
17 by the Secretary, geographic area, for  
18 identifying whether a prescriber in a  
19 specialty and geographic area is a sta-  
20 tistical outlier prescriber of opioids as  
21 compared to other prescribers of  
22 opioids within such specialty and area.

23 “(III) EXCLUSIONS.—The fol-  
24 lowing shall not be included in the  
25 analysis for identifying statistical

1 outlier prescribers of opioids under  
2 this clause:

3 “(aa) Claims for covered  
4 part D drugs for part D eligible  
5 individuals who are receiving hos-  
6 pice care under this title.

7 “(bb) Claims for covered  
8 part D drugs for part D eligible  
9 individuals who are receiving on-  
10 cology services under this title.

11 “(cc) Prescribers who are  
12 the subject of an investigation by  
13 the Centers for Medicare & Med-  
14 icaid Services or the Inspector  
15 General of the Department of  
16 Health and Human Services.

17 “(iii) CONTENTS OF NOTIFICATION.—  
18 The Secretary shall include the following  
19 information in the notifications provided  
20 under clause (i):

21 “(I) Information on how such  
22 prescriber compares to other pre-  
23 scribers within the same specialty  
24 and, if determined appropriate by the  
25 Secretary, geographic area.

1                   “(II) Information on opioid pre-  
2                   scribing guidelines, based on input  
3                   from stakeholders, that may include  
4                   the Centers for Disease Control and  
5                   Prevention guidelines for prescribing  
6                   opioids for chronic pain and guidelines  
7                   developed by physician organizations.

8                   “(III) Other information deter-  
9                   mined appropriate by the Secretary.

10                   “(iv) MODIFICATIONS AND EXPAN-  
11                   SIONS.—

12                   “(I) FREQUENCY.—Beginning 5  
13                   years after the date of the enactment  
14                   of this subparagraph, the Secretary  
15                   may change the frequency of the noti-  
16                   fications described in clause (i) based  
17                   on stakeholder input and changes in  
18                   opioid prescribing utilization and  
19                   trends.

20                   “(II) EXPANSION TO OTHER  
21                   PRESCRIPTIONS.—The Secretary may  
22                   expand notifications under this sub-  
23                   paragraph to include identifications  
24                   and notifications with respect to con-  
25                   current prescriptions of covered Part

1 D drugs used in combination with  
2 opioids that are considered to have  
3 adverse side effects when so used in  
4 such combination, as determined by  
5 the Secretary.

6 “(v) ADDITIONAL REQUIREMENTS FOR  
7 PERSISTENT STATISTICAL OUTLIER PRE-  
8 SCRIBERS.—In the case of a prescriber  
9 who the Secretary determines is persist-  
10 ently identified under clause (ii) as a sta-  
11 tistical outlier prescriber of opioids, the fol-  
12 lowing shall apply:

13 “(I) The Secretary shall provide  
14 an opportunity for such prescriber to  
15 receive technical assistance or edu-  
16 cational resources on opioid pre-  
17 scribing guidelines (such as the guide-  
18 lines described in clause (iii)(II)) from  
19 an entity that furnishes such assist-  
20 ance or resources, which may include  
21 a quality improvement organization  
22 under part B of title XI, as available  
23 and appropriate.

24 “(II) Such prescriber may be re-  
25 quired to enroll in the program under

1           this title under section 1866(j) if such  
2           prescriber is not otherwise required to  
3           enroll. The Secretary shall determine  
4           the length of the period for which  
5           such prescriber is required to main-  
6           tain such enrollment.

7                       “(III) Not less frequently than  
8           annually (and in a form and manner  
9           determined appropriate by the Sec-  
10          retary), the Secretary shall commu-  
11          nicate information on such prescribers  
12          to sponsors of a prescription drug  
13          plan and Medicare Advantage organi-  
14          zations offering an MA–PD plan.

15                      “(vi) PUBLIC AVAILABILITY OF IN-  
16          FORMATION.—The Secretary shall make  
17          aggregate information under this subpara-  
18          graph available on the Internet website of  
19          the Centers for Medicare & Medicaid Serv-  
20          ices. Such information shall be in a form  
21          and manner determined appropriate by the  
22          Secretary and shall not identify any spe-  
23          cific prescriber. In carrying out this clause,  
24          the Secretary shall consult with interested  
25          stakeholders.

1                   “(vii) OPIOIDS DEFINED.—For pur-  
2                   poses of this subparagraph, the term  
3                   ‘opioids’ has such meaning as specified by  
4                   the Secretary.

5                   “(viii) OTHER ACTIVITIES.—Nothing  
6                   in this subparagraph shall preclude the  
7                   Secretary from conducting activities that  
8                   provide prescribers with information as to  
9                   how they compare to other prescribers that  
10                  are in addition to the activities under this  
11                  subparagraph, including activities that  
12                  were being conducted as of the date of the  
13                  enactment of this subparagraph.”.

14 **SEC. 2108. FIGHTING THE OPIOID EPIDEMIC WITH SUN-**  
15 **SHINE.**

16                  (a) INCLUSION OF INFORMATION REGARDING PAY-  
17 MENTS TO ADVANCE PRACTICE NURSES.—

18                  (1) IN GENERAL.—Section 1128G(e)(6) of the  
19 Social Security Act (42 U.S.C. 1320a–7h(e)(6)) is  
20 amended—

21                  (A) in subparagraph (A), by adding at the  
22 end the following new clauses:

23                  “(iii) A physician assistant, nurse  
24 practitioner, or clinical nurse specialist (as

1 such terms are defined in section  
2 1861(aa)(5)).

3 “(iv) A certified registered nurse an-  
4 esthetist (as defined in section  
5 1861(bb)(2)).

6 “(v) A certified nurse-midwife (as de-  
7 fined in section 1861(gg)(2)).”; and

8 (B) in subparagraph (B), by inserting “,  
9 physician assistant, nurse practitioner, clinical  
10 nurse specialist, certified nurse anesthetist, or  
11 certified nurse-midwife” after “physician”.

12 (2) EFFECTIVE DATE.—The amendments made  
13 by this subsection shall apply with respect to infor-  
14 mation required to be submitted under section  
15 1128G of the Social Security Act (42 U.S.C. 1320a-  
16 7h) on or after January 1, 2022.

17 (b) SUNSET OF EXCLUSION OF NATIONAL PROVIDER  
18 IDENTIFIER OF COVERED RECIPIENT IN INFORMATION  
19 MADE PUBLICLY AVAILABLE.—Section  
20 1128G(e)(1)(C)(viii) of the Social Security Act (42 U.S.C.  
21 1320a-7h(e)(1)(C)(viii))) is amended by striking “does  
22 not contain” and inserting “in the case of information  
23 made available under this subparagraph prior to January  
24 1, 2022, does not contain”.



1 (c) ADMINISTRATION.—Chapter 35 of title 44,  
2 United States Code, shall not apply to this section or the  
3 amendments made by this section.

4 **SEC. 2109. DEMONSTRATION TESTING COVERAGE OF CER-**  
5 **TAIN SERVICES FURNISHED BY OPIOID**  
6 **TREATMENT PROGRAMS.**

7 Title XVIII of the Social Security Act (42 U.S.C.  
8 1395 et seq.) is amended by inserting after section 1866E  
9 the following:

10 “DEMONSTRATION TESTING COVERAGE OF CERTAIN  
11 SERVICES FURNISHED BY OPIOID TREATMENT PROGRAMS

12 “SEC. 1866F. (a) ESTABLISHMENT.—

13 “(1) IN GENERAL.—The Secretary shall con-  
14 duct a demonstration (in this section referred to as  
15 the ‘demonstration’) to test coverage of and payment  
16 for opioid use disorder treatment services (as defined  
17 in paragraph (2)(B)) furnished by opioid treatment  
18 programs (as defined in paragraph (2)(A)) to indi-  
19 viduals under part B using a bundled payment as  
20 described in paragraph (3).

21 “(2) DEFINITIONS.—In this section:

22 “(A) OPIOID TREATMENT PROGRAM.—The  
23 term ‘opioid treatment program’ means an enti-  
24 ty that is an opioid treatment program (as de-  
25 fined in section 8.2 of title 42 of the Code of

1 Federal Regulations, or any successor regula-  
2 tion) that—

3 “(i) is selected for participation in the  
4 demonstration;

5 “(ii) has in effect a certification by  
6 the Substance Abuse and Mental Health  
7 Services Administration for such a pro-  
8 gram;

9 “(iii) is accredited by an accrediting  
10 body approved by the Substance Abuse and  
11 Mental Health Services Administration;

12 “(iv) submits to the Secretary data  
13 and information needed to monitor the  
14 quality of services furnished and conduct  
15 the evaluation described in subsection (c);  
16 and

17 “(v) meets such additional require-  
18 ments as the Secretary may find necessary.

19 “(B) OPIOID USE DISORDER TREATMENT  
20 SERVICES.—The term ‘opioid use disorder  
21 treatment services’ means items and services  
22 that are furnished by an opioid treatment pro-  
23 gram for the treatment of opioid use disorder,  
24 including—

1                   “(i) opioid agonist and antagonist  
2                   treatment medications (including oral, in-  
3                   jected, or implanted versions) that are ap-  
4                   proved by the Food and Drug Administra-  
5                   tion under section 505 of the Federal  
6                   Food, Drug and Cosmetic Act for use in  
7                   the treatment of opioid use disorder;

8                   “(ii) dispensing and administration of  
9                   such medications, if applicable;

10                   “(iii) substance use counseling by a  
11                   professional to the extent authorized under  
12                   State law to furnish such services;

13                   “(iv) individual and group therapy  
14                   with a physician or psychologist (or other  
15                   mental health professional to the extent  
16                   authorized under State law);

17                   “(v) toxicology testing; and

18                   “(vi) other items and services that the  
19                   Secretary determines are appropriate (but  
20                   in no case to include meals or transpor-  
21                   tation).

22                   “(3) BUNDLED PAYMENT UNDER PART B.—

23                   “(A) IN GENERAL.—The Secretary shall  
24                   pay, from the Federal Supplementary Medical  
25                   Insurance Trust Fund under section 1841, to

1 an opioid treatment program participating in  
2 the demonstration a bundled payment as deter-  
3 mined by the Secretary for opioid use disorder  
4 treatment services that are furnished by such  
5 treatment program to an individual under part  
6 B during an episode of care (as defined by the  
7 Secretary).

8 “(B) CONSIDERATIONS.—The Secretary  
9 may implement this paragraph through one or  
10 more bundles based on the type of medication  
11 provided (such as buprenorphine, methadone,  
12 naltrexone, or a new innovative drug), the fre-  
13 quency of services furnished, the scope of serv-  
14 ices furnished, characteristics of the individuals  
15 furnished such services, or other factors as the  
16 Secretary determines appropriate. In developing  
17 such bundles, the Secretary may consider pay-  
18 ment rates paid to opioid treatment programs  
19 for comparable services under State plans  
20 under title XIX or under the TRICARE pro-  
21 gram under chapter 55 of title 10 of the United  
22 States Code.

23 “(b) IMPLEMENTATION.—



1                   “(iii) overall expenditures under this  
2                   title; and

3                   “(B) the performance of opioid treatment  
4                   programs participating in the demonstration  
5                   with respect to applicable quality and cost  
6                   metrics, including whether any additional qual-  
7                   ity measures related to opioid use disorder  
8                   treatment are needed with respect to such pro-  
9                   grams under this title.

10                  “(2) REPORT.—Not later than 2 years after the  
11                  completion of the demonstration, the Secretary shall  
12                  submit to Congress a report containing the results  
13                  of the evaluation conducted under paragraph (1), to-  
14                  gether with recommendations for such legislation  
15                  and administrative action as the Secretary deter-  
16                  mines appropriate.

17                  “(d) FUNDING.—For purposes of administering and  
18                  carrying out the demonstration, in addition to funds other-  
19                  wise appropriated, there shall be transferred to the Sec-  
20                  retary for the Center for Medicare & Medicaid Services  
21                  Program Management Account from the Federal Supple-  
22                  mentary Medical Insurance Trust Fund under section  
23                  1841 \$5,000,000, to remain available until expended.”.

1 **SEC. 2110. ENCOURAGING APPROPRIATE PRESCRIBING**  
2 **UNDER MEDICARE FOR VICTIMS OF OPIOID**  
3 **OVERDOSE.**

4 Section 1860D–4(c)(5)(C) of the Social Security Act  
5 (42 U.S.C. 1395w–104(c)(5)(C)) is amended—

6 (1) in clause (i), in the matter preceding sub-  
7 clause (I), by striking “For purposes” and inserting  
8 “Except as provided in clause (v), for purposes”;  
9 and

10 (2) by adding at the end the following new  
11 clause:

12 “(v) TREATMENT OF ENROLLEES  
13 WITH A HISTORY OF OPIOID-RELATED  
14 OVERDOSE.—

15 “(I) IN GENERAL.—For plan  
16 years beginning not later than Janu-  
17 ary 1, 2021, a part D eligible indi-  
18 vidual who is not an exempted indi-  
19 vidual described in clause (ii) and who  
20 is identified under this clause as a  
21 part D eligible individual with a his-  
22 tory of opioid-related overdose (as de-  
23 fined by the Secretary) shall be in-  
24 cluded as a potentially at-risk bene-  
25 ficiary for prescription drug abuse

1 under the drug management program  
2 under this paragraph.

3 “(II) IDENTIFICATION AND NO-  
4 TICE.—For purposes of this clause,  
5 the Secretary shall—

6 “(aa) identify part D eligible  
7 individuals with a history of  
8 opioid-related overdose (as so de-  
9 fined); and

10 “(bb) notify the PDP spon-  
11 sor of the prescription drug plan  
12 in which such an individual is en-  
13 rolled of such identification.”.

14 **SEC. 2111. AUTOMATIC ESCALATION TO EXTERNAL REVIEW**  
15 **UNDER A MEDICARE PART D DRUG MANAGE-**  
16 **MENT PROGRAM FOR AT-RISK BENE-**  
17 **FICIARIES.**

18 (a) IN GENERAL.—Section 1860D–4(c)(5) of the So-  
19 cial Security Act (42 U.S.C. 1395ww–10(e)(5)) is amend-  
20 ed—

21 (1) in subparagraph (B), in each of clauses  
22 (ii)(III) and (iii)(IV), by striking “and the option of  
23 an automatic escalation to external review” and in-  
24 serting “, including notice that if on reconsideration  
25 a PDP sponsor affirms its denial, in whole or in



1 part, the case shall be automatically forwarded to  
2 the independent, outside entity contracted with the  
3 Secretary for review and resolution”; and

4 (2) in subparagraph (E), by striking “and the  
5 option” and all that follows and inserting the fol-  
6 lowing: “and if on reconsideration a PDP sponsor  
7 affirms its denial, in whole or in part, the case shall  
8 be automatically forwarded to the independent, out-  
9 side entity contracted with the Secretary for review  
10 and resolution.”.

11 (b) **EFFECTIVE DATE.**—The amendments made by  
12 subsection (a) shall apply beginning not later January 1,  
13 2021.

14 **SEC. 2112. TESTING OF INCENTIVE PAYMENTS FOR BEHAV-**  
15 **IORAL HEALTH PROVIDERS FOR ADOPTION**  
16 **AND USE OF CERTIFIED ELECTRONIC**  
17 **HEALTH RECORD TECHNOLOGY.**

18 Section 1115A(b)(2)(B) of the Social Security Act  
19 (42 U.S.C. 1315a(b)(2)(B)) is amended by adding at the  
20 end the following new clause:

21 “(xxv) Providing incentive payments  
22 to behavioral health providers for the adop-  
23 tion and use of certified electronic health  
24 record technology (as defined in section  
25 1848(o)(4)) to improve the quality and co-

1 ordination of care through the electronic  
2 documentation and exchange of health in-  
3 formation. Behavioral health providers may  
4 include—

5 “(I) psychiatric hospitals (as de-  
6 fined in section 1861(f));

7 “(II) community mental health  
8 centers (as defined in section  
9 1861(ff)(3)(B));

10 “(III) clinical psychologists (as  
11 defined in section 1861(ii));

12 “(IV) clinical social workers (as  
13 defined in section 1861(hh)(1)); and

14 “(V) hospitals, treatment facili-  
15 ties, and mental health or substance  
16 use disorder providers that participate  
17 in a State plan under title XIX or a  
18 waiver of such plan.”.

19 **SEC. 2113. MEDICARE IMPROVEMENT FUND.**

20 Section 1898(b)(1) of the Social Security Act (42  
21 U.S.C. 1395iii(b)(1)) is amended by striking “fiscal year  
22 2021, \$0” and inserting “fiscal year 2024, \$65,000,000”.



1 items and services for which medical assistance is  
2 available under the State plan to infants with the di-  
3 agnosis of neonatal abstinence syndrome without any  
4 other significant medical risk factors.

5 “(2) COUNSELING AND SERVICES.—A residen-  
6 tial pediatric recovery center may offer counseling  
7 and other services to mothers (and other appropriate  
8 family members and caretakers) of infants receiving  
9 treatment at such centers if such services are other-  
10 wise covered under the State plan under this title or  
11 under a waiver of such plan. Such other services  
12 may include the following:

13 “(A) Counseling or referrals for services.

14 “(B) Activities to encourage caregiver-in-  
15 fant bonding.

16 “(C) Training on caring for such infants.”.

17 (c) EFFECTIVE DATE.—The amendments made by  
18 this section take effect on the date of enactment of this  
19 Act and shall apply to medical assistance furnished on or  
20 after that date, without regard to final regulations to carry  
21 out such amendments being promulgated as of such date.

22 **SEC. 2202. PEER SUPPORT ENHANCEMENT AND EVALUA-**  
23 **TION REVIEW.**

24 (a) IN GENERAL.—Not later than 2 years after the  
25 date of the enactment of this Act, the Comptroller General

1 of the United States shall submit to the Committee on  
2 Energy and Commerce of the House of Representatives,  
3 the Committee on Finance of the Senate, and the Com-  
4 mittee on Health, Education, Labor, and Pensions of the  
5 Senate a report on the provision of peer support services  
6 under the Medicaid program.

7 (b) CONTENT OF REPORT.—

8 (1) IN GENERAL.—The report required under  
9 subsection (a) shall include the following informa-  
10 tion:

11 (A) Information on State coverage of peer  
12 support services under Medicaid, including—

13 (i) the mechanisms through which  
14 States may provide such coverage, includ-  
15 ing through existing statutory authority or  
16 through waivers;

17 (ii) the populations to which States  
18 have provided such coverage;

19 (iii) the payment models, including  
20 any alternative payment models, used by  
21 States to pay providers of such services;  
22 and

23 (iv) where available, information on  
24 Federal and State spending under Med-  
25 icaid for peer support services.

1 (B) Information on selected State experi-  
2 ences in providing medical assistance for peer  
3 support services under State Medicaid plans  
4 and whether States measure the effects of pro-  
5 viding such assistance with respect to—

6 (i) improving access to behavioral  
7 health services;

8 (ii) improving early detection, and  
9 preventing worsening, of behavioral health  
10 disorders;

11 (iii) reducing chronic and comorbid  
12 conditions; and

13 (iv) reducing overall health costs.

14 (2) RECOMMENDATIONS.—The report required  
15 under subsection (a) shall include recommendations,  
16 including recommendations for such legislative and  
17 administrative actions related to improving services,  
18 including peer support services, and access to peer  
19 support services under Medicaid as the Comptroller  
20 General of the United States determines appro-  
21 priate.

22 **SEC. 2203. MEDICAID SUBSTANCE USE DISORDER TREAT-**  
23 **MENT VIA TELEHEALTH.**

24 (a) DEFINITIONS.—In this section:

1           (1) COMPTROLLER GENERAL.—The term  
2           “Comptroller General” means the Comptroller Gen-  
3           eral of the United States.

4           (2) SCHOOL-BASED HEALTH CENTER.—The  
5           term “school-based health center” has the meaning  
6           given that term in section 2110(c)(9) of the Social  
7           Security Act (42 U.S.C. 1397jj(c)(9)).

8           (3) SECRETARY.—The term “Secretary” means  
9           the Secretary of Health and Human Services.

10          (4) UNDERSERVED AREA.—The term “under-  
11          served area” means a health professional shortage  
12          area (as defined in section 332(a)(1)(A) of the Pub-  
13          lic Health Service Act (42 U.S.C. 254e(a)(1)(A)))  
14          and a medically underserved area (according to a  
15          designation under section 330(b)(3)(A) of the Public  
16          Health Service Act (42 U.S.C. 254b(b)(3)(A))).

17          (b) GUIDANCE TO STATES REGARDING FEDERAL RE-  
18          IMBURSEMENT FOR FURNISHING SERVICES AND TREAT-  
19          MENT FOR SUBSTANCE USE DISORDERS UNDER MED-  
20          ICAID USING SERVICES DELIVERED VIA TELEHEALTH,  
21          INCLUDING IN SCHOOL-BASED HEALTH CENTERS.—Not  
22          later than 1 year after the date of enactment of this Act,  
23          the Secretary, acting through the Administrator of the  
24          Centers for Medicare & Medicaid Services, shall issue  
25          guidance to States on the following:

1           (1) State options for Federal reimbursement of  
2           expenditures under Medicaid for furnishing services  
3           and treatment for substance use disorders, including  
4           assessment, medication-assisted treatment, coun-  
5           seling, and medication management, using services  
6           delivered via telehealth. Such guidance shall also in-  
7           clude guidance on furnishing services and treatments  
8           that address the needs of high risk individuals, in-  
9           cluding at least the following groups:

10                   (A) American Indians and Alaska Natives.

11                   (B) Adults under the age of 40.

12                   (C) Individuals with a history of nonfatal  
13           overdose.

14           (2) State options for Federal reimbursement of  
15           expenditures under Medicaid for education directed  
16           to providers serving Medicaid beneficiaries with sub-  
17           stance use disorders using the hub and spoke model,  
18           through contracts with managed care entities,  
19           through administrative claiming for disease manage-  
20           ment activities, and under Delivery System Reform  
21           Incentive Payment (“DSRIP”) programs.

22           (3) State options for Federal reimbursement of  
23           expenditures under Medicaid for furnishing services  
24           and treatment for substance use disorders for indi-



1       viduals enrolled in Medicaid in a school-based health  
2       center using services delivered via telehealth.

3       (c) GAO EVALUATION OF CHILDREN'S ACCESS TO  
4 SERVICES AND TREATMENT FOR SUBSTANCE USE DIS-  
5 ORDERS UNDER MEDICAID.—

6           (1) STUDY.—The Comptroller General shall  
7       evaluate children's access to services and treatment  
8       for substance use disorders under Medicaid. The  
9       evaluation shall include an analysis of State options  
10      for improving children's access to such services and  
11      treatment and for improving outcomes, including by  
12      increasing the number of Medicaid providers who  
13      offer services or treatment for substance use dis-  
14      orders in a school-based health center using services  
15      delivered via telehealth, particularly in rural and un-  
16      derserved areas. The evaluation shall include an  
17      analysis of Medicaid provider reimbursement rates  
18      for services and treatment for substance use dis-  
19      orders.

20           (2) REPORT.—Not later than 1 year after the  
21      date of enactment of this Act, the Comptroller Gen-  
22      eral shall submit to Congress a report containing the  
23      results of the evaluation conducted under paragraph  
24      (1), together with recommendations for such legisla-

1           tion and administrative action as the Comptroller  
2           General determines appropriate.

3           (d) REPORT ON REDUCING BARRIERS TO USING  
4 SERVICES DELIVERED VIA TELEHEALTH AND REMOTE  
5 PATIENT MONITORING FOR PEDIATRIC POPULATIONS  
6 UNDER MEDICAID.—

7           (1) IN GENERAL.—Not later than 1 year after  
8           the date of enactment of this Act, the Secretary, act-  
9           ing through the Administrator of the Centers for  
10          Medicare & Medicaid Services, shall issue a report to  
11          the Committee on Finance of the Senate and the  
12          Committee on Energy and Commerce of the House  
13          of Representative identifying best practices and po-  
14          tential solutions for reducing barriers to using serv-  
15          ices delivered via telehealth to furnish services and  
16          treatment for substance use disorders among pedi-  
17          atric populations under Medicaid. The report shall  
18          include—

19                 (A) analyses of the best practices, barriers,  
20                 and potential solutions for using services deliv-  
21                 ered via telehealth to diagnose and provide serv-  
22                 ices and treatment for children with substance  
23                 use disorders, including opioid use disorder; and

24                 (B) identification and analysis of the dif-  
25                 ferences, if any, in furnishing services and

1 treatment for children with substance use dis-  
2 orders using services delivered via telehealth  
3 and using services delivered in person, such as,  
4 and to the extent feasible, with respect to—  
5 (i) utilization rates;  
6 (ii) costs;  
7 (iii) avoidable inpatient admissions  
8 and readmissions;  
9 (iv) quality of care; and  
10 (v) patient, family, and provider satis-  
11 faction.

12 (2) PUBLICATION.—The Secretary shall publish  
13 the report required under paragraph (1) on a public  
14 Internet website of the Department of Health and  
15 Human Services.

16 **SEC. 2204. ENHANCING PATIENT ACCESS TO NON-OPIOID**  
17 **TREATMENT OPTIONS.**

18 Not later than January 1, 2019, the Secretary of  
19 Health and Human Services, acting through the Adminis-  
20 trator of the Centers for Medicare & Medicaid Services,  
21 shall issue 1 or more final guidance documents, or update  
22 existing guidance documents, to States regarding manda-  
23 tory and optional items and services that may be provided  
24 under a State plan under title XIX of the Social Security  
25 Act (42 U.S.C. 1396 et seq.), or under a waiver of such

1 a plan, for non-opioid treatment and management of pain,  
2 including, but not limited to, evidence-based non-opioid  
3 pharmacological therapies and non-pharmacological thera-  
4 pies.

5 **SEC. 2205. ASSESSING BARRIERS TO OPIOID USE DISORDER**  
6 **TREATMENT.**

7 (a) STUDY.—

8 (1) IN GENERAL.—The Comptroller General of  
9 the United States (in this section referred to as the  
10 “Comptroller General”) shall conduct a study re-  
11 garding the barriers to providing medication used in  
12 the treatment of substance use disorders under Med-  
13 icaid distribution models such as the “buy-and-bill”  
14 model, and options for State Medicaid programs to  
15 remove or reduce such barriers. The study shall in-  
16 clude analyses of each of the following models of dis-  
17 tribution of substance use disorder treatment medi-  
18 cations, particularly buprenorphine, naltrexone, and  
19 buprenorphine-naloxone combinations:

20 (A) The purchasing, storage, and adminis-  
21 tration of substance use disorder treatment  
22 medications by providers.

23 (B) The dispensing of substance use dis-  
24 order treatment medications by pharmacists.

1           (C) The ordering, prescribing, and obtain-  
2           ing substance use disorder treatment medica-  
3           tions on demand from specialty pharmacies by  
4           providers.

5           (2) REQUIREMENTS.—For each model of dis-  
6           tribution specified in paragraph (1), the Comptroller  
7           General shall evaluate how each model presents bar-  
8           riers or could be used by selected State Medicaid  
9           programs to reduce the barriers related to the provi-  
10          sion of substance use disorder treatment by exam-  
11          ining what is known about the effects of the model  
12          of distribution on—

13                 (A) Medicaid beneficiaries' access to sub-  
14                 stance use disorder treatment medications;

15                 (B) the differential cost to the program be-  
16                 tween each distribution model for medication  
17                 assisted treatment; and

18                 (C) provider willingness to provide or pre-  
19                 scribe substance use disorder treatment medica-  
20                 tions.

21          (b) REPORT.—Not later than 15 months after the  
22          date of the enactment of this Act, the Comptroller General  
23          shall submit to Congress a report containing the results  
24          of the study conducted under subsection (a), together with

1 recommendations for such legislation and administrative  
2 action as the Comptroller General determines appropriate.

3 **SEC. 2206. HELP FOR MOMS AND BABIES.**

4 (a) **MEDICAID STATE PLAN.**—Section 1905(a) of the  
5 Social Security Act (42 U.S.C. 1396d(a)) is amended by  
6 adding at the end the following new sentence: “In the case  
7 of a woman who is eligible for medical assistance on the  
8 basis of being pregnant (including through the end of the  
9 month in which the 60-day period beginning on the last  
10 day of her pregnancy ends), who is a patient in an institu-  
11 tion for mental diseases for purposes of receiving treat-  
12 ment for a substance use disorder, and who was enrolled  
13 for medical assistance under the State plan immediately  
14 before becoming a patient in an institution for mental dis-  
15 eases or who becomes eligible to enroll for such medical  
16 assistance while such a patient, the exclusion from the def-  
17 inition of ‘medical assistance’ set forth in the subdivision  
18 (B) following paragraph (29) of the first sentence of this  
19 subsection shall not be construed as prohibiting Federal  
20 financial participation for medical assistance for items or  
21 services that are provided to the woman outside of the in-  
22 stitution.”.

23 (b) **EFFECTIVE DATE.**—

24 (1) **IN GENERAL.**—Except as provided in para-  
25 graph (2), the amendment made by subsection (a)

1 shall take effect on the date of enactment of this  
2 Act.

3 (2) RULE FOR CHANGES REQUIRING STATE  
4 LEGISLATION.—In the case of a State plan under  
5 title XIX of the Social Security Act which the Sec-  
6 retary of Health and Human Services determines re-  
7 quires State legislation (other than legislation appro-  
8 priating funds) in order for the plan to meet the ad-  
9 ditional requirements imposed by the amendment  
10 made by subsection (a), the State plan shall not be  
11 regarded as failing to comply with the requirements  
12 of such title solely on the basis of its failure to meet  
13 these additional requirements before the first day of  
14 the first calendar quarter beginning after the close  
15 of the first regular session of the State legislature  
16 that begins after the date of the enactment of this  
17 Act. For purposes of the previous sentence, in the  
18 case of a State that has a 2-year legislative session,  
19 each year of such session shall be deemed to be a  
20 separate regular session of the State legislature.

21 **SEC. 2207. SECURING FLEXIBILITY TO TREAT SUBSTANCE**  
22 **USE DISORDERS.**

23 Section 1903(m) of the Social Security Act (42  
24 U.S.C. 1396b(m)) is amended by adding at the end the  
25 following new paragraph:

1 “(7) Payment shall be made under this title to a  
2 State for expenditures for capitation payments described  
3 in section 438.6(e) of title 42, Code of Federal Regula-  
4 tions (or any successor regulation).”.

5 **SEC. 2208. MACPAC STUDY AND REPORT ON MAT UTILIZA-**  
6 **TION CONTROLS UNDER STATE MEDICAID**  
7 **PROGRAMS.**

8 (a) STUDY.—The Medicaid and CHIP Payment and  
9 Access Commission shall conduct a study and analysis of  
10 utilization control policies applied to medication-assisted  
11 treatment for substance use disorders under State Med-  
12 icaid programs, including policies and procedures applied  
13 both in fee-for-service Medicaid and in risk-based man-  
14 aged care Medicaid, which shall—

15 (1) include an inventory of such utilization con-  
16 trol policies and related protocols for ensuring access  
17 to medically necessary treatment;

18 (2) determine whether managed care utilization  
19 control policies and procedures for medication as-  
20 sisted treatment for substance use disorders are con-  
21 sistent with section 438.210(a)(4)(ii) of title 42,  
22 Code of Federal Regulations; and

23 (3) identify policies that—

24 (A) limit an individual’s access to medica-  
25 tion-assisted treatment for a substance use dis-



1 order by limiting the quantity of medication-as-  
2 sisted treatment prescriptions, or the number of  
3 refills for such prescriptions, available to the in-  
4 dividual as part of a prior authorization process  
5 or similar utilization protocols; and

6 (B) apply without evaluating individual in-  
7 stances of fraud, waste, or abuse.

8 (b) REPORT.—Not later than 1 year after the date  
9 of the enactment of this Act, the Medicaid and CHIP Pay-  
10 ment and Access Commission shall make publicly available  
11 a report containing the results of the study conducted  
12 under subsection (a).

13 **SEC. 2209. OPIOID ADDICTION TREATMENT PROGRAMS EN-**  
14 **HANCEMENT.**

15 (a) T-MSIS SUBSTANCE USE DISORDER DATA  
16 BOOK.—

17 (1) IN GENERAL.—Not later than the date that  
18 is 12 months after the date of enactment of this Act,  
19 the Secretary of Health and Human Services (in this  
20 section referred to as the “Secretary”) shall publish  
21 on the public website of the Centers for Medicare &  
22 Medicaid Services a report with comprehensive data  
23 on the prevalence of substance use disorders in the  
24 Medicaid beneficiary population and services pro-

1 vided for the treatment of substance use disorders  
2 under Medicaid.

3 (2) CONTENT OF REPORT.—The report re-  
4 quired under paragraph (1) shall include, at a min-  
5 imum, the following data for each State (including,  
6 to the extent available, for the District of Columbia,  
7 Puerto Rico, the Virgin Islands, Guam, the North-  
8 ern Mariana Islands, and American Samoa):

9 (A) The number and percentage of individ-  
10 uals enrolled in the State Medicaid plan or  
11 waiver of such plan in each of the major enroll-  
12 ment categories (as defined in a public letter  
13 from the Medicaid and CHIP Payment and Ac-  
14 cess Commission to the Secretary) who have  
15 been diagnosed with a substance use disorder  
16 and whether such individuals are enrolled under  
17 the State Medicaid plan or a waiver of such  
18 plan, including the specific waiver authority  
19 under which they are enrolled, to the extent  
20 available.

21 (B) A list of the substance use disorder  
22 treatment services by each major type of serv-  
23 ice, such as counseling, medication assisted  
24 treatment, peer support, residential treatment,  
25 and inpatient care, for which beneficiaries in

1 each State received at least 1 service under the  
2 State Medicaid plan or a waiver of such plan.

3 (C) The number and percentage of individ-  
4 uals with a substance use disorder diagnosis en-  
5 rolled in the State Medicaid plan or waiver of  
6 such plan who received substance use disorder  
7 treatment services under such plan or waiver by  
8 each major type of service under subparagraph  
9 (B) within each major setting type, such as out-  
10 patient, inpatient, residential, and other home  
11 and community-based settings.

12 (D) The number of services provided under  
13 the State Medicaid plan or waiver of such plan  
14 per individual with a substance use disorder di-  
15 agnosis enrolled in such plan or waiver for each  
16 major type of service under subparagraph (B).

17 (E) The number and percentage of individ-  
18 uals enrolled in the State Medicaid plan or  
19 waiver, by major enrollment category, who re-  
20 ceived substance use disorder treatment  
21 through—

22 (i) a medicaid managed care entity  
23 (as defined in section 1932(a)(1)(B) of the  
24 Social Security Act (42 U.S.C. 1396u-  
25 2(a)(1)(B))), including the number of such

1 individuals who received such assistance  
2 through a prepaid inpatient health plan or  
3 a prepaid ambulatory health plan;

4 (ii) a fee-for-service payment model;  
5 or

6 (iii) an alternative payment model, to  
7 the extent available.

8 (F) The number and percentage of individ-  
9 uals with a substance use disorder who receive  
10 substance use disorder treatment services in an  
11 outpatient or home and community-based set-  
12 ting after receiving treatment in an inpatient or  
13 residential setting, and the number of services  
14 received by such individuals in the outpatient or  
15 home and community-based setting.

16 (3) ANNUAL UPDATES.—The Secretary shall  
17 issue an updated version of the report required  
18 under paragraph (1) not later than January 1 of  
19 each calendar year through 2024.

20 (4) USE OF T-MSIS DATA.—The report required  
21 under paragraph (1) and updates required under  
22 paragraph (3) shall—

23 (A) use data and definitions from the  
24 Transformed Medicaid Statistical Information  
25 System (“T-MSIS”) data set that is no more

1 than 12 months old on the date that the report  
2 or update is published; and

3 (B) as appropriate, include a description  
4 with respect to each State of the quality and  
5 completeness of the data and caveats describing  
6 the limitations of the data reported to the Sec-  
7 retary by the State that is sufficient to commu-  
8 nicate the appropriate uses for the information.

9 (b) MAKING T-MSIS DATA ON SUBSTANCE USE  
10 DISORDERS AVAILABLE TO RESEARCHERS.—

11 (1) IN GENERAL.—The Secretary shall publish  
12 in the Federal Register a system of records notice  
13 for the data specified in paragraph (2) for the  
14 Transformed Medicaid Statistical Information Sys-  
15 tem, in accordance with section 552a(e)(4) of title 5,  
16 United States Code. The notice shall outline policies  
17 that protect the security and privacy of the data  
18 that, at a minimum, meet the security and privacy  
19 policies of SORN 09-70-0541 for the Medicaid Sta-  
20 tistical Information System.

21 (2) REQUIRED DATA.—The data covered by the  
22 systems of records notice required under paragraph  
23 (1) shall be sufficient for researchers and States to  
24 analyze the prevalence of substance use disorders in  
25 the Medicaid beneficiary population and the treat-

1       ment of substance use disorders under Medicaid  
2       across all States (including the District of Columbia,  
3       Puerto Rico, the Virgin Islands, Guam, the North-  
4       ern Mariana Islands, and American Samoa), forms  
5       of treatment, and treatment settings.

6               (3) INITIATION OF DATA-SHARING ACTIVI-  
7       TIES.—Not later than January 1, 2019, the Sec-  
8       retary shall initiate the data-sharing activities out-  
9       lined in the notice required under paragraph (1).

10 **SEC. 2210. BETTER DATA SHARING TO COMBAT THE OPIOID**  
11 **CRISIS.**

12       (a) IN GENERAL.—Section 1903(m) of the Social Se-  
13       curity Act (42 U.S.C. 1396b(m)), as amended by section  
14       2207, is amended by adding at the end the following new  
15       paragraph:

16               “(8)(A) The State agency administering the State  
17       plan under this title may have reasonable access, as deter-  
18       mined by the State, to 1 or more prescription drug moni-  
19       toring program databases administered or accessed by the  
20       State to the extent the State agency is permitted to access  
21       such databases under State law.

22               “(B) Such State agency may facilitate reasonable ac-  
23       cess, as determined by the State, to 1 or more prescription  
24       drug monitoring program databases administered or  
25       accessed by the State, to same extent that the State agen-

1 cy is permitted under State law to access such databases,  
2 for—

3 “(i) any provider enrolled under the State plan  
4 to provide services to Medicaid beneficiaries; and

5 “(ii) any managed care entity (as defined under  
6 section 1932(a)(1)(B)) that has a contract with the  
7 State under this subsection or under section  
8 1905(t)(3).

9 “(C) Such State agency may share information in  
10 such databases, to the same extent that the State agency  
11 is permitted under State law to share information in such  
12 databases, with—

13 “(i) any provider enrolled under the State plan  
14 to provide services to Medicaid beneficiaries; and

15 “(ii) any managed care entity (as defined under  
16 section 1932(a)(1)(B)) that has a contract with the  
17 State under this subsection or under section  
18 1905(t)(3).”.

19 (b) SECURITY AND PRIVACY.—All applicable State  
20 and Federal security and privacy protections and laws  
21 shall apply to any State agency, individual, or entity ac-  
22 ccessing 1 or more prescription drug monitoring program  
23 databases or obtaining information in such databases in  
24 accordance with section 1903(m)(8) of the Social Security

1 Act (42 U.S.C. 1396b(m)(8)) (as added by subsection  
2 (a)).

3 (c) EFFECTIVE DATE.—The amendment made by  
4 subsection (a) shall take effect on the date of enactment  
5 of this Act.

6 **SEC. 2211. MANDATORY REPORTING WITH RESPECT TO**  
7 **ADULT BEHAVIORAL HEALTH MEASURES.**

8 Section 1139B of the Social Security Act (42 U.S.C.  
9 1320b–9b) is amended—

10 (1) in subsection (b)—

11 (A) in paragraph (3)—

12 (i) by striking “Not later than Janu-  
13 ary 1, 2013” and inserting the following:

14 “(A) VOLUNTARY REPORTING.—Not later  
15 than January 1, 2013”; and

16 (ii) by adding at the end the fol-  
17 lowing:

18 “(B) MANDATORY REPORTING WITH RE-  
19 SPECT TO BEHAVIORAL HEALTH MEASURES.—  
20 Beginning with the State report required under  
21 subsection (d)(1) for 2024, the Secretary shall  
22 require States to use all behavioral health meas-  
23 ures included in the core set of adult health  
24 quality measures and any updates or changes to  
25 such measures to report information, using the



1 standardized format for reporting information  
2 and procedures developed under subparagraph  
3 (A), regarding the quality of behavioral health  
4 care for Medicaid eligible adults.”;

5 (B) in paragraph (5), by adding at the end  
6 the following new subparagraph:

7 “(C) BEHAVIORAL HEALTH MEASURES.—  
8 Beginning with respect to State reports re-  
9 quired under subsection (d)(1) for 2024, the  
10 core set of adult health quality measures main-  
11 tained under this paragraph (and any updates  
12 or changes to such measures) shall include be-  
13 havioral health measures.”; and

14 (2) in subsection (d)(1)(A)—

15 (A) by striking “the such plan” and insert-  
16 ing “such plan”; and

17 (B) by striking “subsection (a)(5)” and in-  
18 serting “subsection (b)(5) and, beginning with  
19 the report for 2024, all behavioral health meas-  
20 ures included in the core set of adult health  
21 quality measures maintained under such sub-  
22 section (b)(5) and any updates or changes to  
23 such measures (as required under subsection  
24 (b)(3))”.

1 **SEC. 2212. REPORT ON INNOVATIVE STATE INITIATIVES**  
2 **AND STRATEGIES TO PROVIDE HOUSING-RE-**  
3 **LATED SERVICES AND SUPPORTS TO INDI-**  
4 **VIDUALS STRUGGLING WITH SUBSTANCE USE**  
5 **DISORDERS UNDER MEDICAID.**

6 (a) IN GENERAL.—Not later than 1 year after the  
7 date of enactment of this Act, the Secretary of Health and  
8 Human Services shall issue a report to Congress describ-  
9 ing innovative State initiatives and strategies for providing  
10 housing-related services and supports under a State Med-  
11 icaid program to individuals with substance use disorders  
12 who are experiencing or at risk of experiencing homeless-  
13 ness.

14 (b) CONTENT OF REPORT.—The report required  
15 under subsection (a) shall describe the following:

16 (1) Existing methods and innovative strategies  
17 developed and adopted by State Medicaid programs  
18 that have achieved positive outcomes in increasing  
19 housing stability among Medicaid beneficiaries with  
20 substance use disorders who are experiencing or at  
21 risk of experiencing homelessness, including Med-  
22 icaid beneficiaries with substance use disorders who  
23 are—

24 (A) receiving treatment for substance use  
25 disorders in inpatient, residential, outpatient, or  
26 home and community-based settings;

1 (B) transitioning between substance use  
2 disorder treatment settings; or

3 (C) living in supportive housing or another  
4 model of affordable housing.

5 (2) Strategies employed by Medicaid managed  
6 care organizations, primary care case managers, hos-  
7 pitals, accountable care organizations, and other  
8 care coordination providers to deliver housing-related  
9 services and supports and to coordinate services pro-  
10 vided under State Medicaid programs across dif-  
11 ferent treatment settings.

12 (3) Innovative strategies and lessons learned by  
13 States with Medicaid waivers approved under section  
14 1115 or 1915 of the Social Security Act (42 U.S.C.  
15 1315, 1396n), including—

16 (A) challenges experienced by States in de-  
17 signing, securing, and implementing such waiv-  
18 ers or plan amendments;

19 (B) how States developed partnerships  
20 with other organizations such as behavioral  
21 health agencies, State housing agencies, hous-  
22 ing providers, health care services agencies and  
23 providers, community-based organizations, and  
24 health insurance plans to implement waivers or  
25 State plan amendments; and

1           (C) how and whether States plan to pro-  
2           vide Medicaid coverage for housing-related serv-  
3           ices and supports in the future, including by  
4           covering such services and supports under State  
5           Medicaid plans or waivers.

6           (4) Existing opportunities for States to provide  
7           housing-related services and supports through a  
8           Medicaid waiver under sections 1115 or 1915 of the  
9           Social Security Act (42 U.S.C. 1315, 1396n) or  
10          through a State Medicaid plan amendment, such as  
11          the Assistance in Community Integration Service  
12          pilot program, which promotes supportive housing  
13          and other housing-related supports under Medicaid  
14          for individuals with substance use disorders and for  
15          which Maryland has a waiver approved under such  
16          section 1115 to conduct the program.

17          (5) Innovative strategies and partnerships de-  
18          veloped and implemented by State Medicaid pro-  
19          grams or other entities to identify and enroll eligible  
20          individuals with substance use disorders who are ex-  
21          periencing or at risk of experiencing homelessness in  
22          State Medicaid programs.

1 **SEC. 2213. TECHNICAL ASSISTANCE AND SUPPORT FOR IN-**  
2 **NOVATIVE STATE STRATEGIES TO PROVIDE**  
3 **HOUSING-RELATED SUPPORTS UNDER MED-**  
4 **ICAID.**

5 (a) IN GENERAL.—The Secretary of Health and  
6 Human Services shall provide technical assistance and  
7 support to States regarding the development and expan-  
8 sion of innovative State strategies (including through  
9 State Medicaid demonstration projects) to provide hous-  
10 ing-related supports and services and care coordination  
11 services under Medicaid to individuals with substance use  
12 disorders.

13 (b) REPORT.—Not later than 180 days after the date  
14 of enactment of this Act, the Secretary shall issue a report  
15 to Congress detailing a plan of action to carry out the  
16 requirements of subsection (a).

17 **Subtitle C—Human Services**

18 **SEC. 2301. SUPPORTING FAMILY-FOCUSED RESIDENTIAL**  
19 **TREATMENT.**

20 (a) DEFINITIONS.—In this section:

21 (1) FAMILY-FOCUSED RESIDENTIAL TREAT-  
22 MENT PROGRAM.—The term “family-focused resi-  
23 dential treatment program” means a trauma-in-  
24 formed residential program primarily for substance  
25 use disorder treatment for pregnant and postpartum  
26 women and parents and guardians that allows chil-

1       dren to reside with such women or their parents or  
2       guardians during treatment to the extent appro-  
3       priate and applicable.

4           (2) MEDICAID PROGRAM.—The term “Medicaid  
5       program” means the program established under title  
6       XIX of the Social Security Act (42 U.S.C. 1396 et  
7       seq.).

8           (3) SECRETARY.—The term “Secretary” means  
9       the Secretary of Health and Human Services.

10          (4) TITLE IV–E PROGRAM.—The term “title  
11       IV–E program” means the program for foster care,  
12       prevention, and permanency established under part  
13       E of title IV of the Social Security Act (42 U.S.C.  
14       670 et seq.).

15       (b) GUIDANCE ON FAMILY-FOCUSED RESIDENTIAL  
16       TREATMENT PROGRAMS.—

17           (1) IN GENERAL.—Not later than 180 days  
18       after the date of enactment of this Act, the Sec-  
19       retary, in consultation with divisions of the Depart-  
20       ment of Health and Human Services administering  
21       substance use disorder or child welfare programs,  
22       shall develop and issue guidance to States identi-  
23       fying opportunities to support family-focused resi-  
24       dential treatment programs for the provision of sub-  
25       stance use disorder treatment. Before issuing such

1 guidance, the Secretary shall solicit input from rep-  
2 resentatives of States, health care providers with ex-  
3 pertise in addiction medicine, obstetrics and gyne-  
4 cology, neonatology, child trauma, and child develop-  
5 ment, health plans, recipients of family-focused  
6 treatment services, and other relevant stakeholders.

7 (2) ADDITIONAL REQUIREMENTS.—The guid-  
8 ance required under paragraph (1) shall include de-  
9 scriptions of the following:

10 (A) Existing opportunities and flexibilities  
11 under the Medicaid program, including under  
12 waivers authorized under section 1115 or 1915  
13 of the Social Security Act (42 U.S.C. 1315,  
14 1396n), for States to receive Federal Medicaid  
15 funding for the provision of substance use dis-  
16 order treatment for pregnant and postpartum  
17 women and parents and guardians and, to the  
18 extent applicable, their children, in family-fo-  
19 cused residential treatment programs.

20 (B) How States can employ and coordinate  
21 funding provided under the Medicaid program,  
22 the title IV-E program, and other programs ad-  
23 ministered by the Secretary to support the pro-  
24 vision of treatment and services provided by a  
25 family-focused residential treatment facility

1           such as substance use disorder treatment and  
2           services, including medication-assisted treat-  
3           ment, family, group, and individual counseling,  
4           case management, parenting education and  
5           skills development, the provision, assessment, or  
6           coordination of care and services for children,  
7           including necessary assessments and appro-  
8           priate interventions, non-emergency transpor-  
9           tation for necessary care provided at or away  
10          from a program site, transitional services and  
11          supports for families leaving treatment, and  
12          other services.

13                 (C) How States can employ and coordinate  
14          funding provided under the Medicaid program  
15          and the title IV–E program (including as  
16          amended by the Family First Prevention Serv-  
17          ices Act enacted under title VII of division E of  
18          Public Law 115–123, and particularly with re-  
19          spect to the authority under subsections  
20          (a)(2)(C) and (j) of section 472 and section  
21          474(a)(1) of the Social Security Act (42 U.S.C.  
22          672, 674(a)(1)) (as amended by section 50712  
23          of Public Law 115–123) to provide foster care  
24          maintenance payments for a child placed with a  
25          parent who is receiving treatment in a licensed



1 residential family-based treatment facility for a  
2 substance use disorder) to support placing chil-  
3 dren with their parents in family-focused resi-  
4 dential treatment programs.

5 **SEC. 2302. IMPROVING RECOVERY AND REUNIFYING FAMI-**  
6 **LIES.**

7 (a) FAMILY RECOVERY AND REUNIFICATION PRO-  
8 GRAM REPLICATION PROJECT.—Section 435 of the Social  
9 Security Act (42 U.S.C. 629e) is amended by adding at  
10 the end the following:

11 “(e) FAMILY RECOVERY AND REUNIFICATION PRO-  
12 GRAM REPLICATION PROJECT.—

13 “(1) PURPOSE.—The purpose of this subsection  
14 is to provide resources to the Secretary to support  
15 the conduct and evaluation of a family recovery and  
16 reunification program replication project (referred to  
17 in this subsection as the ‘project’) and to determine  
18 the extent to which such programs may be appro-  
19 priate for use at different intervention points (such  
20 as when a child is at risk of entering foster care or  
21 when a child is living with a guardian while a parent  
22 is in treatment). The family recovery and reunifica-  
23 tion program conducted under the project shall use  
24 a recovery coach model that is designed to help re-  
25 unify families and protect children by working with

1 parents or guardians with a substance use disorder  
2 who have temporarily lost custody of their children.

3 “(2) PROGRAM COMPONENTS.—The family re-  
4 covery and reunification program conducted under  
5 the project shall adhere closely to the elements and  
6 protocol determined to be most effective in other re-  
7 covery coaching programs that have been rigorously  
8 evaluated and shown to increase family reunification  
9 and protect children and, consistent with such ele-  
10 ments and protocol, shall provide such items and  
11 services as—

12 “(A) assessments to evaluate the needs of  
13 the parent or guardian;

14 “(B) assistance in receiving the appro-  
15 priate benefits to aid the parent or guardian in  
16 recovery;

17 “(C) services to assist the parent or guard-  
18 ian in prioritizing issues identified in assess-  
19 ments, establishing goals for resolving such  
20 issues that are consistent with the goals of the  
21 treatment provider, child welfare agency,  
22 courts, and other agencies involved with the  
23 parent or guardian or their children, and mak-  
24 ing a coordinated plan for achieving such goals;

1           “(D) home visiting services coordinated  
2 with the child welfare agency and treatment  
3 provider involved with the parent or guardian  
4 or their children;

5           “(E) case management services to remove  
6 barriers for the parent or guardian to partici-  
7 pate and continue in treatment, as well as to  
8 re-engage a parent or guardian who is not par-  
9 ticipating or progressing in treatment;

10           “(F) access to services needed to monitor  
11 the parent’s or guardian’s compliance with pro-  
12 gram requirements;

13           “(G) frequent reporting between the treat-  
14 ment provider, child welfare agency, courts, and  
15 other agencies involved with the parent or  
16 guardian or their children to ensure appropriate  
17 information on the parent’s or guardian’s sta-  
18 tus is available to inform decision-making; and

19           “(H) assessments and recommendations  
20 provided by a recovery coach to the child wel-  
21 fare caseworker responsible for documenting the  
22 parent’s or guardian’s progress in treatment  
23 and recovery as well as the status of other  
24 areas identified in the treatment plan for the  
25 parent or guardian, including a recommenda-

1           tion regarding the expected safety of the child  
2           if the child is returned to the custody of the  
3           parent or guardian that can be used by the  
4           caseworker and a court to make permanency  
5           decisions regarding the child.

6           “(3) RESPONSIBILITIES OF THE SECRETARY.—

7                 “(A) IN GENERAL.—The Secretary shall,  
8           through a grant or contract with 1 or more en-  
9           tities, conduct and evaluate the family recovery  
10          and reunification program under the project.

11                 “(B) REQUIREMENTS.—In identifying 1 or  
12          more entities to conduct the evaluation of the  
13          family recovery and reunification program, the  
14          Secretary shall—

15                         “(i) determine that the area or areas  
16           in which the program will be conducted  
17           have sufficient substance use disorder  
18           treatment providers and other resources  
19           (other than those provided with funds  
20           made available to carry out the project) to  
21           successfully conduct the program;

22                         “(ii) determine that the area or areas  
23           in which the program will be conducted  
24           have enough potential program partici-  
25           pants, and will serve a sufficient number of

1 parents or guardians and their children, so  
2 as to allow for the formation of a control  
3 group, evaluation results to be adequately  
4 powered, and preliminary results of the  
5 evaluation to be available within 4 years of  
6 the program's implementation;

7 “(iii) provide the entity or entities  
8 with technical assistance for the program  
9 design, including by working with 1 or  
10 more entities that are or have been in-  
11 volved in recovery coaching programs that  
12 have been rigorously evaluated and shown  
13 to increase family reunification and protect  
14 children so as to make sure the program  
15 conducted under the project adheres closely  
16 to the elements and protocol determined to  
17 be most effective in such other recovery  
18 coaching programs;

19 “(iv) assist the entity or entities in se-  
20 curing adequate coaching, treatment, child  
21 welfare, court, and other resources needed  
22 to successfully conduct the family recovery  
23 and reunification program under the  
24 project; and

1                   “(v) ensure the entity or entities will  
2                   be able to monitor the impacts of the pro-  
3                   gram in the area or areas in which it is  
4                   conducted for at least 5 years after parents  
5                   or guardians and their children are ran-  
6                   domly assigned to participate in the pro-  
7                   gram or to be part of the program’s con-  
8                   trol group.

9                   “(4) EVALUATION REQUIREMENTS.—

10                   “(A) IN GENERAL.—The Secretary, in con-  
11                   sultation with the entity or entities conducting  
12                   the family recovery and reunification program  
13                   under the project, shall conduct an evaluation  
14                   to determine whether the program has been im-  
15                   plemented effectively and resulted in improve-  
16                   ments for children and families. The evaluation  
17                   shall have 3 components: a pilot phase, an im-  
18                   pact study, and an implementation study.

19                   “(B) PILOT PHASE.—The pilot phase com-  
20                   ponent of the evaluation shall consist of the  
21                   Secretary providing technical assistance to the  
22                   entity or entities conducting the family recovery  
23                   and reunification program under the project to  
24                   ensure—



1 to increase family reunification and protect  
2 children, measure outcomes for parents  
3 and guardians and their children over mul-  
4 tiple time periods, including for a period of  
5 5 years; and

6 “(iii) include measurements of family  
7 stability and parent, guardian, and child  
8 safety for program participants and the  
9 program control group that are consistent  
10 with measurements of such factors for par-  
11 ticipants and control groups from previous  
12 studies of other recovery coaching pro-  
13 grams so as to allow results of the impact  
14 study to be compared with the results of  
15 such prior studies, including with respect  
16 to comparisons between program partici-  
17 pants and the program control group re-  
18 garding—

19 “(I) safe family reunification;

20 “(II) time to reunification;

21 “(III) permanency (such as  
22 through measures of reunification,  
23 adoption, or placement with guard-  
24 ians);





1 evaluated and shown to increase family re-  
2 unification and protect children; and

3 “(ii) the difference in services received  
4 or proposed to be received by the program  
5 participants and the program control  
6 group.

7 “(E) REPORT.—The Secretary shall pub-  
8 lish on an internet website maintained by the  
9 Secretary the following information:

10 “(i) A report on the pilot phase com-  
11 ponent of the evaluation.

12 “(ii) A report on the impact study  
13 component of the evaluation.

14 “(iii) A report on the implementation  
15 study component of the evaluation.

16 “(iv) A report that includes—

17 “(I) analyses of the extent to  
18 which the program has resulted in in-  
19 creased reunifications, increased per-  
20 manency, case closures, net savings to  
21 the State or States involved (taking  
22 into account both costs borne by  
23 States and the Federal government),  
24 or other outcomes, or if the program  
25 did not produce such outcomes, an

1 analysis of why the replication of the  
2 program did not yield such results;

3 “(II) if, based on such analyses,  
4 the Secretary determines the program  
5 should be replicated, a replication  
6 plan; and

7 “(III) such recommendations for  
8 legislation and administrative action  
9 as the Secretary determines appro-  
10 priate.

11 “(5) APPROPRIATION.—In addition to any  
12 amounts otherwise made available to carry out this  
13 subpart, out of any money in the Treasury of the  
14 United States not otherwise appropriated, there are  
15 appropriated \$15,000,000 for fiscal year 2019 to  
16 carry out the project, which shall remain available  
17 through fiscal year 2026.”.

18 (b) CLARIFICATION OF PAYER OF LAST RESORT AP-  
19 PPLICATION TO CHILD WELFARE PREVENTION AND FAM-  
20 ILY SERVICES.—Section 471(e)(10) of the Social Security  
21 Act (42 U.S.C. 671(e)(10)), as added by section  
22 50711(a)(2) of division E of Public Law 115–123, is  
23 amended—

24 (1) in subparagraph (A), by inserting “, nor  
25 shall the provision of such services or programs be

1 construed to permit the State to reduce medical or  
2 other assistance available to a recipient of such serv-  
3 ices or programs” after “under this Act”; and

4 (2) by adding at the end the following:

5 “(C) PAYER OF LAST RESORT.—In car-  
6 rying out its responsibilities to ensure access to  
7 services or programs under this subsection, the  
8 State agency shall not be considered to be a le-  
9 gally liable third party for purposes of satis-  
10 fying a financial commitment for the cost of  
11 providing such services or programs with re-  
12 spect to any individual for whom such cost  
13 would have been paid for from another public  
14 or private source but for the enactment of this  
15 subsection (except that whenever considered  
16 necessary to prevent a delay in the receipt of  
17 appropriate early intervention services by a  
18 child or family in a timely fashion, funds pro-  
19 vided under section 474(a)(6) may be used to  
20 pay the provider of services or programs pend-  
21 ing reimbursement from the public or private  
22 source that has ultimate responsibility for the  
23 payment).”.

1 (c) EFFECTIVE DATE.—The amendments made by  
2 subsection (b) shall take effect as if included in section  
3 50711 of division E of Public Law 115–123.

4 **SEC. 2303. BUILDING CAPACITY FOR FAMILY-FOCUSED RES-**  
5 **IDENTIAL TREATMENT.**

6 (a) DEFINITIONS.—In this section:

7 (1) ELIGIBLE ENTITY.—The term “eligible enti-  
8 ty” means a State, county, local, or tribal health or  
9 child welfare agency, a private nonprofit organiza-  
10 tion, a research organization, a treatment service  
11 provider, an institution of higher education (as de-  
12 fined under section 101 of the Higher Education Act  
13 of 1965 (20 U.S.C. 1001)), or another entity speci-  
14 fied by the Secretary.

15 (2) FAMILY-FOCUSED RESIDENTIAL TREAT-  
16 MENT PROGRAM.—The term “family-focused resi-  
17 dential treatment program” means a trauma-in-  
18 formed residential program primarily for substance  
19 use disorder treatment for pregnant and postpartum  
20 women and parents and guardians that allows chil-  
21 dren to reside with such women or their parents or  
22 guardians during treatment to the extent appro-  
23 priate and applicable.

24 (3) SECRETARY.—The term “Secretary” means  
25 the Secretary of Health and Human Services.

1 (b) SUPPORT FOR THE DEVELOPMENT OF EVI-  
2 DENCE-BASED FAMILY-FOCUSED RESIDENTIAL TREAT-  
3 MENT PROGRAMS.—

4 (1) AUTHORITY TO AWARD GRANTS.—The Sec-  
5 retary shall award grants to eligible entities for pur-  
6 poses of developing, enhancing, or evaluating family-  
7 focused residential treatment programs to increase  
8 the availability of such programs that meet the re-  
9 quirements for promising, supported, or well-sup-  
10 ported practices specified in section 471(e)(4)(C) of  
11 the Social Security Act (42 U.S.C. 671(e)(4)(C))  
12 (as added by the Family First Prevention Services  
13 Act enacted under title VII of division E of Public  
14 Law 115–123).

15 (2) EVALUATION REQUIREMENT.—The Sec-  
16 retary shall require any evaluation of a family-fo-  
17 cused residential treatment program by an eligible  
18 entity that uses funds awarded under this section for  
19 all or part of the costs of the evaluation be designed  
20 to assist in the determination of whether the pro-  
21 gram may qualify as a promising, supported, or well-  
22 supported practice in accordance with the require-  
23 ments of such section 471(e)(4)(C).

24 (c) AUTHORIZATION OF APPROPRIATIONS.—There is  
25 authorized to be appropriated to the Secretary to carry

1 out this section, \$20,000,000 for fiscal year 2019, which  
2 shall remain available through fiscal year 2023.

3 **Subtitle D—Synthetics Trafficking**  
4 **and Overdose Prevention**

5 **SEC. 2401. SHORT TITLE.**

6 This subtitle may be cited as the “Synthetics Traf-  
7 ficking and Overdose Prevention Act of 2018” or “STOP  
8 Act of 2018”.

9 **SEC. 2402. CUSTOMS FEES.**

10 (a) IN GENERAL.—Section 13031(b)(9) of the Con-  
11 solidated Omnibus Budget Reconciliation Act of 1985 (19  
12 U.S.C. 58c(b)(9)) is amended by adding at the end the  
13 following:

14 “(D)(i) With respect to the processing of items  
15 that are sent to the United States through the inter-  
16 national postal network by ‘Inbound Express Mail  
17 service’ or ‘Inbound EMS’ (as that service is de-  
18 scribed in the mail classification schedule referred to  
19 in section 3631 of title 39, United States Code), the  
20 following payments are required:

21 “(I) \$1 per Inbound EMS item.

22 “(II) If an Inbound EMS item is formally  
23 entered, the fee provided for under subsection  
24 (a)(9), if applicable.

1           “(ii) Notwithstanding section 451 of the Tariff  
2 Act of 1930 (19 U.S.C. 1451), the payments re-  
3 quired by clause (i), as allocated pursuant to clause  
4 (iii)(I), shall be the only payments required for reim-  
5 bursement of U.S. Customs and Border Protection  
6 for customs services provided in connection with the  
7 processing of an Inbound EMS item.

8           “(iii)(I) The payments required by clause (i)(I)  
9 shall be allocated as follows:

10           “(aa) 50 percent of the amount of the pay-  
11 ments shall be paid on a quarterly basis by the  
12 United States Postal Service to the Commis-  
13 sioner of U.S. Customs and Border Protection  
14 in accordance with regulations prescribed by the  
15 Secretary of the Treasury to reimburse U.S.  
16 Customs and Border Protection for customs  
17 services provided in connection with the proc-  
18 essing of Inbound EMS items.

19           “(bb) 50 percent of the amount of the pay-  
20 ments shall be retained by the Postal Service to  
21 reimburse the Postal Service for services pro-  
22 vided in connection with the customs processing  
23 of Inbound EMS items.

24           “(II) Payments received by U.S. Customs and  
25 Border Protection under subclause (I)(aa) shall, in



1       accordance with section 524 of the Tariff Act of  
2       1930 (19 U.S.C. 1524), be deposited in the Customs  
3       User Fee Account and used to directly reimburse  
4       each appropriation for the amount paid out of that  
5       appropriation for the costs incurred in providing  
6       services to international mail facilities. Amounts de-  
7       posited in accordance with the preceding sentence  
8       shall be available until expended for the provision of  
9       such services.

10           “(III) Payments retained by the Postal Service  
11       under subclause (I)(bb) shall be used to directly re-  
12       imburse the Postal Service for the costs incurred in  
13       providing services in connection with the customs  
14       processing of Inbound EMS items.

15           “(iv) Beginning in fiscal year 2021, the Sec-  
16       retary, in consultation with the Postmaster General,  
17       may adjust, not more frequently than once each fis-  
18       cal year, the amount described in clause (i)(I) to an  
19       amount commensurate with the costs of services pro-  
20       vided in connection with the customs processing of  
21       Inbound EMS items, consistent with the obligations  
22       of the United States under international agree-  
23       ments.”.

1 (b) CONFORMING AMENDMENTS.—Section 13031(a)  
2 of the Consolidated Omnibus Budget Reconciliation Act  
3 of 1985 (19 U.S.C. 58c(a)) is amended—

4 (1) in paragraph (6), by inserting “(other than  
5 an item subject to a fee under subsection  
6 (b)(9)(D))” after “customs officer”; and

7 (2) in paragraph (10)—

8 (A) in subparagraph (C), in the matter  
9 preceding clause (i), by inserting “(other than  
10 Inbound EMS items described in subsection  
11 (b)(9)(D))” after “release”; and

12 (B) in the flush at the end, by inserting  
13 “or of Inbound EMS items described in sub-  
14 section (b)(9)(D),” after “(C),”.

15 (c) EFFECTIVE DATE.—The amendments made by  
16 this section shall take effect on January 1, 2020.

17 **SEC. 2403. MANDATORY ADVANCE ELECTRONIC INFORMA-**  
18 **TION FOR POSTAL SHIPMENTS.**

19 (a) MANDATORY ADVANCE ELECTRONIC INFORMA-  
20 TION.—

21 (1) IN GENERAL.—Section 343(a)(3)(K) of the  
22 Trade Act of 2002 (Public Law 107–210; 19 U.S.C.  
23 2071 note) is amended to read as follows:

24 “(K)(i) The Secretary shall prescribe regu-  
25 lations requiring the United States Postal Serv-

1 ice to transmit the information described in  
2 paragraphs (1) and (2) to the Commissioner of  
3 U.S. Customs and Border Protection for inter-  
4 national mail shipments by the Postal Service  
5 (including shipments to the Postal Service from  
6 foreign postal operators that are transported by  
7 private carrier) consistent with the require-  
8 ments of this subparagraph.

9 “(ii) In prescribing regulations under  
10 clause (i), the Secretary shall impose require-  
11 ments for the transmission to the Commissioner  
12 of information described in paragraphs (1) and  
13 (2) for mail shipments described in clause (i)  
14 that are comparable to the requirements for the  
15 transmission of such information imposed on  
16 similar non-mail shipments of cargo, taking into  
17 account the parameters set forth in subpara-  
18 graphs (A) through (J).

19 “(iii) The regulations prescribed under  
20 clause (i) shall require the transmission of the  
21 information described in paragraphs (1) and (2)  
22 with respect to a shipment as soon as prac-  
23 ticable in relation to the transportation of the  
24 shipment, consistent with subparagraph (H).

1           “(iv) Regulations prescribed under clause  
2 (i) shall allow for the requirements for the  
3 transmission to the Commissioner of informa-  
4 tion described in paragraphs (1) and (2) for  
5 mail shipments described in clause (i) to be im-  
6 plemented in phases, as appropriate, by—

7           “(I) setting incremental targets for in-  
8 creasing the percentage of such shipments  
9 for which information is required to be  
10 transmitted to the Commissioner; and

11           “(II) taking into consideration—

12           “(aa) the risk posed by such  
13 shipments;

14           “(bb) the volume of mail shipped  
15 to the United States by or through a  
16 particular country; and

17           “(cc) the capacities of foreign  
18 postal operators to provide that infor-  
19 mation to the Postal Service.

20           “(v)(I) Notwithstanding clause (iv), the  
21 Postal Service shall, not later than December  
22 31, 2018, arrange for the transmission to the  
23 Commissioner of the information described in  
24 paragraphs (1) and (2) for not less than 70  
25 percent of the aggregate number of mail ship-

1           ments, including 100 percent of mail shipments  
2           from the People’s Republic of China, described  
3           in clause (i).

4           “(II) If the requirements of subclause (I)  
5           are not met, the Comptroller General of the  
6           United States shall submit to the appropriate  
7           congressional committees, not later than June  
8           30, 2019, a report—

9                   “(aa) assessing the reasons for the  
10                   failure to meet those requirements; and

11                   “(bb) identifying recommendations to  
12                   improve the collection by the Postal Serv-  
13                   ice of the information described in para-  
14                   graphs (1) and (2).

15           “(vi)(I) Notwithstanding clause (iv), the  
16           Postal Service shall, not later than December  
17           31, 2020, arrange for the transmission to the  
18           Commissioner of the information described in  
19           paragraphs (1) and (2) for 100 percent of the  
20           aggregate number of mail shipments described  
21           in clause (i).

22           “(II) The Commissioner, in consultation  
23           with the Postmaster General, may determine to  
24           exclude a country from the requirement de-  
25           scribed in subclause (I) to transmit information

1 for mail shipments described in clause (i) from  
2 the country if the Commissioner determines  
3 that the country—

4 “(aa) does not have the capacity to  
5 collect and transmit such information;

6 “(bb) represents a low risk for mail  
7 shipments that violate relevant United  
8 States laws and regulations; and

9 “(cc) accounts for low volumes of mail  
10 shipments that can be effectively screened  
11 for compliance with relevant United States  
12 laws and regulations through an alternate  
13 means.

14 “(III) The Commissioner shall, at a min-  
15 imum on an annual basis, re-evaluate any de-  
16 termination made under subclause (II) to ex-  
17 clude a country from the requirement described  
18 in subclause (I). If, at any time, the Commis-  
19 sioner determines that a country no longer  
20 meets the requirements under subclause (II),  
21 the Commissioner may not further exclude the  
22 country from the requirement described in sub-  
23 clause (I).

1           “(IV) The Commissioner shall, on an an-  
2 nual basis, submit to the appropriate congres-  
3 sional committees—

4                   “(aa) a list of countries with respect  
5 to which the Commissioner has made a de-  
6 termination under subclause (II) to exclude  
7 the countries from the requirement de-  
8 scribed in subclause (I); and

9                   “(bb) information used to support  
10 such determination with respect to such  
11 countries.

12           “(vii)(I) The Postmaster General shall, in  
13 consultation with the Commissioner, refuse any  
14 shipments received after December 31, 2020,  
15 for which the information described in para-  
16 graphs (1) and (2) is not transmitted as re-  
17 quired under this subparagraph, except as pro-  
18 vided in subclause (II).

19           “(II) If remedial action is warranted in  
20 lieu of refusal of shipments pursuant to sub-  
21 clause (I), the Postmaster General and the  
22 Commissioner shall take remedial action with  
23 respect to the shipments, including destruction,  
24 seizure, controlled delivery or other law enforce-  
25 ment initiatives, or correction of the failure to

1 provide the information described in paragraphs  
2 (1) and (2) with respect to the shipment.

3 “(viii) Nothing in this subparagraph shall  
4 be construed to limit the authority of the Sec-  
5 retary to obtain information relating to inter-  
6 national mail shipments from private carriers or  
7 other appropriate parties.

8 “(ix) In this subparagraph, the term ‘ap-  
9 propriate congressional committees’ means—

10 “(I) the Committee on Finance and  
11 the Committee on Homeland Security and  
12 Governmental Affairs of the Senate; and

13 “(II) the Committee on Ways and  
14 Means, the Committee on Oversight and  
15 Government Reform, and the Committee  
16 on Homeland Security of the House of  
17 Representatives.”.

18 (2) JOINT STRATEGIC PLAN ON MANDATORY  
19 ADVANCE INFORMATION.—Not later than 60 days  
20 after the date of the enactment of this Act, the Sec-  
21 retary of Homeland Security and the Postmaster  
22 General shall develop and submit to the appropriate  
23 congressional committees a joint strategic plan de-  
24 tailing specific performance measures for achiev-  
25 ing—



1 (A) the transmission of information as re-  
2 quired by section 343(a)(3)(K) of the Trade  
3 Act of 2002, as amended by paragraph (1); and

4 (B) the presentation by the Postal Service  
5 to U.S. Customs and Border Protection of all  
6 mail targeted by U.S. Customs and Border Pro-  
7 tection for inspection.

8 (b) CAPACITY BUILDING.—

9 (1) IN GENERAL.—Section 343(a) of the Trade  
10 Act of 2002 (Public Law 107–210; 19 U.S.C. 2071  
11 note) is amended by adding at the end the following:

12 “(5) CAPACITY BUILDING.—

13 “(A) IN GENERAL.—The Secretary, with  
14 the concurrence of the Secretary of State, and  
15 in coordination with the Postmaster General  
16 and the heads of other Federal agencies, as ap-  
17 propriate, may provide technical assistance,  
18 equipment, technology, and training to enhance  
19 the capacity of foreign postal operators—

20 “(i) to gather and provide the infor-  
21 mation required by paragraph (3)(K); and

22 “(ii) to otherwise gather and provide  
23 postal shipment information related to—

24 “(I) terrorism;

1                   “(II) items the importation or in-  
2                   troduction of which into the United  
3                   States is prohibited or restricted, in-  
4                   cluding controlled substances; and  
5                   “(III) such other concerns as the  
6                   Secretary determines appropriate.

7                   “(B) PROVISION OF EQUIPMENT AND  
8                   TECHNOLOGY.—With respect to the provision of  
9                   equipment and technology under subparagraph  
10                  (A), the Secretary may lease, loan, provide, or  
11                  otherwise assist in the deployment of such  
12                  equipment and technology under such terms  
13                  and conditions as the Secretary may prescribe,  
14                  including nonreimbursable loans or the transfer  
15                  of ownership of equipment and technology.”.

16                  (2) JOINT STRATEGIC PLAN ON CAPACITY  
17                  BUILDING.—Not later than one year after the date  
18                  of the enactment of this Act, the Secretary of Home-  
19                  land Security and the Postmaster General shall, in  
20                  consultation with the Secretary of State, jointly de-  
21                  velop and submit to the appropriate congressional  
22                  committees a joint strategic plan—

23                         (A) detailing the extent to which U.S. Cus-  
24                         toms and Border Protection and the United  
25                         States Postal Service are engaged in capacity

1 building efforts under section 343(a)(5) of the  
2 Trade Act of 2002, as added by paragraph (1);

3 (B) describing plans for future capacity  
4 building efforts; and

5 (C) assessing how capacity building has in-  
6 creased the ability of U.S. Customs and Border  
7 Protection and the Postal Service to advance  
8 the goals of this subtitle and the amendments  
9 made by this subtitle.

10 (c) REPORT AND CONSULTATIONS BY SECRETARY OF  
11 HOMELAND SECURITY AND POSTMASTER GENERAL.—

12 (1) REPORT.—Not later than 180 days after  
13 the date of the enactment of this Act, and annually  
14 thereafter until 3 years after the Postmaster Gen-  
15 eral has met the requirement under clause (vi) of  
16 subparagraph (K) of section 343(a)(3) of the Trade  
17 Act of 2002, as amended by subsection (a)(1), the  
18 Secretary of Homeland Security and the Postmaster  
19 General shall, in consultation with the Secretary of  
20 State, jointly submit to the appropriate congres-  
21 sional committees a report on compliance with that  
22 subparagraph that includes the following:

23 (A) An assessment of the status of the reg-  
24 ulations required to be promulgated under that  
25 subparagraph.

1 (B) An update regarding new and existing  
2 agreements reached with foreign postal opera-  
3 tors for the transmission of the information re-  
4 quired by that subparagraph.

5 (C) A summary of deliberations between  
6 the United States Postal Service and foreign  
7 postal operators with respect to issues relating  
8 to the transmission of that information.

9 (D) A summary of the progress made in  
10 achieving the transmission of that information  
11 for the percentage of shipments required by  
12 that subparagraph.

13 (E) An assessment of the quality of that  
14 information being received by foreign postal op-  
15 erators, as determined by the Secretary of  
16 Homeland Security, and actions taken to im-  
17 prove the quality of that information.

18 (F) A summary of policies established by  
19 the Universal Postal Union that may affect the  
20 ability of the Postmaster General to obtain the  
21 transmission of that information.

22 (G) A summary of the use of technology to  
23 detect illicit synthetic opioids and other illegal  
24 substances in international mail parcels and

1           planned acquisitions and advancements in such  
2           technology.

3           (H) Such other information as the Sec-  
4           retary of Homeland Security and the Post-  
5           master General consider appropriate with re-  
6           spect to obtaining the transmission of informa-  
7           tion required by that subparagraph.

8           (2) CONSULTATIONS.—Not later than 180 days  
9           after the date of the enactment of this Act, and  
10          every 180 days thereafter until the Postmaster Gen-  
11          eral has met the requirement under clause (vi) of  
12          section 343(a)(3)(K) of the Trade Act of 2002, as  
13          amended by subsection (a)(1), to arrange for the  
14          transmission of information with respect to 100 per-  
15          cent of the aggregate number of mail shipments de-  
16          scribed in clause (i) of that section, the Secretary of  
17          Homeland Security and the Postmaster General  
18          shall provide briefings to the appropriate congres-  
19          sional committees on the progress made in achieving  
20          the transmission of that information for that per-  
21          centage of shipments.

22          (d) GOVERNMENT ACCOUNTABILITY OFFICE RE-  
23          PORT.—Not later than June 30, 2019, the Comptroller  
24          General of the United States shall submit to the appro-  
25          priate congressional committees a report—

1           (1) assessing the progress of the United States  
2           Postal Service in achieving the transmission of the  
3           information required by subparagraph (K) of section  
4           343(a)(3) of the Trade Act of 2002, as amended by  
5           subsection (a)(1), for the percentage of shipments  
6           required by that subparagraph;

7           (2) assessing the quality of the information re-  
8           ceived from foreign postal operators for targeting  
9           purposes;

10          (3) assessing the specific percentage of targeted  
11          mail presented by the Postal Service to U.S. Cus-  
12          toms and Border Protection for inspection;

13          (4) describing the costs of collecting the infor-  
14          mation required by such subparagraph (K) from for-  
15          eign postal operators and the costs of implementing  
16          the use of that information;

17          (5) assessing the benefits of receiving that in-  
18          formation with respect to international mail ship-  
19          ments;

20          (6) assessing the feasibility of assessing a cus-  
21          toms fee under section 13031(b)(9) of the Consoli-  
22          dated Omnibus Budget Reconciliation Act of 1985,  
23          as amended by section 2402, on international mail  
24          shipments other than Inbound Express Mail service

1 in a manner consistent with the obligations of the  
2 United States under international agreements; and

3 (7) identifying recommendations, including rec-  
4 ommendations for legislation, to improve the compli-  
5 ance of the Postal Service with such subparagraph  
6 (K), including an assessment of whether the detec-  
7 tion of illicit synthetic opioids in the international  
8 mail would be improved by—

9 (A) requiring the Postal Service to serve as  
10 the consignee for international mail shipments  
11 containing goods; or

12 (B) designating a customs broker to act as  
13 an importer of record for international mail  
14 shipments containing goods.

15 (e) TECHNICAL CORRECTION.—Section 343 of the  
16 Trade Act of 2002 (Public Law 107–210; 19 U.S.C. 2071  
17 note) is amended in the section heading by striking “**AD-**  
18 **VANCED**” and inserting “**ADVANCE**”.

19 (f) APPROPRIATE CONGRESSIONAL COMMITTEES DE-  
20 FINED.—In this section, the term “appropriate congres-  
21 sional committees” means—

22 (1) the Committee on Finance and the Com-  
23 mittee on Homeland Security and Governmental Af-  
24 fairs of the Senate; and

1           (2) the Committee on Ways and Means, the  
2           Committee on Oversight and Government Reform,  
3           and the Committee on Homeland Security of the  
4           House of Representatives.

5 **SEC. 2404. INTERNATIONAL POSTAL AGREEMENTS.**

6           (a) **EXISTING AGREEMENTS.—**

7           (1) **IN GENERAL.—**In the event that any provi-  
8           sion of this subtitle, or any amendment made by this  
9           subtitle, is determined to be in violation of obliga-  
10          tions of the United States under any postal treaty,  
11          convention, or other international agreement related  
12          to international postal services, or any amendment  
13          to such an agreement, the Secretary of State should  
14          negotiate to amend the relevant provisions of the  
15          agreement so that the United States is no longer in  
16          violation of the agreement.

17          (2) **RULE OF CONSTRUCTION.—**Nothing in this  
18          subsection shall be construed to permit delay in the  
19          implementation of this subtitle or any amendment  
20          made by this subtitle.

21          (b) **FUTURE AGREEMENTS.—**

22          (1) **CONSULTATIONS.—**Before entering into, on  
23          or after the date of the enactment of this Act, any  
24          postal treaty, convention, or other international  
25          agreement related to international postal services, or



1 any amendment to such an agreement, that is re-  
2 lated to the ability of the United States to secure  
3 the provision of advance electronic information by  
4 foreign postal operators, the Secretary of State  
5 should consult with the appropriate congressional  
6 committees (as defined in section 2403(f)).

7 (2) EXPEDITED NEGOTIATION OF NEW AGREE-  
8 MENT.—To the extent that any new postal treaty,  
9 convention, or other international agreement related  
10 to international postal services would improve the  
11 ability of the United States to secure the provision  
12 of advance electronic information by foreign postal  
13 operators as required by regulations prescribed  
14 under section 343(a)(3)(K) of the Trade Act of  
15 2002, as amended by section 2403(a)(1), the Sec-  
16 retary of State should expeditiously conclude such  
17 an agreement.

18 **SEC. 2405. COST RECOUPMENT.**

19 (a) IN GENERAL.—The United States Postal Service  
20 shall, to the extent practicable and otherwise recoverable  
21 by law, ensure that all costs associated with complying  
22 with this subtitle and amendments made by this subtitle  
23 are charged directly to foreign shippers or foreign postal  
24 operators.

1 (b) COSTS NOT CONSIDERED REVENUE.—The recov-  
2 ery of costs under subsection (a) shall not be deemed rev-  
3 enue for purposes of subchapter I and II of chapter 36  
4 of title 39, United States Code, or regulations prescribed  
5 under that chapter.

6 **SEC. 2406. DEVELOPMENT OF TECHNOLOGY TO DETECT IL-**  
7 **LICIT NARCOTICS.**

8 (a) IN GENERAL.—The Postmaster General and the  
9 Commissioner of U.S. Customs and Border Protection, in  
10 coordination with the heads of other agencies as appro-  
11 priate, shall collaborate to identify and develop technology  
12 for the detection of illicit fentanyl, other synthetic opioids,  
13 and other narcotics and psychoactive substances entering  
14 the United States by mail.

15 (b) OUTREACH TO PRIVATE SECTOR.—The Post-  
16 master General and the Commissioner shall conduct out-  
17 reach to private sector entities to gather information re-  
18 garding the current state of technology to identify areas  
19 for innovation relating to the detection of illicit fentanyl,  
20 other synthetic opioids, and other narcotics and  
21 psychoactive substances entering the United States.

22 **SEC. 2407. CIVIL PENALTIES FOR POSTAL SHIPMENTS.**

23 Section 436 of the Tariff Act of 1930 (19 U.S.C.  
24 1436) is amended by adding at the end the following new  
25 subsection:

1 “(e) CIVIL PENALTIES FOR POSTAL SHIPMENTS.—

2 “(1) CIVIL PENALTY.—A civil penalty shall be  
3 imposed against the United States Postal Service if  
4 the Postal Service accepts a shipment in violation of  
5 section 343(a)(3)(K)(vii)(I) of the Trade Act of  
6 2002.

7 “(2) MODIFICATION OF CIVIL PENALTY.—

8 “(A) IN GENERAL.—U.S. Customs and  
9 Border Protection shall reduce or dismiss a civil  
10 penalty imposed pursuant to paragraph (1) if  
11 U.S. Customs and Border Protection deter-  
12 mines that the United States Postal Service—

13 “(i) has a low error rate in compliance  
14 with section 343(a)(3)(K) of the Trade Act  
15 of 2002;

16 “(ii) is cooperating with U.S. Customs  
17 and Border Protection with respect to the  
18 violation of section 343(a)(3)(K)(vii)(I) of  
19 the Trade Act of 2002; or

20 “(iii) has taken remedial action to  
21 prevent future violations of section  
22 343(a)(3)(K)(vii)(I) of the Trade Act of  
23 2002.

24 “(B) WRITTEN NOTIFICATION.—U.S. Cus-  
25 toms and Border Protection shall issue a writ-

1           ten notification to the Postal Service with re-  
2           spect to each exercise of the authority of sub-  
3           paragraph (A) to reduce or dismiss a civil pen-  
4           alty imposed pursuant to paragraph (1).

5           “(3) ONGOING LACK OF COMPLIANCE.—If U.S.  
6           Customs and Border Protection determines that the  
7           United States Postal Service—

8                   “(A) has repeatedly committed violations  
9                   of section 343(a)(3)(K)(vii)(I) of the Trade Act  
10                  of 2002,

11                  “(B) has failed to cooperate with U.S.  
12                  Customs and Border Protection with respect to  
13                  violations of section 343(a)(3)(K)(vii)(I) of the  
14                  Trade Act of 2002, and

15                  “(C) has an increasing error rate in com-  
16                  pliance with section 343(a)(3)(K) of the Trade  
17                  Act of 2002,

18           civil penalties may be imposed against the United  
19           States Postal Service until corrective action, satis-  
20           factory to U.S. Customs and Border Protection, is  
21           taken.”.

1 **SEC. 2408. REPORT ON VIOLATIONS OF ARRIVAL, REPORT-**  
2 **ING, ENTRY, AND CLEARANCE REQUIRE-**  
3 **MENTS AND FALSITY OR LACK OF MANIFEST.**

4 (a) IN GENERAL.—The Commissioner of U.S. Cus-  
5 toms and Border Protection shall submit to the appro-  
6 priate congressional committees an annual report that  
7 contains the information described in subsection (b) with  
8 respect to each violation of section 436 of the Tariff Act  
9 of 1930 (19 U.S.C. 1436), as amended by section 7, and  
10 section 584 of such Act (19 U.S.C. 1584) that occurred  
11 during the previous year.

12 (b) INFORMATION DESCRIBED.—The information de-  
13 scribed in this subsection is the following:

14 (1) The name and address of the violator.

15 (2) The specific violation that was committed.

16 (3) The location or port of entry through which  
17 the items were transported.

18 (4) An inventory of the items seized, including  
19 a description of the items and the quantity seized.

20 (5) The location from which the items origi-  
21 nated.

22 (6) The entity responsible for the apprehension  
23 or seizure, organized by location or port of entry.

24 (7) The amount of penalties assessed by U.S.  
25 Customs and Border Protection, organized by name  
26 of the violator and location or port of entry.

1           (8) The amount of penalties that U.S. Customs  
2           and Border Protection could have levied, organized  
3           by name of the violator and location or port of entry.

4           (9) The rationale for negotiating lower pen-  
5           alties, organized by name of the violator and location  
6           or port of entry.

7           (c) APPROPRIATE CONGRESSIONAL COMMITTEES DE-  
8           FINED.—In this section, the term “appropriate congres-  
9           sional committees” means—

10           (1) the Committee on Finance and the Com-  
11           mittee on Homeland Security and Governmental Af-  
12           fairs of the Senate; and

13           (2) the Committee on Ways and Means, the  
14           Committee on Oversight and Government Reform,  
15           and the Committee on Homeland Security of the  
16           House of Representatives.

17 **SEC. 2409. EFFECTIVE DATE; REGULATIONS.**

18           (a) EFFECTIVE DATE.—This subtitle and the amend-  
19           ments made by this subtitle (other than the amendments  
20           made by section 2402) shall take effect on the date of the  
21           enactment of this Act.

22           (b) REGULATIONS.—Not later than one year after the  
23           date of the enactment of this Act, such regulations as are  
24           necessary to carry out this subtitle and the amendments  
25           made by this subtitle shall be prescribed.

1                   **TITLE III—JUDICIARY**  
2           **Subtitle A—Access to Increased**  
3                   **Drug Disposal**

4 **SEC. 3101. SHORT TITLE.**

5           This subtitle may be cited as the “Access to In-  
6 creased Drug Disposal Act of 2018”.

7 **SEC. 3102. DEFINITIONS.**

8           In this subtitle—

9                   (1) the term “Attorney General” means the At-  
10           torney General, acting through the Assistant Attor-  
11           ney General for the Office of Justice Programs;

12                   (2) the term “authorized collector” means a  
13           narcotic treatment program, a hospital or clinic with  
14           an on-site pharmacy, a retail pharmacy, or a reverse  
15           distributor, that is authorized as a collector under  
16           section 1317.40 of title 21, Code of Federal Regula-  
17           tions (or any successor regulation);

18                   (3) the term “covered grant” means a grant  
19           awarded under section 3003; and

20                   (4) the term “eligible collector” means a person  
21           who is eligible to be an authorized collector.

22 **SEC. 3103. AUTHORITY TO MAKE GRANTS.**

23           The Attorney General shall award grants to States  
24           to enable the States to increase the participation of eligible  
25           collectors as authorized collectors.

1 **SEC. 3104. APPLICATION.**

2 A State desiring a covered grant shall submit to the  
3 Attorney General an application that, at a minimum—

4 (1) identifies the single State agency that over-  
5 sees pharmaceutical care and will be responsible for  
6 complying with the requirements of the grant;

7 (2) details a plan to increase participation rates  
8 of eligible collectors as authorized collectors; and

9 (3) describes how the State will select eligible  
10 collectors to be served under the grant.

11 **SEC. 3105. USE OF GRANT FUNDS.**

12 A State that receives a covered grant, and any sub-  
13 recipient of the grant, may use the grant amounts only  
14 for the costs of installation, maintenance, training, pur-  
15 chasing, and disposal of controlled substances associated  
16 with the participation of eligible collectors as authorized  
17 collectors.

18 **SEC. 3106. ELIGIBILITY FOR GRANT.**

19 The Attorney General shall award a covered grant to  
20 5 States, not less than 3 of which shall be States in the  
21 lowest quartile of States based on the participation rate  
22 of eligible collectors as authorized collectors, as deter-  
23 mined by the Attorney General.

24 **SEC. 3107. DURATION OF GRANTS.**

25 The Attorney General shall determine the period of  
26 years for which a covered grant is made to a State.



1 **SEC. 3108. ACCOUNTABILITY AND OVERSIGHT.**

2 A State that receives a covered grant shall submit  
3 to the Attorney General a report, at such time and in such  
4 manner as the Attorney General may reasonably require,  
5 that—

6 (1) lists the ultimate recipients of the grant  
7 amounts;

8 (2) describes the activities undertaken by the  
9 State using the grant amounts; and

10 (3) contains performance measures relating to  
11 the effectiveness of the grant, including changes in  
12 the participation rate of eligible collectors as author-  
13 ized collectors.

14 **SEC. 3109. DURATION OF PROGRAM.**

15 The Attorney General may award covered grants for  
16 each of the first 5 fiscal years beginning after the date  
17 of enactment of this Act.

18 **SEC. 3110. AUTHORIZATION OF APPROPRIATIONS.**

19 There is authorized to be appropriated to the Attor-  
20 ney General such sums as may be necessary to carry out  
21 this subtitle.

22 **Subtitle B—Using Data To Prevent**  
23 **Opioid Diversion**

24 **SEC. 3201. SHORT TITLE.**

25 This subtitle may be cited as the “Using Data to Pre-  
26 vent Opioid Diversion Act of 2018”.

1 **SEC. 3202. PURPOSE.**

2 (a) IN GENERAL.—The purpose of this subtitle is to  
3 provide drug manufacturers and distributors with access  
4 to anonymized information through the Automated Re-  
5 ports and Consolidated Orders System to help drug manu-  
6 facturers and distributors identify, report, and stop sus-  
7 picious orders of opioids and reduce diversion rates.

8 (b) RULE OF CONSTRUCTION.—Nothing in this sub-  
9 title should be construed to absolve a drug manufacturer,  
10 drug distributor, or other Drug Enforcement Administra-  
11 tion registrant from the responsibility of the manufac-  
12 turer, distributor, or other registrant to—

13 (1) identify, stop, and report suspicious orders;

14 or

15 (2) maintain effective controls against diversion  
16 in accordance with section 303 of the Controlled  
17 Substances Act (21 U.S.C. 823) or any successor  
18 law or associated regulation.

19 **SEC. 3203. AMENDMENTS.**

20 (a) RECORDS AND REPORTS OF REGISTRANTS.—Sec-  
21 tion 307 of the Controlled Substances Act (21 U.S.C. 827)  
22 is amended—

23 (1) by redesignating subsections (f), (g), and  
24 (h) as subsections (g), (h), and (i), respectively;

25 (2) by inserting after subsection (e) the fol-  
26 lowing:

1           “(f)(1) The Attorney General shall, not less fre-  
2           quently than quarterly, make the following information  
3           available to manufacturer and distributor registrants  
4           through the Automated Reports and Consolidated Orders  
5           System, or any subsequent automated system developed  
6           by the Drug Enforcement Administration to monitor se-  
7           lected controlled substances:

8                   “(A) The total number of distributor reg-  
9                   istrants that distribute controlled substances to a  
10                  pharmacy or practitioner registrant, aggregated by  
11                  the name and address of each pharmacy and practi-  
12                  tioner registrant.

13                   “(B) The total quantity and type of opioids dis-  
14                  tributed, listed by Administration Controlled Sub-  
15                  stances Code Number, to each pharmacy and practi-  
16                  tioner registrant described in subparagraph (A).

17           “(2) The information required to be made available  
18           under paragraph (1) shall be made available not later than  
19           the 30th day of the first month following the quarter to  
20           which the information relates.

21           “(3)(A) All registered manufacturers and distributors  
22           shall be responsible for reviewing the information made  
23           available by the Attorney General under this subsection.

24           “(B) In determining whether to initiate proceedings  
25           under this title against a registered manufacturer or dis-

1 tributor based on the failure of the registrant to maintain  
2 effective controls against diversion or otherwise comply  
3 with the requirements of this title or the regulations issued  
4 thereunder, the Attorney General may take into account  
5 that the information made available under this subsection  
6 was available to the registrant.”; and

7 (3) by inserting after subsection (i), as so re-  
8 designated, the following:

9 “(j) All of the reports required under this section  
10 shall be provided in an electronic format.”.

11 (b) COOPERATIVE ARRANGEMENTS.—Section 503 of  
12 the Controlled Substances Act (21 U.S.C. 873) is amend-  
13 ed—

14 (1) by striking subsection (c) and inserting the  
15 following:

16 “(c)(1) The Attorney General shall, once every 6  
17 months, prepare and make available to regulatory, licens-  
18 ing, attorneys general, and law enforcement agencies of  
19 States a standardized report containing descriptive and  
20 analytic information on the actual distribution patterns,  
21 as gathered through the Automated Reports and Consoli-  
22 dated Orders System, or any subsequent automated sys-  
23 tem, pursuant to section 307 and which includes detailed  
24 amounts, outliers, and trends of distributor and pharmacy  
25 registrants, in such States for the controlled substances

1 contained in schedule II, which, in the discretion of the  
2 Attorney General, are determined to have the highest  
3 abuse.

4 “(2) If the Attorney General publishes the report de-  
5 scribed in paragraph (1) once every 6 months as required  
6 under paragraph (1), nothing in this subsection shall be  
7 construed to bring an action in any court to challenge the  
8 sufficiency of the information or to compel the Attorney  
9 General to produce any documents or reports referred to  
10 in this subsection.”.

11 (c) CIVIL AND CRIMINAL PENALTIES.—Section 402  
12 of the Controlled Substances Act (21 U.S.C. 842) is  
13 amended—

14 (1) in subsection (a)—

15 (A) in paragraph (15), by striking “or” at  
16 the end;

17 (B) in paragraph (16), by striking the pe-  
18 riod at the end and inserting “; or”; and

19 (C) by inserting after paragraph (16) the  
20 following:

21 “(17) in the case of a registered manufacturer  
22 or distributor of opioids, to fail to review the most  
23 recent information, directly related to the customers  
24 of the manufacturer or distributor, made available

1 by the Attorney General in accordance with section  
2 307(f).”; and

3 (2) in subsection (c)—

4 (A) in paragraph (1), by striking subpara-  
5 graph (B) and inserting the following:

6 “(B)(i) Except as provided in clause (ii), in the case  
7 of a violation of paragraph (5), (10), or (17) of subsection  
8 (a), the civil penalty shall not exceed \$10,000.

9 “(ii) In the case of a violation described in clause (i)  
10 committed by a registered manufacturer or distributor of  
11 opioids and related to the reporting of suspicious orders  
12 for opioids, failing to maintain effective controls against  
13 diversion of opioids, or failing to review the most recent  
14 information made available by the Attorney General in ac-  
15 cordance with section 307(f), the penalty shall not exceed  
16 \$100,000.”; and

17 (B) in paragraph (2)—

18 (i) in subparagraph (A), by inserting  
19 “or (D)” after “subparagraph (B)”; and

20 (ii) by adding at the end the fol-  
21 lowing:

22 “(D) In the case of a violation described in subpara-  
23 graph (A) that was a violation of paragraph (5), (10), or  
24 (17) of subsection (a) committed by a registered manufac-  
25 turer or distributor of opioids that relates to the reporting

1 of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 307(f), the criminal fine under title 18, United States Code, shall not exceed \$500,000.”.

7 **SEC. 3204. REPORT.**

8 Not later than 1 year after the date of enactment of this Act, the Attorney General shall submit to Congress a report that provides information about how the Attorney General is using data in the Automation of Reports and Consolidated Orders System to identify and stop suspicious activity, including whether the Attorney General is looking at aggregate orders from individual pharmacies to multiple distributors that in total are suspicious, even if no individual order rises to the level of a suspicious order to a given distributor.

18 **Subtitle C—Substance Abuse**  
19 **Prevention**

20 **SEC. 3301. SHORT TITLE.**

21 This subtitle may be cited as the “Substance Abuse  
22 Prevention Act of 2018”.

1 **SEC. 3302. REAUTHORIZATION OF THE OFFICE OF NA-**  
2 **TIONAL DRUG CONTROL POLICY.**

3 (a) OFFICE OF NATIONAL DRUG CONTROL POLICY  
4 REAUTHORIZATION ACT OF 1998.—

5 (1) IN GENERAL.—The Office of National Drug  
6 Control Policy Reauthorization Act of 1998 (21  
7 U.S.C. 1701 et seq.), as in effect on September 29,  
8 2003, and as amended by the laws described in  
9 paragraph (2), is revived and restored.

10 (2) LAWS DESCRIBED.—The laws described in  
11 this paragraph are:

12 (A) The Office of National Drug Control  
13 Policy Reauthorization Act of 2006 (Public  
14 Law 109–469; 120 Stat. 3502).

15 (B) The Presidential Appointment Effi-  
16 ciency and Streamlining Act of 2011 (Public  
17 Law 112–166; 126 Stat. 1283).

18 (b) REAUTHORIZATION.—Section 715(a) of the Of-  
19 fice of National Drug Control Policy Reauthorization Act  
20 of 1998 (21 U.S.C. 1712(a)) is amended by striking  
21 “2010” and inserting “2022”.

22 **SEC. 3303. REAUTHORIZATION OF THE DRUG-FREE COMMU-**  
23 **NITIES PROGRAM.**

24 Section 1024 of the National Narcotics Leadership  
25 Act of 1988 (21 U.S.C. 1524(a)) is amended by striking  
26 subsections (a) and (b) and inserting the following:





1           “(6) \$280,000,000 for each of fiscal years 2018  
2           through 2022.”.

3 **SEC. 3306. REAUTHORIZATION OF DRUG COURT PROGRAM.**

4           Section 1001(a)(25)(A) of title I of the Omnibus  
5 Crime Control and Safe Streets Act of 1968 (34 U.S.C.  
6 10261(a)(25)(A)) is amended by striking “Except as pro-  
7 vided” and all that follows and inserting the following:  
8 “Except as provided in subparagraph (C), there is author-  
9 ized to be appropriated to carry out part EE \$75,000,000  
10 for each of fiscal years 2018 through 2022.”.

11 **SEC. 3307. DRUG COURT TRAINING AND TECHNICAL AS-**  
12 **SISTANCE.**

13           Section 705 of the Office of National Drug Control  
14 Policy Reauthorization Act of 1998 (21 U.S.C. 1704) is  
15 amended by adding at the end the following—

16           “(e) DRUG COURT TRAINING AND TECHNICAL AS-  
17 SISTANCE PROGRAM.—Using funds appropriated to carry  
18 out this title, the Director may make grants to nonprofit  
19 organizations for the purpose of providing training and  
20 technical assistance to drug courts.”.

21 **SEC. 3308. DRUG OVERDOSE RESPONSE STRATEGY.**

22           Section 707 of the Office of National Drug Control  
23 Policy Reauthorization Act of 1998 (21 U.S.C. 1706) is  
24 amended by adding at the end the following:

1       “(r) DRUG OVERDOSE RESPONSE STRATEGY IMPL-  
2       MENTATION.—The Director may use funds appropriated  
3       to carry out this section to implement a drug overdose re-  
4       sponse strategy in high intensity drug trafficking areas on  
5       a nationwide basis by—

6               “(1) coordinating multi-disciplinary efforts to  
7       prevent, reduce, and respond to drug overdoses, in-  
8       cluding the uniform reporting of fatal and non-fatal  
9       overdoses to public health and safety officials;

10              “(2) increasing data sharing among public safe-  
11       ty and public health officials concerning drug-related  
12       abuse trends, including new psychoactive substances,  
13       and related crime; and

14              “(3) enabling collaborative deployment of pre-  
15       vention, intervention, and enforcement resources to  
16       address substance use addiction and narcotics traf-  
17       ficking.”.

18       **SEC. 3309. PROTECTING LAW ENFORCEMENT OFFICERS**  
19                               **FROM ACCIDENTAL EXPOSURE.**

20       Section 707 of the Office of National Drug Control  
21       Policy Reauthorization Act of 1998 (21 U.S.C. 1706), as  
22       amended by section 3308, is amended by adding at the  
23       end the following:

24              “(s) SUPPLEMENTAL GRANTS.—The Director is au-  
25       thorized to use not more than \$10,000,000 of the amounts

1 otherwise appropriated to carry out this section to provide  
2 supplemental competitive grants to high intensity drug  
3 trafficking areas that have experienced high seizures of  
4 fentanyl and new psychoactive substances for the purposes  
5 of—

6           “(1) purchasing portable equipment to test for  
7 fentanyl and other substances;

8           “(2) training law enforcement officers and  
9 other first responders on best practices for handling  
10 fentanyl and other substances; and

11           “(3) purchasing protective equipment, including  
12 overdose reversal drugs.”.

13 **SEC. 3310. COPS ANTI-METH PROGRAM.**

14           Section 1701 of title I of the Omnibus Crime Control  
15 and Safe Streets Act of 1968 (34 U.S.C. 10381) is amend-  
16 ed—

17           (1) by redesignating subsection (k) as sub-  
18 section (l); and

19           (2) by inserting after subsection (j) the fol-  
20 lowing:

21           “(k) COPS ANTI-METH PROGRAM.—The Attorney  
22 General shall use amounts otherwise appropriated to carry  
23 out this section to make competitive grants, in amounts  
24 of not less than \$1,000,000 for a fiscal year, to State law  
25 enforcement agencies with high seizures of precursor

1 chemicals, finished methamphetamine, laboratories, and  
2 laboratory dump seizures for the purpose of locating or  
3 investigating illicit activities, such as precursor diversion,  
4 laboratories, or methamphetamine traffickers.”.

5 **SEC. 3311. COPS ANTI-HEROIN TASK FORCE PROGRAM.**

6 Section 1701 of title I of the Omnibus Crime Control  
7 and Safe Streets Act of 1968 (34 U.S.C. 10381) is amend-  
8 ed—

9 (1) by redesignating subsection (l), as so redesi-  
10 gnated by section 3310, as subsection (m); and

11 (2) by inserting after subsection (k), as added  
12 by section 3310, the following:

13 “(l) COPS ANTI-HEROIN TASK FORCE PROGRAM.—  
14 The Attorney General shall use amounts otherwise appro-  
15 priated to carry out this section, or other amounts as ap-  
16 propriated, to make competitive grants to State law en-  
17 forcement agencies in States with high per capita rates  
18 of primary treatment admissions, for the purpose of locat-  
19 ing or investigating illicit activities, through Statewide col-  
20 laboration, relating to the distribution of heroin, fentanyl,  
21 or carfentanil or relating to the unlawful distribution of  
22 prescription opioids.”.

1 **SEC. 3312. COMPREHENSIVE ADDICTION AND RECOVERY**  
2 **ACT EDUCATION AND AWARENESS.**

3 Title VII of the Comprehensive Addiction and Recov-  
4 ery Act of 2016 (Public Law 114–198; 130 Stat. 735)  
5 is amended by adding at the end the following:

6 **“SEC. 709. SERVICES FOR FAMILIES AND PATIENTS IN CRI-**  
7 **SIS.**

8 “(a) **IN GENERAL.**—The Attorney General may make  
9 grants to entities that focus on addiction and substance  
10 use disorders and specialize in family and patient services,  
11 advocacy for patients and families, and educational infor-  
12 mation.

13 “(b) **ALLOWABLE USES.**—A grant awarded under  
14 this section may be used for nonprofit national, State, or  
15 local organizations that engage in the following activities:

16 “(1) Expansion of resource center services with  
17 professional, clinical staff that provide, for families  
18 and individuals impacted by a substance use dis-  
19 order, support, access to treatment resources, brief  
20 assessments, medication and overdose prevention  
21 education, compassionate listening services, recovery  
22 support or peer specialists, bereavement and grief  
23 support, and case management.

24 “(2) Continued development of health informa-  
25 tion technology systems that leverage new and up-  
26 coming technology and techniques for prevention,

1 intervention, and filling resource gaps in commu-  
2 nities that are underserved.

3 “(3) Enhancement and operation of treatment  
4 and recovery resources, easy-to-read scientific and  
5 evidence-based education on addiction and substance  
6 use disorders, and other informational tools for fam-  
7 ilies and individuals impacted by a substance use  
8 disorder and community stakeholders, such as law  
9 enforcement agencies.

10 “(4) Provision of training and technical assist-  
11 ance to State and local governments, law enforce-  
12 ment agencies, health care systems, research institu-  
13 tions, and other stakeholders.

14 “(5) Expanding upon and implementing edu-  
15 cational information using evidence-based informa-  
16 tion on substance use disorders.

17 “(6) Expansion of training of community stake-  
18 holders, law enforcement officers, and families  
19 across a broad-range of addiction, health, and re-  
20 lated topics on substance use disorders, local issues  
21 and community-specific issues related to the drug  
22 epidemic.

23 “(7) Program evaluation.

24 “(c) AUTHORIZATION OF APPROPRIATIONS.—For  
25 each of fiscal years 2018 through 2022, the Attorney Gen-

1 eral is authorized to award not more than \$10,000,000  
2 of amounts otherwise appropriated to the Attorney Gen-  
3 eral for comprehensive opioid abuse reduction activities for  
4 purposes of carrying out this section.”.

5 **SEC. 3313. PROTECTING CHILDREN WITH ADDICTED PAR-**  
6 **ENTS.**

7 Part D of title V of the Public Health Service Act  
8 (42 U.S.C. 290dd et seq.) is amended by adding at the  
9 end the following:

10 **“SEC. 550. PROTECTING CHILDREN WITH ADDICTED PAR-**  
11 **ENTS.**

12 “(a) BEST PRACTICES.—The Secretary, acting  
13 through the Assistant Secretary and in cooperation with  
14 the Commissioner of the Administration on Children,  
15 Youth and Families, shall collect and disseminate best  
16 practices for States regarding interventions and strategies  
17 to keep families affected by a substance use disorder to-  
18 gether, when it can be done safely. Such best practices  
19 shall—

20 “(1) utilize comprehensive family-centered ap-  
21 proaches;

22 “(2) ensure that families have access to drug  
23 screening, substance use disorder treatment, medica-  
24 tion-assisted treatment approved by the Food and  
25 Drug Administration, and parental support; and



1 “(3) build upon lessons learned from—

2 “(A) programs such as the maternal, in-  
3 fant, and early childhood home visiting program  
4 under section 511 of the Social Security Act;  
5 and

6 “(B) identifying substance abuse preven-  
7 tion and treatment services that meet the re-  
8 quirements for promising, supported, or well-  
9 supported practices specified in section  
10 471(e)(4)(C) of the Social Security Act (as such  
11 section shall be in effect beginning on October  
12 1, 2018).

13 “(b) GRANT PROGRAM.—The Secretary shall award  
14 grants to States, units of local government, and tribal gov-  
15 ernments to—

16 “(1) develop programs and models designed to  
17 keep pregnant and post-partum women who have a  
18 substance use disorder together with their newborns,  
19 including programs and models that provide for  
20 screenings of pregnant and post-partum women for  
21 substance use disorders, treatment interventions,  
22 supportive housing, nonpharmacological interven-  
23 tions for children born with neonatal abstinence syn-  
24 drome, medication assisted treatment, and other re-  
25 covery supports; and

1           “(2) support the attendance of children who  
2           have a family member living with a substance use  
3           disorder at therapeutic camps or other therapeutic  
4           programs aimed at addiction prevention education  
5           and delaying the onset of first use, providing trusted  
6           mentors and education on coping strategies that  
7           these children can use in their daily lives, and family  
8           support initiatives aimed at keeping these families  
9           together.”.

10 **SEC. 3314. REIMBURSEMENT OF SUBSTANCE USE DIS-**  
11 **ORDER TREATMENT PROFESSIONALS.**

12           Not later than January 1, 2020, the Comptroller  
13           General of the United States shall submit to Congress a  
14           report examining how substance use disorder services are  
15           reimbursed.

16 **SEC. 3315. SOBRIETY TREATMENT AND RECOVERY TEAMS**  
17 **(START).**

18           Title V of the Public Health Service Act (42 U.S.C.  
19           290dd et seq.), as amended by section 3313, is further  
20           amended by adding at the end the following:

21 **“SEC. 551. SOBRIETY TREATMENT AND RECOVERY TEAMS.**

22           “(a) IN GENERAL.—The Secretary may make grants  
23           to States, units of local government, or tribal governments  
24           to establish or expand Sobriety Treatment And Recovery  
25           Team (referred to in this section as ‘START’) or other

1 similar programs to determine the effectiveness of pairing  
2 social workers or mentors with families that are struggling  
3 with a substance use disorder and child abuse or neglect  
4 in order to help provide peer support, intensive treatment,  
5 and child welfare services to such families.

6 “(b) ALLOWABLE USES.—A grant awarded under  
7 this section may be used for one or more of the following  
8 activities:

9 “(1) Training eligible staff, including social  
10 workers, social services coordinators, child welfare  
11 specialists, substance use disorder treatment profes-  
12 sionals, and mentors.

13 “(2) Expanding access to substance use dis-  
14 order treatment services and drug testing.

15 “(3) Enhancing data sharing with law enforce-  
16 ment agencies, child welfare agencies, substance use  
17 disorder treatment providers, judges, and court per-  
18 sonnel.

19 “(4) Program evaluation and technical assist-  
20 ance.

21 “(c) PROGRAM REQUIREMENTS.—A State, unit of  
22 local government, or tribal government receiving a grant  
23 under this section shall—

24 “(1) serve only families for which—

1           “(A) there is an open record with the child  
2           welfare agency; and

3           “(B) substance use disorder was a reason  
4           for the record or finding described in paragraph  
5           (1); and

6           “(2) coordinate any grants awarded under this  
7           section with any grant awarded under section 437(f)  
8           of the Social Security Act focused on improving out-  
9           comes for children affected by substance abuse.

10          “(d) TECHNICAL ASSISTANCE.—The Secretary may  
11          reserve not more than 5 percent of funds provided under  
12          this section to provide technical assistance on the estab-  
13          lishment or expansion of programs funded under this sec-  
14          tion from the National Center on Substance Abuse and  
15          Child Welfare.

16          “(e) AUTHORIZATION OF APPROPRIATIONS.—For  
17          each of fiscal years 2018 through 2022, the Secretary is  
18          authorized to award not more than \$10,000,000 of  
19          amounts otherwise appropriated to the Secretary for com-  
20          prehensive opioid abuse reduction activities for purposes  
21          of carrying out this section.”.

22          **SEC. 3316. PROVIDER EDUCATION.**

23          Not later than 60 days after the date of enactment  
24          of this Act, the Attorney General, in consultation with the  
25          Secretary of Health and Human Services, shall complete

1 the plan related to medical registration coordination re-  
2 quired by Senate Report 114–239, which accompanied the  
3 Veterans Care Financial Protection Act of 2017 (Public  
4 Law 115–131; 132 Stat. 334).

5 **SEC. 3317. DEMAND REDUCTION.**

6 Section 702(1) of the Office of National Drug Con-  
7 trol Policy Reauthorization Act of 1998 (21 U.S.C.  
8 1701(1)) is amended—

9 (1) by redesignating subparagraphs (F)  
10 through (J) as subparagraphs (G) through (K), re-  
11 spectively; and

12 (2) by inserting after subparagraph (E) the fol-  
13 lowing:

14 “(F) support for long-term recovery from  
15 substance use disorders;”.

16 **SEC. 3318. ANTI-DRUG MEDIA CAMPAIGN.**

17 Section 709 of the Office of National Drug Control  
18 Policy Reauthorization Act of 1998 (21 U.S.C. 1708) is  
19 amended—

20 (1) in the section heading, by striking  
21 “**YOUTH**”;

22 (2) in subsection (a)—

23 (A) in the matter preceding paragraph (1),  
24 by striking “youth”;

25 (B) in paragraph (1), by striking “young”;

1 (C) in paragraph (2), by striking “of  
2 adults of the impact of drug abuse on young  
3 people” and inserting “among the population  
4 about the impact of drug abuse”; and

5 (D) in paragraph (3), by striking “parents  
6 and other interested adults to discuss with  
7 young people” and inserting “interested persons  
8 to discuss”; and

9 (3) in subsection (b)(2)(C)(ii), by striking  
10 “among youth”.

11 **SEC. 3319. TECHNICAL CORRECTIONS TO THE OFFICE OF**  
12 **NATIONAL DRUG CONTROL POLICY REAU-**  
13 **THORIZATION ACT OF 1998.**

14 The Office of National Drug Control Policy Reau-  
15 thorization Act of 1998 (21 U.S.C. 1701 et seq.) is  
16 amended—

17 (1) in section 703(b)(3)(E) (21 U.S.C.  
18 1702(b)(3)(E))—

19 (A) in clause (i), by adding “and” at the  
20 end;

21 (B) in clause (ii), by striking “; and” and  
22 inserting a period; and

23 (C) by striking clause (iii);

24 (2) in section 704 (21 U.S.C. 1703)—

25 (A) in subsection (c)(3)(C)—

1 (i) in clause (v), by adding “and” at  
2 the end;

3 (ii) in clause (vi), by striking “; and”  
4 and inserting a period; and

5 (iii) by striking clause (vii); and  
6 (B) in subsection (f)—

7 (i) by striking the first paragraph (5);  
8 and

9 (ii) by striking the second paragraph  
10 (4);

11 (3) in section 706(a)(2)(A) (21 U.S.C.  
12 1705(a)(2)(A))—

13 (A) by striking clause (ix); and

14 (B) by redesignating clauses (x) through  
15 (xiv) as clauses (ix) through (xiii), respectively;

16 and

17 (4) by striking section 708 (21 U.S.C. 1707).

18 **Subtitle D—Synthetic Abuse and**  
19 **Labeling of Toxic Substances**

20 **SEC. 3401. SHORT TITLE.**

21 This subtitle may be cited as the “Synthetic Abuse  
22 and Labeling of Toxic Substances Act of 2017” or the  
23 “SALTS Act”.

1 **SEC. 3402. CONTROLLED SUBSTANCE ANALOGUES.**

2 Section 203 of the Controlled Substances Act (21  
3 U.S.C. 813) is amended—

4 (1) by striking “A controlled” and inserting  
5 “(a) IN GENERAL.—A controlled”; and

6 (2) by adding at the end the following:

7 “(b) DETERMINATION.—In determining whether a  
8 controlled substance analogue was intended for human  
9 consumption under subsection (a), evidence related to the  
10 following factors may be considered, along with all other  
11 relevant evidence:

12 “(1) The marketing, advertising, and labeling  
13 of the substance.

14 “(2) The known efficacy or usefulness of the  
15 substance for the marketed, advertised, or labeled  
16 purpose.

17 “(3) The difference between the price at which  
18 the substance is sold and the price at which the sub-  
19 stance it is purported to be or advertised as is nor-  
20 mally sold.

21 “(4) The diversion of the substance from legiti-  
22 mate channels and the clandestine importation, man-  
23 ufacture, or distribution of the substance.

24 “(5) Whether the defendant knew or should  
25 have known the substance was intended to be con-



1       sumed by injection, inhalation, ingestion, or any  
2       other immediate means.

3       “(c) LIMITATION.—For purposes of this section, the  
4       existence of evidence that a substance was not marketed,  
5       advertised, or labeled for human consumption shall not  
6       preclude the Government from establishing, based on all  
7       the evidence, that the substance was intended for human  
8       consumption.”.

## 9       **Subtitle E—Opioid Quota Reform**

### 10       **SEC. 3501. SHORT TITLE.**

11       This subtitle may be cited as the “Opioid Quota Re-  
12       form Act”.

### 13       **SEC. 3502. STRENGTHENING CONSIDERATIONS FOR DEA** 14       **OPIOID QUOTAS.**

15       (a) IN GENERAL.—Section 306 of the Controlled  
16       Substances Act (21 U.S.C. 826) is amended—

17               (1) in subsection (a)—

18                       (A) by inserting “(1)” after “(a)”;

19                       (B) in the second sentence, by striking  
20               “Production” and inserting “Except as pro-  
21               vided in paragraph (2), production”; and

22                       (C) by adding at the end the following:

23               “(2) The Attorney General may, if the Attorney Gen-  
24       eral determines it will assist in avoiding the overproduc-  
25       tion, shortages, or diversion of a controlled substance, es-

1 tablish an aggregate or individual production quota under  
2 this subsection, or a procurement quota established by the  
3 Attorney General by regulation, in terms of pharma-  
4 ceutical dosage forms prepared from or containing the  
5 controlled substance.”;

6 (2) in subsection (b), in the first sentence, by  
7 striking “production” and inserting “manufac-  
8 turing”;

9 (3) in subsection (c), by striking “October” and  
10 inserting “December”; and

11 (4) by adding at the end the following:

12 “(i)(1)(A) In establishing any quota under this sec-  
13 tion, or any procurement quota established by the Attor-  
14 ney General by regulation, for fentanyl, oxycodone,  
15 hydrocodone, oxymorphone, or hydromorphone (in this  
16 subsection referred to as a ‘covered controlled substance’),  
17 the Attorney General shall estimate the amount of diver-  
18 sion of the covered controlled substance that occurs in the  
19 United States.

20 “(B) In estimating diversion under this paragraph,  
21 the Attorney General—

22 “(i) shall consider information the Attorney  
23 General, in consultation with the Secretary of  
24 Health and Human Services, determines reliable on  
25 rates of overdose deaths and abuse and overall pub-

1       lic health impact related to the covered controlled  
2       substance in the United States; and

3               “(ii) may take into consideration whatever other  
4       sources of information the Attorney General deter-  
5       mines reliable.

6       “(C) After estimating the amount of diversion of a  
7       covered controlled substance, the Attorney General shall  
8       make appropriate quota reductions, as determined by the  
9       Attorney General, from the quota the Attorney General  
10      would have otherwise established had such diversion not  
11      been considered.

12       “(2)(A) For any year for which the approved aggre-  
13      gate production quota for a covered controlled substance  
14      is higher than the approved aggregate production quota  
15      for the covered controlled substance for the previous year,  
16      the Attorney General shall include in the final order an  
17      explanation of why the public health benefits of increasing  
18      the quota clearly outweigh the consequences of having an  
19      increased volume of the covered controlled substance avail-  
20      able for sale, and potential diversion, in the United States.

21       “(B) Not later than 1 year after the date of enact-  
22      ment of this subsection, and every year thereafter, the At-  
23      torney General shall submit to the Caucus on Inter-  
24      national Narcotics Control, the Committee on the Judici-  
25      ary, the Committee on Health, Education, Labor, and

1 Pensions, and the Committee on Appropriations of the  
2 Senate and the Committee on the Judiciary, the Com-  
3 mittee on Energy and Commerce, and the Committee on  
4 Appropriations of the House of Representatives the fol-  
5 lowing information with regard to each covered controlled  
6 substance:

7           “(i) An anonymized count of the total number  
8           of manufacturers issued individual manufacturing  
9           quotas that year for the covered controlled sub-  
10          stance.

11           “(ii) An anonymized count of how many such  
12          manufacturers were issued an approved manufac-  
13          turing quota that was higher than the quota issued  
14          to that manufacturer for the covered controlled sub-  
15          stance in the previous year.

16          “(3) Not later than 1 year after the date of enact-  
17          ment of this subsection, the Attorney General shall submit  
18          to Congress a report on how the Attorney General, when  
19          fixing and adjusting production and manufacturing quotas  
20          under this section for covered controlled substances, will—

21               “(A) take into consideration changes in the ac-  
22               cepted medical use of the covered controlled sub-  
23               stances; and

24               “(B) work with the Secretary of Health and  
25               Human Services on methods to appropriately and

1       anonymously estimate the type and amount of cov-  
2       ered controlled substances that are submitted for  
3       collection from approved drug collection receptacles,  
4       mail-back programs, and take-back events.”.

5       (b) CONFORMING CHANGE.—The Law Revision  
6       Counsel is directed to amend the heading for subsection  
7       (b) of section 826 of title 21, United States Code, by strik-  
8       ing “PRODUCTION” and inserting “MANUFACTURING”.

9                   **Subtitle F—Preventing Drug**  
10                   **Diversion**

11       **SEC. 3601. SHORT TITLE.**

12       This subtitle may be cited as the “Preventing Drug  
13       Diversion Act of 2018”.

14       **SEC. 3602. IMPROVEMENTS TO PREVENT DRUG DIVERSION.**

15       (a) DEFINITION.—Section 102 of the Controlled Sub-  
16       stances Act (21 U.S.C. 802) is amended by adding at the  
17       end the following:

18                   “(57) The term ‘suspicious order’ includes—

19                   “(A) an order of a controlled substance of  
20                   unusual size;

21                   “(B) an order of a controlled substance de-  
22                   viating substantially from a normal pattern;

23                   “(C) orders of controlled substances of un-  
24                   usual frequency; and

1           “(D) an order having any characteristic  
2           that would indicate to a reasonable registrant  
3           that it is suspicious or not legitimate.”.

4           (b) **SUSPICIOUS ORDERS.**—Part C of the Controlled  
5 Substances Act (21 U.S.C. 821 et seq.) is amended by  
6 adding at the end the following:

7           **“SEC. 312. SUSPICIOUS ORDERS.**

8           “(a) **REPORTING.**—Each registrant shall—

9           “(1) design and operate a system to identify  
10           suspicious orders for the registrant;

11           “(2) ensure that the system designed and oper-  
12           ated under paragraph (1) by the registrant complies  
13           with applicable Federal and State privacy laws; and

14           “(3) upon discovering a suspicious order or se-  
15           ries of orders, notify the Administrator of the Drug  
16           Enforcement Administration and the Special Agent  
17           in Charge of the Division Office of the Drug En-  
18           forcement Administration for the area in which the  
19           registrant is located or conducts business.

20           “(b) **SUSPICIOUS ORDER DATABASE.**—

21           “(1) **IN GENERAL.**—Not later than 1 year after  
22           the date of enactment of this section, the Attorney  
23           General shall establish a centralized database for  
24           collecting reports of suspicious orders.

1           “(2) SATISFACTION OF REPORTING REQUIRE-  
2           MENTS.—If a registrant reports a suspicious order  
3           to the centralized database established under para-  
4           graph (1), the registrant shall be considered to have  
5           complied with the requirement under subsection  
6           (a)(3) to notify the Administrator of the Drug En-  
7           forcement Administration and the Special Agent in  
8           Charge of the Division Office of the Drug Enforce-  
9           ment Administration for the area in which the reg-  
10          istrant is located or conducts business.

11          “(c) SHARING INFORMATION WITH THE STATES.—

12           “(1) IN GENERAL.—The Attorney General shall  
13           prepare and make available information regarding  
14           suspicious orders in a State, including information  
15           in the database established under subsection (b)(1),  
16           to the point of contact for purposes of administra-  
17           tive, civil, and criminal oversight relating to the di-  
18           version of controlled substances for the State, as  
19           designated by the Governor or chief executive officer  
20           of the State.

21           “(2) TIMING.—The Attorney General shall pro-  
22           vide information in accordance with paragraph (1)  
23           within a reasonable period of time after obtaining  
24           the information.

1           “(3) COORDINATION.—In establishing the proc-  
2           ess for the provision of information under this sub-  
3           section, the Attorney General shall coordinate with  
4           States to ensure that the Attorney General has ac-  
5           cess to information, as permitted under State law,  
6           possessed by the States relating to prescriptions for  
7           controlled substances that will assist in enforcing  
8           Federal law.”.

9           (c) REPORTS TO CONGRESS.—

10           (1) DEFINITION.—In this subsection, the term  
11           “suspicious order” has the meaning given that term  
12           in section 102 of the Controlled Substances Act, as  
13           amended by this subtitle.

14           (2) ONE TIME REPORT.—Not later than 1 year  
15           after the date of enactment of this Act, the Attorney  
16           General shall submit to Congress a report on the re-  
17           porting of suspicious orders, which shall include—

18                   (A) a description of the centralized data-  
19                   base established under section 312 of the Con-  
20                   trolled Substances Act, as added by this sec-  
21                   tion, to collect reports of suspicious orders;

22                   (B) a description of the system and reports  
23                   established under section 312 of the Controlled  
24                   Substances Act, as added by this section, to  
25                   share information with States;



1           (C) information regarding how the Attor-  
2           ney General used reports of suspicious orders  
3           before the date of enactment of this Act and  
4           after the date of enactment of this Act, includ-  
5           ing how the Attorney General received the re-  
6           ports and what actions were taken in response  
7           to the reports; and

8           (D) descriptions of the data analyses con-  
9           ducted on reports of suspicious orders to iden-  
10          tify, analyze, and stop suspicious activity.

11          (3) *ADDITIONAL REPORTS.*—Not later than 1  
12          year after the date of enactment of this Act, and an-  
13          nually thereafter until the date that is 5 years after  
14          the date of enactment of this Act, the Attorney Gen-  
15          eral shall submit to Congress a report providing, for  
16          the previous year—

17                (A) the number of reports of suspicious or-  
18                ders;

19                (B) a summary of actions taken in re-  
20                sponse to reports, in the aggregate, of sus-  
21                picious orders; and

22                (C) a description of the information shared  
23                with States based on reports of suspicious or-  
24                ders.

1           (4) ONE TIME GAO REPORT.—Not later than 1  
2           year after the date of enactment of this Act, the  
3           Comptroller General of the United States, in con-  
4           sultation with the Administrator of the Drug En-  
5           forcement Administration, shall submit to Congress  
6           a report on the reporting of suspicious orders, which  
7           shall include an evaluation of the utility of real-time  
8           reporting of potential suspicious orders of opioids on  
9           a national level using computerized algorithms, in-  
10          cluding the extent to which such algorithms—

11                   (A) would help ensure that potentially sus-  
12                   picious orders are more accurately captured,  
13                   identified, and reported in real-time to suppliers  
14                   before orders are filled;

15                   (B) may produce false positives of sus-  
16                   picious order reports that could result in mar-  
17                   ket disruptions for legitimate orders of opioids;  
18                   and

19                   (C) would reduce the overall length of an  
20                   investigation that prevents the diversion of sus-  
21                   picious orders of opioids.

## 22           **Subtitle G—Sense of Congress**

### 23           **SEC. 3701. SENSE OF CONGRESS.**

24           It is the sense of Congress that:

1           (1) As the incidence and prevalence of sub-  
2           stance use disorders continue to rise, many Ameri-  
3           cans seek treatment through clinical treatment fa-  
4           cilities that offer detoxification, risk reduction, out-  
5           patient treatment, residential treatment, or rehabili-  
6           tation for substance use.

7           (2) Many Americans with substance use dis-  
8           orders also utilize recovery housing or sober living  
9           homes, which are peer-run or peer-managed drug  
10          and alcohol-free supportive housing for individuals in  
11          recovery from substance use disorders, to assist  
12          them in their recovery efforts.

13          (3) When properly operated, most of these fa-  
14          cilities can provide a critical function in addressing  
15          substance misuse and abuse.

16          (4) Yet, there are some bad actors in the indus-  
17          try that, through telemarketing and other schemes,  
18          actively recruit individuals with private insurance so  
19          that programs can bill the insurers without pro-  
20          viding the necessary treatment services. These bad  
21          actors are often referred to as “patient brokers”.

22          (5) Patient brokers are typically incentivized to  
23          recommend individuals, even at low risk levels, to  
24          the most aggressive and most expensive treatment

1 programs. They are similarly financially incentivized  
2 as they are paid for successfully recruiting patients.

3 (6) The Federal Government must work to pre-  
4 vent these patient brokers from taking advantage of  
5 those with substance use disorders while simulta-  
6 neously ensuring that legitimate entities can con-  
7 tinue to assist individuals in need of treatment find  
8 reputable treatment providers, sober living, or recov-  
9 ery homes.

10 **TITLE IV—COMMERCE**  
11 **Subtitle A—Fighting Opioid Abuse**  
12 **in Transportation**

13 **SEC. 4101. SHORT TITLE.**

14 This subtitle may be cited as the “Fighting Opioid  
15 Abuse in Transportation Act”.

16 **SEC. 4102. RAIL MECHANICAL EMPLOYEE CONTROLLED**  
17 **SUBSTANCES AND ALCOHOL TESTING.**

18 (a) RAIL MECHANICAL EMPLOYEES.—Not later than  
19 2 years after the date of enactment of this Act, the Sec-  
20 retary of Transportation shall publish a final rule in the  
21 Federal Register revising the regulations promulgated  
22 under section 20140 of title 49, United States Code, to  
23 designate a rail mechanical employee as a railroad em-  
24 ployee responsible for safety-sensitive functions for pur-  
25 poses of that section.

1 (b) DEFINITION OF RAIL MECHANICAL EM-  
2 PLOYEE.—The Secretary shall define the term “rail me-  
3 chanical employee” by regulation under subsection (a).

4 (c) SAVINGS CLAUSE.—Nothing in this section may  
5 be construed as limiting or otherwise affecting the discre-  
6 tion of the Secretary of Transportation to set different re-  
7 quirements by railroad size or other factors, consistent  
8 with applicable law.

9 **SEC. 4103. RAIL YARDMASTER CONTROLLED SUBSTANCES**  
10 **AND ALCOHOL TESTING.**

11 (a) YARDMASTERS.—Not later than 2 years after the  
12 date of enactment of this Act, the Secretary of Transpor-  
13 tation shall publish a final rule in the Federal Register  
14 revising the regulations promulgated under section 20140  
15 of title 49, United States Code, to designate a yardmaster  
16 as a railroad employee responsible for safety-sensitive  
17 functions for purposes of that section.

18 (b) DEFINITION OF YARDMASTER.—The Secretary  
19 shall define the term “yardmaster” by regulation under  
20 subsection (a).

21 (c) SAVINGS CLAUSE.—Nothing in this section may  
22 be construed as limiting or otherwise affecting the discre-  
23 tion of the Secretary of Transportation to set different re-  
24 quirements by railroad size or other factors, consistent  
25 with applicable law.

1 **SEC. 4104. DEPARTMENT OF TRANSPORTATION PUBLIC**  
2 **DRUG AND ALCOHOL TESTING DATABASE.**

3 (a) IN GENERAL.—Subject to subsection (c), the Sec-  
4 retary of Transportation shall—

5 (1) not later than March 31, 2019, establish  
6 and make publicly available on its website a data-  
7 base of the drug and alcohol testing data reported  
8 by employers for each mode of transportation; and

9 (2) update the database annually.

10 (b) CONTENTS.—The database under subsection (a)  
11 shall include, for each mode of transportation—

12 (1) the total number of drug and alcohol tests  
13 by type of substance tested;

14 (2) the drug and alcohol test results by type of  
15 substance tested;

16 (3) the reason for the drug or alcohol test, such  
17 as pre-employment, random, post-accident, reason-  
18 able suspicion or cause, return-to-duty, or follow-up,  
19 by type of substance tested; and

20 (4) the number of individuals who refused test-  
21 ing.

22 (c) COMMERCIALY SENSITIVE DATA.—The Depart-  
23 ment of Transportation shall not release any commercially  
24 sensitive data furnished by an employer under this section  
25 unless the data is aggregated or otherwise in a form that  
26 does not identify the employer providing the data.

1 (d) SAVINGS CLAUSE.—Nothing in this section may  
2 be construed as limiting or otherwise affecting the require-  
3 ments of the Secretary of Transportation to adhere to re-  
4 quirements applicable to confidential business information  
5 and sensitive security information, consistent with applica-  
6 ble law.

7 **SEC. 4105. GAO REPORT ON DEPARTMENT OF TRANSPOR-**  
8 **TATION'S COLLECTION AND USE OF DRUG**  
9 **AND ALCOHOL TESTING DATA.**

10 (a) IN GENERAL.—Not later than 2 years after the  
11 date the Department of Transportation public drug and  
12 alcohol testing database is established under section 4104,  
13 the Comptroller General of the United States shall—

14 (1) review the Department of Transportation  
15 Drug and Alcohol Testing Management Information  
16 System; and

17 (2) submit to the Committee on Commerce,  
18 Science, and Transportation of the Senate and the  
19 Committee on Transportation and Infrastructure of  
20 the House of Representatives a report on the review,  
21 including recommendations under subsection (c).

22 (b) CONTENTS.—The report under subsection (a)  
23 shall include—

24 (1) a description of the process the Department  
25 of Transportation uses to collect and record drug

1 and alcohol testing data submitted by employers for  
2 each mode of transportation;

3 (2) an assessment of whether and, if so, how  
4 the Department of Transportation uses the data de-  
5 scribed in paragraph (1) in carrying out its respon-  
6 sibilities; and

7 (3) an assessment of the Department of Trans-  
8 portation public drug and alcohol testing database  
9 under section 4104.

10 (c) RECOMMENDATIONS.—The report under sub-  
11 section (a) may include recommendations regarding—

12 (1) how the Department of Transportation can  
13 best use the data described in subsection (b)(1);

14 (2) any improvements that could be made to  
15 the process described in subsection (b)(1);

16 (3) whether and, if so, how the Department of  
17 Transportation public drug and alcohol testing data-  
18 base under section 4104 could be made more effec-  
19 tive; and

20 (4) such other recommendations as the Comp-  
21 troller General considers appropriate.



1 **SEC. 4106. TRANSPORTATION WORKPLACE DRUG AND AL-**  
2 **COHOL TESTING PROGRAM; ADDITION OF**  
3 **FENTANYL.**

4 (a) MANDATORY GUIDELINES FOR FEDERAL WORK-  
5 PLACE DRUG TESTING PROGRAMS.—

6 (1) IN GENERAL.—Not later than 180 days  
7 after the date of enactment of this Act, the Sec-  
8 retary of Health and Human Services shall deter-  
9 mine whether a revision of the Mandatory Guidelines  
10 for Federal Workplace Drug Testing Programs to  
11 expand the opioid category on the list of authorized  
12 drug testing to include fentanyl is justified, based on  
13 the reliability and cost-effectiveness of available test-  
14 ing.

15 (2) REVISION OF GUIDELINES.—If the expan-  
16 sion of the opioid category is determined to be justi-  
17 fied under paragraph (1), the Secretary of Health  
18 and Human Services shall—

19 (A) notify the Committee on Commerce,  
20 Science, and Transportation of the Senate and  
21 the Committee on Transportation and Infra-  
22 structure of the House of Representatives of  
23 the determination; and

24 (B) publish in the Federal Register, not  
25 later than 18 months after the date of the de-  
26 termination under that paragraph, a final no-

1           tice of the revision of the Mandatory Guidelines  
2           for Federal Workplace Drug Testing Programs  
3           to expand the opioid category on the list of au-  
4           thorized drug testing to include fentanyl.

5           (3) REPORT.—If the expansion of the opioid  
6           category is determined not to be justified under  
7           paragraph (1), the Secretary of Health and Human  
8           Services shall submit to the Committee on Com-  
9           merce, Science, and Transportation of the Senate  
10          and the Committee on Transportation and Infra-  
11          structure of the House of Representatives a report  
12          explaining, in detail, the reasons the expansion of  
13          the opioid category on the list of authorized drugs  
14          to include fentanyl is not justified.

15          (b) DEPARTMENT OF TRANSPORTATION DRUG-TEST-  
16          ING PANEL.—If the expansion of the opioid category is  
17          determined to be justified under subsection (a)(1), the  
18          Secretary of Transportation shall publish in the Federal  
19          Register, not later than 18 months after the date the final  
20          notice is published under subsection (a)(2), a final rule  
21          revising part 40 of title 49, Code of Federal Regulations,  
22          to include fentanyl in the Department of Transportation’s  
23          drug-testing panel, consistent with the Mandatory Guide-  
24          lines for Federal Workplace Drug Testing Programs as

1 revised by the Secretary of Health and Human Services  
2 under subsection (a).

3 (c) SAVINGS PROVISION.—Nothing in this section  
4 may be construed as—

5 (1) delaying the publication of the notices de-  
6 scribed in sections 4107 and 4108 until the Sec-  
7 retary of Health and Human Services makes a de-  
8 termination or publishes a notice under this section;  
9 or

10 (2) limiting or otherwise affecting any authority  
11 of the Secretary of Health and Human Services or  
12 the Secretary of Transportation to expand the list of  
13 authorized drug testing to include an additional sub-  
14 stance.

15 **SEC. 4107. STATUS REPORTS ON HAIR TESTING GUIDE-**  
16 **LINES.**

17 (a) IN GENERAL.—Not later than 30 days after the  
18 date of enactment of this Act, and every 180 days there-  
19 after until the date that the Secretary of Health and  
20 Human Services publishes in the Federal Register a final  
21 notice of scientific and technical guidelines for hair testing  
22 in accordance with section 5402(b) of the Fixing Amer-  
23 ica’s Surface Transportation Act (Public Law 114–94;  
24 129 Stat. 1312), the Secretary of Health and Human  
25 Services shall submit to the Committee on Commerce,

1 Science, and Transportation of the Senate and the Com-  
2 mittee on Transportation and Infrastructure of the House  
3 of Representatives a report on—

4 (1) the status of the hair testing guidelines;

5 (2) an explanation for why the hair testing  
6 guidelines have not been issued;

7 (3) a schedule, including benchmarks, for the  
8 completion of the hair testing guidelines; and

9 (4) an estimated date of completion of the hair  
10 testing guidelines.

11 (b) REQUIREMENT.—To the extent practicable and  
12 consistent with the objective of the hair testing described  
13 in subsection (a) to detect illegal or unauthorized use of  
14 substances by the individual being tested, the final notice  
15 of scientific and technical guidelines under that sub-  
16 section, as determined by the Secretary of Health and  
17 Human Services, shall eliminate the risk of positive test  
18 results of the individual being tested caused solely by the  
19 drug use of others and not caused by the drug use of the  
20 individual being tested.

21 **SEC. 4108. MANDATORY GUIDELINES FOR FEDERAL WORK-**  
22 **PLACE DRUG TESTING PROGRAMS USING**  
23 **ORAL FLUID.**

24 (a) DEADLINE.—Not later than December 31, 2018,  
25 the Secretary of Health and Human Services shall publish

1 in the Federal Register a final notice of the Mandatory  
2 Guidelines for Federal Workplace Drug Testing Programs  
3 using Oral Fluid, based on the notice of proposed manda-  
4 tory guidelines published in the Federal Register on May  
5 15, 2015 (80 Fed. Reg. 28054).

6 (b) REQUIREMENT.—To the extent practicable and  
7 consistent with the objective of the testing described in  
8 subsection (a) to detect illegal or unauthorized use of sub-  
9 stances by the individual being tested, the final notice of  
10 scientific and technical guidelines under that subsection,  
11 as determined by the Secretary of Health and Human  
12 Services, shall eliminate the risk of positive test results  
13 of the individual being tested caused solely by the drug  
14 use of others and not caused by the drug use of the indi-  
15 vidual being tested.

16 (c) RULE OF CONSTRUCTION.—Nothing in this sec-  
17 tion may be construed as requiring the Secretary of  
18 Health and Human Services to reissue a notice of pro-  
19 posed mandatory guidelines to carry out subsection (a).

20 **SEC. 4109. ELECTRONIC RECORDKEEPING.**

21 (a) DEADLINE.—Not later than 1 year after the date  
22 of enactment of this Act, the Secretary of Health and  
23 Human Services shall—

24 (1) ensure that each certified laboratory that  
25 requests approval for the use of completely paperless

1 electronic Federal Drug Testing Custody and Con-  
2 trol Forms from the National Laboratory Certifi-  
3 cation Program's Electronic Custody and Control  
4 Form systems receives approval for those completely  
5 paperless electronic forms instead of forms that in-  
6 clude any combination of electronic traditional hand-  
7 written signatures executed on paper forms; and

8 (2) establish a deadline for a certified labora-  
9 tory to request approval under paragraph (1).

10 (b) SAVINGS CLAUSE.—Nothing in this section may  
11 be construed as limiting or otherwise affecting any author-  
12 ity of the Secretary of Health and Human Services to  
13 grant approval to a certified laboratory for use of com-  
14 pletely paperless electronic Federal Drug Testing Custody  
15 and Control Forms, including to grant approval outside  
16 of the process under subsection (a).

17 (c) ELECTRONIC SIGNATURES.—Not later than 18  
18 months after the date of the deadline under subsection  
19 (a)(2), the Secretary of Transportation shall issue a final  
20 rule revising part 40 of title 49, Code of Federal Regula-  
21 tions, to authorize, to the extent practicable, the use of  
22 electronic signatures or digital signatures executed to elec-  
23 tronic forms instead of traditional handwritten signatures  
24 executed on paper forms.

1 **SEC. 4110. STATUS REPORTS ON COMMERCIAL DRIVER'S LI-**  
2 **CENSE DRUG AND ALCOHOL CLEARING-**  
3 **HOUSE.**

4 (a) IN GENERAL.—Not later than 180 days after the  
5 date of enactment of this Act, and biannually thereafter  
6 until the compliance date, the Administrator of the Fed-  
7 eral Motor Carrier Safety Administration shall submit to  
8 the Committee on Commerce, Science, and Transportation  
9 of the Senate and the Committee on Transportation and  
10 Infrastructure of the House of Representatives a status  
11 report on implementation of the final rule for the Com-  
12 mercial Driver's License Drug and Alcohol Clearinghouse  
13 (81 Fed. Reg. 87686), including—

- 14 (1) an updated schedule, including benchmarks,  
15 for implementing the final rule as soon as prac-  
16 ticable, but not later than the compliance date; and  
17 (2) a description of each action the Federal  
18 Motor Carrier Safety Administration is taking to im-  
19 plement the final rule before the compliance date.

20 (b) DEFINITION OF COMPLIANCE DATE.—In this sec-  
21 tion, the term “compliance date” means the earlier of—

- 22 (1) January 6, 2020; or  
23 (2) the date that the national clearinghouse re-  
24 quired under section 31306a of title 49, United  
25 States Code, is operational.

1           **Subtitle B—Opioid Addiction**  
2           **Recovery Fraud Prevention**

3 **SEC. 4201. SHORT TITLE.**

4           This subtitle may be cited as the “Opioid Addiction  
5 Recovery Fraud Prevention Act of 2018”.

6 **SEC. 4202. DEFINITIONS.**

7           In this subtitle:

8                   (1) OPIOID TREATMENT PRODUCT.—The term  
9           “opioid treatment product” means a product, includ-  
10          ing any supplement or medication, for use or mar-  
11          keted for use in the treatment, cure, or prevention  
12          of an opioid use disorder.

13                   (2) OPIOID TREATMENT PROGRAM.—The term  
14          “opioid treatment program” means a program that  
15          provides treatment for people diagnosed with, hav-  
16          ing, or purporting to have an opioid use disorder.

17                   (3) OPIOID USE DISORDER.—The term “opioid  
18          use disorder” means a cluster of cognitive, behav-  
19          ioral, or physiological symptoms in which the indi-  
20          vidual continues use of opioids despite significant  
21          opioid-induced problems, such as adverse health ef-  
22          fects.



1 **SEC. 4203. FALSE OR MISLEADING REPRESENTATIONS**  
2 **WITH RESPECT TO OPIOID TREATMENT PRO-**  
3 **GRAMS AND PRODUCTS.**

4 (a) **UNLAWFUL ACTIVITY.**—It is unlawful to make  
5 any deceptive representation with respect to the cost,  
6 price, efficacy, performance, benefit, risk, or safety of any  
7 opioid treatment program or opioid treatment product.

8 (b) **ENFORCEMENT BY THE FEDERAL TRADE COM-**  
9 **MISSION.**—

10 (1) **UNFAIR OR DECEPTIVE ACTS OR PRAC-**  
11 **TICES.**—A violation of subsection (a) shall be treated  
12 as a violation of a rule under section 18 of the Fed-  
13 eral Trade Commission Act (15 U.S.C. 57a) regard-  
14 ing unfair or deceptive acts or practices.

15 (2) **POWERS OF THE FEDERAL TRADE COMMIS-**  
16 **SION.**—

17 (A) **IN GENERAL.**—The Federal Trade  
18 Commission shall enforce this section in the  
19 same manner, by the same means, and with the  
20 same jurisdiction, powers, and duties as though  
21 all applicable terms and provisions of the Fed-  
22 eral Trade Commission Act (15 U.S.C. 41 et  
23 seq.) were incorporated into and made a part of  
24 this section.

25 (B) **PRIVILEGES AND IMMUNITIES.**—Any  
26 person who violates subsection (a) shall be sub-

1           ject to the penalties and entitled to the privi-  
2           leges and immunities provided in the Federal  
3           Trade Commission Act as though all applicable  
4           terms and provisions of the Federal Trade  
5           Commission Act (15 U.S.C. 41 et seq.) were in-  
6           corporated and made part of this section.

7           (c) ENFORCEMENT BY STATES.—

8           (1) IN GENERAL.—Except as provided in para-  
9           graph (4), in any case in which the attorney general  
10          of a State has reason to believe that an interest of  
11          the residents of the State has been or is threatened  
12          or adversely affected by any person who violates sub-  
13          section (a), the attorney general of the State, as  
14          *parens patriae*, may bring a civil action on behalf of  
15          the residents of the State in an appropriate district  
16          court of the United States to obtain appropriate re-  
17          lief.

18          (2) RIGHTS OF FEDERAL TRADE COMMIS-  
19          SION.—

20                 (A) NOTICE TO FEDERAL TRADE COMMIS-  
21                 SION.—

22                 (i) IN GENERAL.—Except as provided  
23                 in clause (iii), the attorney general of a  
24                 State shall notify the Federal Trade Com-  
25                 mission in writing that the attorney gen-

1 eral intends to bring a civil action under  
2 paragraph (1) before initiating the civil ac-  
3 tion.

4 (ii) CONTENTS.—The notification re-  
5 quired by clause (i) with respect to a civil  
6 action shall include a copy of the complaint  
7 to be filed to initiate the civil action.

8 (iii) EXCEPTION.—If it is not feasible  
9 for the attorney general of a State to pro-  
10 vide the notification required by clause (i)  
11 before initiating a civil action under para-  
12 graph (1), the attorney general shall notify  
13 the Federal Trade Commission imme-  
14 diately upon instituting the civil action.

15 (B) INTERVENTION BY FEDERAL TRADE  
16 COMMISSION.—The Federal Trade Commission  
17 may—

18 (i) intervene in any civil action  
19 brought by the attorney general of a State  
20 under paragraph (1); and

21 (ii) upon intervening—

22 (I) be heard on all matters aris-  
23 ing in the civil action; and

24 (II) file petitions for appeal.

1           (3) INVESTIGATORY POWERS.—Nothing in this  
2 subsection shall be construed to prevent the attorney  
3 general of a State from exercising the powers con-  
4 ferred on the attorney general by the laws of the  
5 State to conduct investigations, to administer oaths  
6 or affirmations, or to compel the attendance of wit-  
7 nesses or the production of documentary or other  
8 evidence.

9           (4) PREEMPTIVE ACTION BY FEDERAL TRADE  
10 COMMISSION.—If the Federal Trade Commission or  
11 the Attorney General on behalf of the Commission  
12 institutes a civil action, or the Federal Trade Com-  
13 mission institutes an administrative action, with re-  
14 spect to a violation of subsection (a), the attorney  
15 general of a State may not, during the pendency of  
16 that action, bring a civil action under paragraph (1)  
17 against any defendant or respondent named in the  
18 complaint of the Commission for the violation with  
19 respect to which the Commission instituted such ac-  
20 tion.

21           (5) VENUE; SERVICE OF PROCESS.—

22           (A) VENUE.—Any action brought under  
23 paragraph (1) may be brought in any district  
24 court of the United States that meets applicable

1 requirements relating to venue under section  
2 1391 of title 28, United States Code.

3 (B) SERVICE OF PROCESS.—In an action  
4 brought under paragraph (1), process may be  
5 served in any district in which the defendant—

6 (i) is an inhabitant; or

7 (ii) may be found.

8 (6) ACTIONS BY OTHER STATE OFFICIALS.—In  
9 addition to civil actions brought by attorneys general  
10 under paragraph (1), any other consumer protection  
11 officer of a State who is authorized by the State to  
12 do so may bring a civil action under paragraph (1),  
13 subject to the same requirements and limitations  
14 that apply under this subsection to civil actions  
15 brought by attorneys general.

16 (d) AUTHORITY PRESERVED.—Nothing in this title  
17 shall be construed to limit the authority of the Federal  
18 Trade Commission or the Food and Drug Administration  
19 under any other provision of law.